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Zusammenfassung 
Der dramatische Anstieg von Infektionen durch multiresistente, gramnegative Bakterien ist ein 
weltweites Problem, welches möglicherweise eine der größten Herausforderungen moderner 
Medizin darstellt. Bakterielle Krankheitserreger besitzen verschiedenste Mechanismen, um der 
Aktivität einer Vielzahl antimikrobieller Verbindungen zu widerstehen und zeigen eine alarmierende 
Zunahme von multi- oder sogar pan-resistenten Isolaten. 
Die Ziele der vorliegenden Arbeit waren i) die molekularen Mechanismen der Fluorchinolonresistenz 
im opportunistischen Krankheitserreger Pseudomonas aeruginosa zu erklären und ii) die generelle 
Genexpression von Klebsiella pneumoniae zu beschreiben und mit den klinisch relevanten 
Phänotypen der Biofilmbildung, Virulenz und Antibiotikaresistenz zu korrelieren. 
In diesem Zusammenhang untersuchten wir den quantitativen Einfluss von Mutationen und 
Veränderung der Expression von Effluxpumpen auf die Fluorchinolonresistenz in Pseudomonas 
aeruginosa durch die Verwendung einer Kombination von Resequenzierung, quantitativer realtime-
PCR und Transkriptom-Sequenzierung (RNA-Seq) anhand einer Sammlung von 172 klinischen 
Isolaten. Diese umfassenden Daten zeigten die dominierende Rolle bestimmter Mutationen in gyrA 
und parC, während die Kombination mit weiteren Mutationen (zum Beispiel in gyrB und parE) oder 
verstärkter Efflux zwar eine additive Wirkung hatte, aber höchstwahrscheinlich nicht zum hohen 
Resistenzniveau in der Klinik beiträgt. 
Darüber hinaus nutzen wir die Möglichkeiten hoch-auflösenden Transkriptom-Profilings mittels RNA-
Seq um die generelle Gentranskription 37 klinischer K. pneumoniae Isolate unterschiedlichster 
Herkunft aufzuklären und identifizierten eine große Anzahl von 3346 Genen, die in allen Isolaten 
exprimiert wurden. Während dieses Kern-Transkriptom weitgehend homogen zwischen Isolaten des 
gleichen Sequenztypen war, variierte es deutlich zwischen Gruppen unterschiedlicher Sequenztypen. 
Diese detaillierten Informationen über differentiell exprimierte Gene wurde mit den klinisch 
relevanten Phänotypen der Biofilmbildung, bakterieller Virulenz und Antibiotikaresistenz verknüpft. 
Dieses erlaubte die Identifizierung eines Biofilm-spezifischen Genexpressionsprofil in der Gruppe der 
ST258-Isolate, welche hauptverantwortlich für die Verbreitung der KPC-Carbapenemase sind, als ein 
Sequenztyp-spezifisches Merkmal. Außerdem ergab die Analyse, dass die Antibiotikaresistenz durch 
das Auftreten nur weniger, dominanter Resistenzdeterminanten erläutert werden kann. 
Insgesamt trägt diese Arbeit zu unserem Verständnis der molekularen Prozesse der Antibiotika-
Resistenz und Pathogenität bei, welches zukünftig genutzt werden kann, um neue Strategien zur 
Diagnose und Behandlung bakterieller Infektionen zu entwickeln. 
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Abstract 
The dramatic increase of infections caused by multidrug-resistant Gram-negative bacteria is an 
emerging global problem and possibly one of the greatest challenges of modern medicine. Bacterial 
pathogens devise various mechanisms to withstand the activity of a wide range of antimicrobial 
compounds and there is an alarming increase of multi- or even pandrug-resistant isolates. 
The aims of this thesis were i) to elucidate the molecular mechanisms of fluoroquinolone resistance 
in the opportunistic pathogen Pseudomonas aeruginosa and ii) to describe the transcriptomic 
landscape of Klebsiella pneumoniae to correlate gene transcription with the clinical relevant 
phenotypes of biofilm formation, virulence and antibiotic resistance. 
In this context, we evaluated the quantitative contributions of quinolone target alteration and efflux 
pump expression to fluoroquinolone resistance in Pseudomonas aeruginosa by applying a 
combination of directed resequencing methods, quantitative real-time PCRs and whole-
transcriptome sequencing (RNA-Seq) on a broad and cross-sectional panel of 172 clinical isolates. 
This comprehensive data showed the role of distinct mutations in the quinolone resistance-
determining regions of gyrA and parC. The combination with further mutations (e.g. in gyrB and 
parE) or enhanced efflux exhibited additive effects 
Furthermore, we exploited the power of deep transcriptome profiling by RNA-seq to shed light on 
the transcriptomic landscape of 37 clinical K. pneumoniae isolates of diverse phylogenetic origin. We 
identified a large set of 3346 genes which were expressed in all isolates. While these core-
transcriptome profiles were largely homogenous among isolates of the same sequence type, they 
varied substantially between groups of different sequence types. This detailed information on 
differentially expressed genes was linked with the clinically relevant phenotypes of biofilm formation, 
bacterial virulence and antibiotic resistance. This allowed the identification of a low biofilm-specific 
gene expression profile within the group of ST258 isolates, the dominant clonal lineage associated 
with KPC-carbapenemase spread, as a sequence type-specific trait. Moreover, the analysis revealed 
that antimicrobial resistance in this panel of clinical isolates can be explained by the occurrence of 
only a few dominant resistance determinants. 
The results of this thesis contribute to our understanding of molecular processes leading to antibiotic 
resistance and pathogenicity which might be exploited in the future to design novel strategies to 
improve diagnosis and treatment of bacterial infections. 
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1 Introduction 
Adaption of bacteria to complex and changing environments is well reflected by global changes in 
gene expression profiles, which may become fixed by adaptive mutations to facilitate survival in 
challenging habitats [1]. Thus, to study microbial pathogenesis and to fully understand bacterial 
adaptation strategies it is crucial to explore the genomic make-up of a pathogen and to analyze how 
this influences the transcriptional landscape. One of the most crucial adaptations a bacterial 
pathogen has to accomplish is the adaptation to the activity of antimicrobial compounds. In the last 
decade multidrug-resistant bacterial pathogens have been isolated from patients material at 
constantly increasing rates [2]. This poses a serious threat to human health and leads to alarming 
limitations of treatment options especially against Gram-negative pathogens like Pseudomonas 
aeruginosa and Klebsiella pneumoniae [3]. 
1.1 Pseudomonas aeruginosa is a versatile, opportunistic human pathogen 
Pseudomonas aeruginosa, the most prominent and best-studied member of the genus Pseudomonas, 
belonging to the class of γ-Proteobacteria [4], is a highly versatile and adaptable bacterium, able to 
thrive in a vast number of terrestrial and aquatic habitats [5-7]. This variability is achieved by a 
versatile metabolic capacity which allows the utilization of over 80 organic compounds as energy and 
carbon sources [8,9]. Usually, P. aeruginosa generates energy based on oxidative metabolism; 
however, it can also survive and persist under anaerobic conditions using nitrate or nitrite as an 
alternative electron acceptor [10] or the fermentation of arginine and pyruvate [11]. This high 
ecological versatility is facilitated by the large and complex genome which contains almost 10 % 
transcriptional regulators and two-component regulatory systems, which allows a high metabolic 
flexibility [6]. One major contributor to the successful spreading of P. aeruginosa in a variety of 
ecological niches is its ability to forms biofilms on surfaces such as those of rocks and soil but also 
implant material, catheter and other medical devices [12]. Biofilms are surface attached communities 
of bacteria embedded in an extracellular polysaccharide matrix which facilitates survival in hostile 
environments [12]. 
As a result of this genomic and metabolic versatility, P. aeruginosa has the potential to cause severe 
infections in a wide range of diverse hosts, from plants to amoeba, insects and vertebrates. While 
healthy humans become rarely infected, P. aeruginosa accounts for up to 15 % of all hospital-
acquired infections, ranking second to third among Gram-negative pathogens [13-17]. Nearly all 
acute infections caused by P. aeruginosa occur in immunocompromised patients such as patients 
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with AIDS [18] or neutropenia patients undergoing chemotherapy [19], patients with a damaged 
epithelial barrier caused by severe burn wounds [20] or patients undergoing urinary catheterization 
or ventilation [21,22]. 
Besides these acute, health-care associated infections, P. aeruginosa can chronically colonize the 
lung of patients suffering from chronic obstructive pulmonary disease (COPD) or cystic fibrosis (CF) 
which causes severely compromised lung functions. In CF patients infections of P. aeruginosa 
account for the majority of the morbidity and mortality [22]. The autosomal recessive disorder CF, 
also known as mucoviscidosis, is caused by mutations of a chloride ion channel named cystic fibrosis 
transmembrane conductance regulator (CFTR), leading to pathological changes in multiple organs 
and tissues [23]. The most severe implications occur in the lung, where a non-functional CFTR 
disturbs the sodium and chloride ion transport across the epithelium [24] that leads to an inefficient 
mucociliary clearance and/or hyperosmolarity of airway surface liquid which promotes bacterial 
colonization [21]. 
1.2 Klebsiella pneumoniae causes outbreaks throughout the world 
Another bacterium with a high potential of threatening public health is Klebsiella pneumoniae, like P. 
aeruginosa a member of the group of ESKAPE pathogens (Enterococcus faecium, Staphylococcus 
aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter 
species) [25] - bugs with limited remaining treatment options. Although several, diverse mechanisms 
are leading to antimicrobial resistance (AMR) [26-28], the occurrence of the Klebsiella pneumoniae 
carbapenemase (KPC) [29] and the New Delhi metallo-beta-lactamase (NDM) [30] are of serious 
concern and have become a severe threat especially in nosocomial infections [31-33].  
K. pneumoniae is a ubiquitous Gram-negative human pathogen of the family Enterobacteriaceae, and 
therefore closely related to Escherichia coli. While E. coli is primarily a commensal organism, K. 
pneumoniae is capable of surviving in various natural habitats as well as colonizing mucosal surfaces 
of humans and livestock [34]. In humans, K. pneumoniae is able to cause community- and hospital-
acquired infections of the urinary and respiratory tract. Together with E. coli it is the leading cause of 
bacteremia in the UK [35] and causes diseases like liver abscess, pneumonia, meningitis and 
endophthalmitis with mortality rates exceeding 50 % for severe systemic infections [34]. The majority 
of infections caused by K. pneumoniae occurs mainly in hospitalized, immunocompromised patients 
suffering from diseases such as diabetes mellitus or chronic pulmonary obstruction [34] and are 
associated with high rates of morbidity and mortality [36]. However, since the end of the 1980s, K. 
pneumoniae infections causing pyogenic liver abscess (PLA) in otherwise healthy individuals emerged 
in Taiwan and other Asian countries, and cases are increasingly reported [37-40].  
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Pathogenicity of K. pneumoniae depends on various, different virulence factors including the capsular 
serotype, lipopolysaccharide, iron-scavenging systems (siderophores), and adhesins [34]. Among 
these virulence factors, the capsule is thought to be the most important one [40]. It is composed of 
complex acidic polysaccharides and protects the bacterium during the course of an infection from 
phagocytosis [41] and antimicrobial peptides [42]. K. pneumoniae capsules can be classified into 77 
different capsular (K) serotypes. Among these, types K1, K2, K4, and K5 are highly virulent and often 
associated with severe infections [40], noteworthy are K1 and K2 serotypes as the main cause of PLA 
[43]. 
Due to the remarkable collection of virulence factors and an accompanying multidrug resistance 
phenotype, many K. pneumoniae strains are able to spread extensively among patients, leading to 
nosocomial outbreaks, especially in neonatal units [34,44]. Clinical K. pneumoniae outbreaks have 
been described since the 1950s [45] and are becoming a major concern of clinicians. K. pneumoniae 
is responsible for approximately 15 % of Gram-negative infections in hospital intensive care units in 
the United States [46,47] and a PubMed search for the entry “outbreak” in combination with 
“Klebsiella” yielded almost 600 reports (as of March 2015). This enormous potential to threaten 
human health due to very limited treatment options has recently led to the classification of 
carbapenem resistant Enterobacteriaceae as an “urgent threat to human health” by the U.S. Centers 
for Disease Control and Prevention (CDC) [48]. 
1.3 The antibiotic era and its current global crisis 
The term antibiotic was first introduced and defined by Selman A. Waksman in a 1947 paper: 
 
[The term ‘antibiotic’ or ‘antibiotic substance’] "should be used to designate the 
action of the chemical agents, produced by micro-organisms and possibly other 
living bodies, which were responsible for these antimicrobial effects." [49] 
 
Antibiotics are undoubtedly one of the most successful forms of chemotherapy in the history of 
medicine and contributed greatly to the control of bacterial infectious diseases which were the 
leading causes of morbidity and mortality for most of human existence [50]. The ‘antibiotic era’ 
started at the beginning of the 20th century with the work of Noble laureates Paul Ehrlich, Alexander 
Fleming and Selman Waksman. Ehrlich’s work led to the discovery of compound 606 in 1911 (later 
named Salvarsan) against the spirochete Treponema pallidium, the causative agent of syphilis [51]. 
And only a few years after Fleming’s famous observation of a fungus with antimicrobial activity on 
the September 3 in 1928, the first antibacterial drug, Penicillin, was purified and clinically tested by 
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Nobel laureates Howard W. Florey and Ernst B. Chain in 1941, shortly followed by the discovery of 
Streptomycin, the first anti-tuberculosis drug, in 1943 by Waksman and colleagues [50,52,53]. 
Between 1940 and 1962 extensive research and elaborated screening methods led to the discovery 
and development of more than 20 novel classes of antibiotics that have reached the market [54]. The 
vast majority of all classes of antibiotics is based on natural products. Estimates of the origin of 
natural product antibiotics range from 40 million years up to 2 billion years ago and studies suggest 
that resistance mechanism might be similarly old [55,56]. A recent study identified a highly diverse 
collection of resistance conferring genes in 30,000-year-old permafrost samples and could therefore 
demonstrate antibiotic resistance was present long before antibiotics were used in human medicine 
[57]. Therefore, it is of little surprise, that resistance to certain antibiotics occurred only a few years 
after they were introduced as a therapeutic (see Figure 1.1). Interestingly, the first beta-lactamase 
was already identified by the group of Florey and Chain several years before Penicillin was marketed 
[58,59] and Alexander Fleming stated already in 1946: 
 
“There is probably no chemotherapeutic drug to which in suitable circumstances 
the bacteria cannot react by in some way acquiring ‘fastness’ [resistance].” [60] 
 
 
 
Figure 1.1: Brief  history of antibiotics  
The timeline shows the introduction of important antimicrobial drugs and the occurrence of the first resistant microbes. 
Figure adapted from [48]. PDR, pandrug resistant 
 
More dramatically, the often inappropriate usage of these drugs in humans, livestock and poultry has 
been accompanied by a rapid emergence of resistant or even multidrug-resistant strains. Along with 
this spread of (multi-) drug resistance, a constant decline in the discovery of novel antimicrobial 
agents has potentially drastic consequences for human health around the world [61]. Only two new 
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classes of systemic drugs have reached the market: the oxazolidinone drug linezolid in 2000 by Pfizer 
and the cyclic lipopeptide daptomycin in 2003 by Cubist, both active against Gram-positive bacteria 
[54,62]. Moreover, the total number of new systemic antibacterial agents approved by the U.S. Food 
and Drug Administration (FDA) has significantly decreased over the past decades (see Figure 1.1) as 
several large pharmaceutical companies have exited the space. In particular there are almost no 
agents in the clinical pipeline for the treatment of infections caused by resistant Gram-negative 
bacterial pathogens [63]. 
 
 
Figure 1.2: New antibacterial agents approved by the U .S. FDA 
Graph shows the total number of novel systemic antimicrobial agents in 5 year intervals from 1983 to 2007. Figure adapted 
from [64]. 
 
The current rise of antimicrobial resistance (AMR) reaches an alarming rate and poses a growing, 
serious threat to human health [65,66], since infections with MDR isolates are associated with severe 
adverse clinical outcomes, increases in the hospital length of stay, morbidity and mortality, and 
greater overall cost of treating the infection [67-69]. 
Not only is the frequency of AMR increasing, but also the spectrum of antibiotic resistant infections is 
widening world-wide [70]. Figure 1.3 depicts the dramatic increase in the rate of K. pneumoniae 
isolates being non-susceptible to one of the following antibiotics: aminoglycosides, fluoroquinolones, 
third-generation cephalosporins and carbapenems, which are the most important classes of 
antimicrobial agents used to treat infections with this pathogen. Probably most concerning is the rise 
in carbapenem resistant K. pneumoniae isolates, since these drugs are considered to be used as “last-
line agents” or “antibiotics of last resort” when treating resistant bacteria [71]. 
The AMR crisis bears tremendous consequences on human health, the global economy and on 
society in general [68,72,73]. The Infectious Diseases Society of America considers antimicrobial 
resistance as “one of the greatest threats to human health worldwide” [74,75]. Each year, at least 2 
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million people acquire serious infections with bacteria that are resistant to one or more 
antimicrobials in the United States with an estimation of 23,000 deaths per year attributable to these 
antibiotic-resistant infections. Leaving all those neglected, which die from other conditions that were 
complicated by an antibiotic-resistant infection [48]. In Europe, approximately 25,000 people die 
annually from antibiotic-resistant bacteria and added costs and loss of productivity as a result of 
antibiotic resistance conservatively amount to 1.5 billion euro [76,77]. A recent report from the 
British Review on Antimicrobial Resistance presented a scenario of 10 million deaths attributed to 
drug resistant bacteria per year and accumulated costs for the world economy of up to 100 trillion 
U.S. dollar, if antibiotic resistance is not tackled in a concentrated manner [78]. The combination of 
an increase in drug resistant microbes and a steady decrease in novel systemic antimicrobial agents 
resulted in the warning to enter a ‘post antibiotic era’, where these invaluable drugs are no longer 
useful in the treatment of bacterial infections [79]. 
 
 
Figure 1.3: Development of AMR in  K. pneumoniae  in Europe between 2005 and 2013 
Maps showing the development of aminoglycoside-, fluoroquinolone-, third-generation cephalosporin- and carbapenem 
non-susceptibility of K. pneumoniae in Europe between 2005 and 2013. Colors indicate percentage of resistance: 
green < 1 %; light green 1 - 5 %; yellow 5 - 10 %; orange 10 - 25 %; red 25 - 50 %; dark red ≥ 50 %; dark gray no data; light 
gray not included. These graphs have been generated from data submitted to TESSy, The European Surveillance System. 
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1.4 Antimicrobial resistance in Gram-negative bacteria: intrinsic, acquired, 
and adaptive 
Since antibiotics have been introduced in clinical therapy, bacteria have developed sophisticated 
resistance strategies leading to an arms race of clinicians with potential deadly human pathogens 
[80]. The development of antibiotic resistance can thereby be separated into three principal types of 
antibiotic resistance, namely: intrinsic, acquired, and adaptive resistance (see Table 1.1) [81-83]. The 
best studied mechanisms and classical examples of antibiotic resistance are intrinsic and acquired 
resistance, both are irreversible mechanisms and therefore independent of the presence of the 
antibiotic. Adaptive resistance however, is defined as the reversible bacterial response to the 
presence of an antimicrobial agent in the surrounding environment [82]. Therefore, acquired 
resistance might be transmitted vertically to subsequent generations, whereas adaptive resistance is 
transient and usually reverts upon removal of the antimicrobial agent [82]. 
 
Table 1.1: Overview of the different types of resistance 
Resistance 
Shaped by changes of 
Exemplary mechanisms 
genome environment 
Intrinsic + − 
Low outer membrane permeability 
Beta-lactamase production  
Efflux pump expression 
Horizontal gene transfer 
Acquired + − 
Mutations leading to reduced uptake and/or  
Efflux pump overexpression 
Target mutations  
Adaptive − + 
High beta-lactamase production 
Efflux pump overexpression 
Table adapted from [81]. 
 
P. aeruginosa is one of the best studied examples of bacteria with an already high intrinsic resistance 
towards a broad spectrum of antibiotics. This natural low susceptibility is mainly depended on two 
mechanisms: An outer membrane with very low permeability and the presence of several efflux 
systems [84]. The permeability of the outer membrane of P. aeruginosa is approximately 100 times 
lower as compared to the one of E. coli, which is achieved by a lack of high-permeability porins that 
are usually present in most Gram-negative bacteria [84,85]. Additional to this low membrane 
permeability, P. aeruginosa, like most Gram-negative bacteria, contains several efflux pumps which 
reduce the intracellular drug concentration by extruding the antimicrobial agent and provide 
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resistance towards a broad spectrum of antibiotics [86]. Bacterial efflux pumps are highly diverse and 
can be separated into five different classes: the major facilitator superfamily (MFS), the ATP-binding 
cassette (ABC) family, the resistance-nodulation-division (RND) family, the small multidrug resistance 
(SMR), and the multidrug and toxic compound extrusion (MATE) family [87]. The probably best 
studied efflux pumps are those of the RND family, which typically operate as a tripartite system 
composed of a periplasmic membrane fusion protein, an cytoplasmic efflux transporter and an outer-
membrane protein [88]. P. aeruginosa possesses at least 11 RND efflux systems which are able to 
extrude a wide variety of (antimicrobial) compounds (see Figure 1.4). In most cases, all three 
structural genes of RND-pumps are under the control of a single promoter, which is tightly regulated 
by a downstream located negative transcriptional regulator. The strong expression of efflux pumps 
usually occurs due to mutations in these negative regulators, which therefore depicts an example of 
acquired resistance. In some cases, e.g. mexAB-oprM or mexXY, transcriptional regulation is 
controlled by a complex system of regulators [89-91], which allows the expression of these efflux 
pumps upon environmental signals like antibiotic- or peroxide-stress [92-94], therefore representing 
an example for adaptive resistance. 
 
 
Figure 1.4: RND efflux systems in P. aeruginosa  and their substrate specificity  
Genes are illustrated according to their product as indicated by the following color scheme: Orange, transcriptional 
regulator; light blue, oxidoreductase; blue, membrane fusion protein; green, RND efflux transporter; red outer membrane 
protein and purple, protein with unknown function. Exemplary substrates of each RND pumps are listed on the right. 
Adapted from [69] and [95] with additional information from [96] and [97]. 
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1.4.1 Fluoroquinolone resistance in Gram-negative bacteria is defined by target 
modifications 
Fluoroquinolones are very potent antimicrobial agents with excellent oral bioavailability, reaching 
concentrations in serum equivalent to those for intravenous administration. They are broad-
spectrum antibiotics with antibacterial activity against Gram-positive as well as Gram-negative 
bacteria [98,99]. As a consequence, fluoroquinolones are widely and increasingly used for the 
treatment of bacterial infections not only in the hospital setting but also for outpatients. The broad, 
frequent, and worldwide use of the fluoroquinolones, as well as the frequently inappropriate 
application of these antibiotics, is an important factor driving resistance, which has reached clinically 
relevant levels in the last decade [66,100,101]. 
Fluoroquinolones act by directly inhibiting DNA replication, transcription, and recombination via an 
interaction of the drug with complexes composed of DNA and either of the two target enzymes, DNA 
gyrase and topoisomerase IV [98,102]. These enzymes unwind the double stranded DNA molecule by 
binding the DNA, opening the circular molecule, passing another strand through the break and 
resealing the DNA. Fluoroquinolone bind to these enzymes and thereby stabilize the DNA-enzyme 
complex which results in an accumulation of unrepaired double strand breaks [103]. 
The molecular mechanisms of fluoroquinolone resistance include two dominant mechanistic 
categories for all bacterial species studied so far [104,105]. The activity of multidrug resistance (MDR) 
efflux pumps decreases intracellular fluoroquinolone concentrations [86], and alterations of the drug 
target by mutations at key sites in the so called quinolone resistance-determining regions (QRDRs) of 
the genes encoding DNA gyrase (gyrA and gyrB) and/or topoisomerase IV (parC and parE) lead to 
decreased binding affinity of the quinolones for their respective drug targets [106,107]. More 
recently, mobile genetic elements carrying the qnr [108], qepA [109], or aac(6′)-Ib-cr [110] gene, 
which confer reduced susceptibility to quinolones in members of the Enterobacteriaceae family, have 
also been described. These plasmid-mediated resistance determinants exert their activity by either 
reducing the intracellular drug concentration through efflux (qepA), structural modification of the 
drug (aac(6′)-Ib-cr) or by binding to gyrase or topoisomerase IV and thereby inhibiting quinolone 
binding (qnr) [111,112]. 
1.4.2 Beta-lactam resistance through an interplay of enzymes, efflux and porins 
Beta-lactam antibiotics, one of the first drugs used in antimicrobial therapy, represent over 65 % of 
the world’s antibiotic market and are one of the most largest antibiotic classes with more than 
50 different drugs [113,114]. Furthermore, they are one of the largest and most important classes of 
antimicrobial agents against Gram-positive and Gram-negative pathogens [115]. Beta-lactams are 
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characterized by a for-membered beta-lactam ring and exert their antimicrobial activity by 
interfering with the final stage of the bacterial cell wall synthesis [116,117]. They inhibit the 
peptidoglycan biosynthesis which is essential for growth, viability, shape, division and integrity of 
bacterial cells [118-120]. Beta-lactams can be subdivided into several classes including the four most 
prominent ones: penicillins, cephalosporins, carbapenems, and monobactams [113]. Examples of 
beta-lactams of high clinical importance are the third generation cephalosporin ceftazidime and the 
carbapenem meropenem which have a high activity against Pseudomonads [121]. Furthermore, 
carbapenems such as imipenem and meropenem are recommended as first-line therapy for severe 
infections caused by Enterobacteriaceae producing extended spectrum beta-lactamases (ESBLs) 
[122]. Therefore, carbapenems are often 'last resort'-drugs in infections of Gram-negative bacteria 
[123,124] and the emergence of carbapenem resistance is an tremendous threat since only very few 
treatment options remain [75]. 
Although diminished membrane permeability, enhanced efflux or the modification of drug targets in 
the cell wall contribute to beta-lactam resistance [113], production of carbapenemases, especially in 
Enterobacteriaceae, is the most widespread cause of carbapenem resistance [71]. Carbapenemases 
can be either metal-beta-lactamases (e.g. Ambler class B enzymes of VIM, IMP or NDM type) or 
serine-beta-lactamases (e.g. class A enzymes of KPC type or class D enzymes like OXA-48) 
[33,125,126]. The wide spectrum of hydrolyzed antibiotics by KPC and NDM enzymes and their 
location on promiscuous plasmids are major contributors to the rapid and global spread of these 
enzymes, making them a “health nightmare” for clinicians [127]. 
1.4.3 Aminoglycoside resistance via drug modifications 
Aminoglycoside antibiotics, first described in 1944 by the group of Selman Waksman [52], are highly 
potent broad-spectrum antibiotics with bactericidal efficacy against Gram-negative and Gram-
positive bacteria. Aminoglycoside exert their antimicrobial activity through binding to the 30S 
subunit of prokaryotic ribosomes and thereby hinder bacterial protein synthesis [128]. This binding 
perturbs the elongation of the nascent protein chain by impairing the proofreading process which 
leads to misread, truncated or incorrectly folded proteins [128]. Bacterial cell death after 
aminoglycoside uptake occurs due to i) insertion of misread proteins into the inner membrane 
resulting in membrane destabilization [129] and/or ii) accumulation of aminoglycosides to a 
concentration that leads to complete inhibition of ribosomal activity [130,131]. 
Like almost all antibiotics, resistance to aminoglycoside antibiotics in Gram-negative bacteria is 
multifactorial and includes different mechanisms like target mutations, methylation of 16S rRNA, 
altered intracellular drug concentration due to changed uptake and efflux, and enzymatic 
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modification of the drug [131]. The latter one is the most prevalent mechanism in 
Enterobacteriaceae in the clinical setting [132]. Aminoglycoside modifying enzymes (AMEs) are 
usually located on mobile elements like introns or plasmids and can be divided into the three 
different classes of acetyltransferases (AACs), nucleotidyltranferases (ANTs), or phosphotransferases 
(APHs). [132] 
 
Apart from these classical and well-studied mechanisms of antimicrobial resistance, many other 
factors of Gram-negative bacteria might be influential on the susceptibility profile. Large mutant 
library screens in P. aeruginosa have been published which have analyzed the resistance 
development against ciprofloxacin [133], tobramycin [134] or a collection of six [135] and 19 [136] 
different antibiotics, respectively. Although these studies identified between 112 and 233 gene 
knock-outs which altered the minimal inhibitory concentration (MIC) of the studied antibiotics, 
including many known resistance determinants like mexR (transcriptional repressor of mexAB-oprM) 
or oprF (encoding the most common outer membrane protein of P. aeruginosa), the impact of the 
majority of these identified genes on antibiotic non-susceptibility in a clinical setting remains unclear.  
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1.5 Aims of the thesis 
The battle against failure of antibiotic therapy requires a multipronged strategy that includes 
implementation of effective infection control principles, rational use of antimicrobial agents, and 
development of new antimicrobial compounds. Furthermore, investigations on the epidemiology of 
new highly virulent multidrug-resistant strains and detailed knowledge about the molecular 
mechanisms leading to antimicrobial resistance are crucial for designing specific treatment and 
infection control strategies [137]. 
Pseudomonas aeruginosa and Klebsiella pneumoniae are both striking examples of highly successful 
nosocomial and community-acquired Gram-negative pathogens. Both are pathogens with an 
extensive repertoire of virulence traits and are prone to acquire resistance to a broad variety of 
antimicrobial agents. The interplay of intrinsic, acquired and adaptive resistance mechanisms on 
antimicrobial resistance is still not completely understood and large parts of the resistome of these 
organisms remains unexplored [138]. 
 
One aim of this thesis is to evaluate the quantitative contributions of quinolone target alterations 
and efflux pump expression to fluoroquinolone resistance in Pseudomonas aeruginosa and to 
ascertain if further, yet unknown resistance determinants exist. We will explore the complex 
molecular ciprofloxacin resistance mechanisms by applying different resequencing technologies to 
describe the nature and frequency of quinolone resistance determinants. Furthermore, we will use 
deep transcriptome sequencing (RNA-Seq) on a large collection of clinical isolates to perform 
unbiased transcriptome-wide association studies to uncover novel resistance determinants. 
 
A further aim is the description of the transcriptomic landscape of K. pneumoniae and the association 
of transcriptional profiles to the important clinical phenotypes of biofilm formation, virulence and 
antibiotic resistance. We will combine deep transcriptome sequencing data with biological 
experiments to perform global phenotype-genotype associations which have the power to reveal 
novel determinants of these clinically highly important phenotypes.  
 
Materials and Methods 13 
 
 
2 Materials and Methods 
2.1 Bacterial isolates and growth conditions 
Bacterial strains used in this thesis are listed in Table 2.1. All strains were maintained at -70 °C as 
25 % (v/v) glycerol stocks. Escherichia coli strain DH5α was used for all cloning procedures, and E. coli 
strain S17-1 for conjugative DNA transfer. The completely sequenced Pseudomonas aeruginosa strain 
PA14 [139] was used as reference strain. 
Unless indicated otherwise, all P. aeruginosa and E. coli strains were cultured at 37 °C in Luria-Bertani 
broth (LB; 1 5 g/l yeast extract, 7.5 g/l NaCl, 10 g/l tryptone) with vigorous shaking at 180 rpm. For 
cultivation on agar plates, LB medium with 1.6 % (w/v) agar or Columbia agar supplemented with 5 % 
sheep blood (bioMérieux) was used. When required for selection, 100 μg/ml tetracycline and 400 
μg/ml carbenicillin were used for P. aeruginosa PA14 and 12.5 μg/ml tetracycline and 100 μg/ml 
ampicillin for E. coli DH5α or S17.1, respectively. 
 
Table 2.1: Bacterial strains used in this thesis (without clinical isolates) 
2.1.1 Collection of clinical P. aeruginosa isolates 
In total, 172 clinical P. aeruginosa isolates, sampled at several locations in Germany and Europe, 
were included in this study. 100 isolates were collected at the Hannover Medical School (MHH) 
between 2005 and 2007, obtained from 90 individuals, 31 of whom were cystic fibrosis (CF) patients, 
with clinical infections at various sites. Two isolates per patient were analyzed in this study when the 
isolates clearly differed in their antibiotic resistance profiles; otherwise, one isolate per patient was 
analyzed. Furthermore, 40 isolates, sampled in Germany, Rumania, Hungary and Italy, were provided 
from the University of Freiburg. 14 isolates were received from the Robert-Koch-Institute in 
Wernigerode, 10 isolates from the Charité Berlin and 8 isolates from the German National Reference 
Laboratory for Multidrug-Resistant Gram-negative Bacteria in Bochum. The ciprofloxacin 
susceptibility data of each isolate, as shown in Table 2.2, was either derived from the contributing 
Strain Relevant genotype  Reference 
E. coli 
  
DH5α 
F– Φ80lacZ ΔM15 Δ(lacZYA-argF) U169 recA1 endA1 hsdR17 (rK–, 
mK+) phoA supE44 λ– thi-1 gyrA96 relA1 
[140] 
S17.1 recA thi pro hsdR RP4-2-Tc::Mu-Km::Tn7 [141] 
P. aeruginosa 
  
PA14 
 
[139] 
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institution or determined in house using the Vitek2 system (bioMérieux) according to guidelines from 
the Clinical and Laboratory Standards Institute (CLSI) [142]. 
 
Table 2.2: Clinical P. aeruginosa isolates and resistance profiles 
Origin Isolate CF
§
 Material Sample origin CIP MIC* 
RNA-
seq 
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B197 n.d. n.d. n.d. S ≤ 0.125 yes no 
B214 n.d. n.d. n.d. S 0.5 yes no 
B266 n.d. n.d. n.d. S 1 yes no 
B271 n.d. n.d. n.d. S ≤ 0.125 yes no 
B337 n.d. n.d. n.d. S ≤ 0.125 yes no 
B34 n.d. n.d. n.d. S 0.5 yes no 
B428 n.d. n.d. n.d. S 0.5 yes no 
B445 n.d. n.d. n.d. S ≤ 0.25 yes no 
H
an
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r 
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l, 
G
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m
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y 
MHH6827 no midstream urine Hannover, Germany R > 8 yes yes 
MHH6829 no midstream urine Hannover, Germany R > 8 yes yes 
MHH6870 no midstream urine Hannover, Germany R > 8 yes yes 
MHH6887 no tracheal secrete Hannover, Germany I 2 yes yes 
MHH6938 no bronchoalveolar lavage Hannover, Germany R > 8 yes yes 
MHH6964 no wound swab abdomen Hannover, Germany R 8 yes yes 
MHH7032 no venous catheter Hannover, Germany R > 8 yes yes 
MHH7055 no bronchoalveolar lavage Hannover, Germany R 8 yes yes 
MHH7084 no permanent catheter urine Hannover, Germany R > 8 yes yes 
MHH7091 yes lung transplant recipient Hannover, Germany S 1 yes yes 
MHH7125 no tonsil swab Hannover, Germany R > 8 yes yes 
MHH7135 no bronchial secrete Hannover, Germany R 8 yes yes 
MHH7176 no midstream urine Hannover, Germany R > 8 yes yes 
MHH7200 yes tonsil swab Hannover, Germany R > 8 yes yes 
MHH7252 no tracheal secrete Hannover, Germany I 2 yes yes 
MHH7261 no permanent catheter urine Hannover, Germany R > 8 yes yes 
MHH7313 no tracheal secrete Hannover, Germany R 4 yes yes 
MHH7321 no tracheal secrete Hannover, Germany R 4 no yes 
MHH7368 no nasal swab Hannover, Germany R > 8 yes yes 
MHH7444 yes bronchoalveolar lavage Hannover, Germany I 2 yes yes 
MHH7508 yes bronchial secrete Hannover, Germany S 1 yes yes 
MHH7509 yes bronchial secrete Hannover, Germany S 1 no yes 
MHH7624 yes tonsil swab Hannover, Germany S 1 no yes 
MHH7807 yes bronchoalveolar lavage Hannover, Germany S 1 no yes 
MHH7818 yes tracheal secrete Hannover, Germany S 1 yes yes 
MHH7823 no tonsil swab Hannover, Germany R > 8 yes yes 
MHH7863 no bronchial secrete Hannover, Germany R > 8 yes yes 
MHH8044 yes tracheal secrete Hannover, Germany I 2 yes yes 
MHH8349 no midstream urine Hannover, Germany R > 8 yes yes 
MHH8478 no midstream urine Hannover, Germany R > 8 yes yes 
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MHH8481 yes bronchial secrete Hannover, Germany I 2 yes yes 
MHH8482 yes bronchial secrete Hannover, Germany I 2 yes yes 
MHH8607 no sputum Hannover, Germany I 2 yes yes 
MHH8613 no ear swab Hannover, Germany R > 8 yes yes 
MHH8614 no midstream urine Hannover, Germany R > 8 yes yes 
MHH8627 no drainage bile duct Hannover, Germany S 0.25 yes yes 
MHH8694 no midstream urine Hannover, Germany R > 8 no yes 
MHH8697 no rectal swab Hannover, Germany R > 8 yes yes 
MHH9100 yes lung transplant recipient Hannover, Germany I 2 no yes 
MHH9144 no tracheal secrete Hannover, Germany S 1 no yes 
MHH8931 yes lung transplant donor Hannover, Germany R 4 yes yes 
MHH9157 no wound swab abdomen Hannover, Germany S 0.5 yes yes 
MHH9229 no tonsil swab Hannover, Germany S 1 yes yes 
MHH9460 n.d. tracheal secrete Hannover, Germany I 2 yes yes 
MHH9466 no bronchial secrete Hannover, Germany S 1 no yes 
MHH9481 no bronchial rinsing Hannover, Germany R 4 yes yes 
MHH9484 no tonsil swab Hannover, Germany S 1 yes yes 
MHH9509 n.d. tracheal secrete Hannover, Germany I 2 yes yes 
MHH9534 no bronchial secrete Hannover, Germany I 2 yes yes 
MHH9536 n.d. tracheal secrete Hannover, Germany I 2 yes yes 
MHH9561 n.d. tonsil swab Hannover, Germany S 1 yes yes 
MHH9604 n.d. bronchial secrete Hannover, Germany S 1 yes yes 
MHH9619 n.d. tonsil swab Hannover, Germany I 2 yes yes 
MHH9639 n.d. tonsil swab Hannover, Germany S 1 yes yes 
MHH9652 no drainage liquid Hannover, Germany R > 8 yes yes 
MHH9674 no bronchoalveolar lavage Hannover, Germany R 8 yes yes 
MHH9678 n.d. tonsil swab Hannover, Germany S 1 yes yes 
MHH9709 n.d. tonsil swab Hannover, Germany I 2 yes yes 
MHH9717 no tracheal secrete Hannover, Germany R > 8 yes yes 
MHH9748 no tonsil swab Hannover, Germany I 2 yes yes 
MHH9830 no tracheal secrete Hannover, Germany I 2 yes yes 
MHH9847 n.d. tracheal secrete Hannover, Germany S 1 yes yes 
MHH9854 yes nasal swab Hannover, Germany S 1 yes yes 
MHH9923 n.d. tracheal secrete Hannover, Germany I 2 yes yes 
MHH9924 n.d. swab intraoperative Hannover, Germany I 2 yes yes 
MHH10047 no tonsil swab Hannover, Germany S 1 yes yes 
MHH10049 yes nasal swab Hannover, Germany S 0.5 yes yes 
MHH10660 yes lung transplant donor Hannover, Germany I 2 yes yes 
MHH10728 no tracheal secrete Hannover, Germany I 2 no yes 
MHH10978 yes tonsil swab Hannover, Germany R 8 yes yes 
MHH10983 yes lung transplant recipient Hannover, Germany I 2 no yes 
MHH11148 no tonsil swab Hannover, Germany R 4 yes yes 
MHH11444 yes tonsil swab Hannover, Germany S 1 yes yes 
MHH11445 yes tonsil swab Hannover, Germany S 1 yes yes 
MHH11540 no midstream urine Hannover, Germany R > 8 yes yes 
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MHH11572 no midstream urine Hannover, Germany R  -  yes yes 
MHH11785 yes lung transplant donor Hannover, Germany R > 8 yes yes 
MHH11935 no bronchoalveolar lavage Hannover, Germany S 1 yes yes 
MHH11989 yes tonsil swab Hannover, Germany R 4 yes yes 
MHH12178 no catheter swab abdomen Hannover, Germany S 0.5 yes yes 
MHH12207 yes bronchoalveolar lavage Hannover, Germany I 2 yes yes 
MHH12269 yes sputum Hannover, Germany S 1 yes yes 
MHH12274 no bronchoalveolar lavage Hannover, Germany R 4 yes yes 
MHH13062 no permanent catheter urine Hannover, Germany R 8 yes yes 
MHH13224 no bronchial rinsing Hannover, Germany I 2 yes yes 
MHH13281 yes lung transplant recipient Hannover, Germany I 2 no yes 
MHH13305 yes bronchial secrete Hannover, Germany R 4 yes yes 
MHH13395 no bronchoalveolar lavage Hannover, Germany S 0.5 yes yes 
MHH13428 no swab intraop. abdomen Hannover, Germany I 2 yes yes 
MHH13633 no tracheal secrete Hannover, Germany R > 8 yes yes 
MHH13682 yes lung transplant donor Hannover, Germany R > 8 yes yes 
MHH13684 yes lung transplant recipient Hannover, Germany R 8 yes yes 
MHH13714 no permanent catheter urine Hannover, Germany R 4 yes yes 
MHH14039 yes nasal swab Hannover, Germany S 1 no yes 
MHH14088 no perfusate Hannover, Germany I 2 yes yes 
MHH14103 no swab heel Hannover, Germany R > 8 yes yes 
MHH14322 no bronchial rinsing Hannover, Germany R 8 yes yes 
MHH14387 yes lung transplant recipient Hannover, Germany I 2 yes yes 
MHH14449 no bronchial secrete Hannover, Germany S 0.5 yes yes 
MHH14865 yes lung transplant recipient Hannover, Germany R > 4 no yes 
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Psae0613 n.d. n.d. n.d. R 128 yes no 
Psae1152 n.d. drainage catheter Stuttgart, Germany R 32 yes no 
Psae1471 n.d. respiratory tract Berlin, Germany R ≥ 4 yes no 
Psae1640 n.d. urine Munich, Germany R 64 yes no 
Psae1646 n.d. urine Munich, Germany I 2 yes no 
Psae1655 n.d. respiratory tract Munich, Germany I 2 yes no 
Psae1657 n.d. respiratory tract Munich, Germany I 2 yes no 
Psae1659 n.d. respiratory tract Munich, Germany I 2 yes no 
Psae1660 n.d. respiratory tract Munich, Germany I 2 yes no 
Psae1661 n.d. respiratory tract Freiburg, Germany R 8 yes no 
Psae1688 n.d. urine Limburg, Germany S 0.5 yes no 
Psae1695 n.d. respiratory tract Bremen, Germany R 64 yes no 
Psae1711 n.d. n.d. Regensburg, Germany R 128 yes no 
Psae1715 n.d. respiratory tract Freiburg, Germany S 1 yes no 
Psae1716 n.d. blood Freiburg, Germany R 32 yes no 
Psae1747 n.d. respiratory tract Freiburg, Germany R 16 yes no 
Psae1758 n.d. respiratory tract Limburg, Germany R ≥ 4 yes no 
Psae1766 n.d. respiratory tract Bremen, Germany S 1 yes no 
Psae1775 n.d. respiratory tract Ruedesheim, Germany S 0.5 yes no 
Psae1793 n.d. respiratory tract n.d. R 8 yes no 
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Psae1807 n.d. respiratory tract Berlin, Germany S 0.25 yes no 
Psae1829 n.d. respiratory tract Regensburg, Germany I 2 yes no 
Psae1875 n.d. respiratory tract Berlin, Germany S 0.5 yes no 
Psae1892 n.d. respiratory tract Gera, Germany R 32 yes no 
Psae1910 n.d. respiratory tract Regensburg, Germany R 4 yes no 
Psae1928 n.d. respiratory tract Bremen, Germany R 32 yes no 
Psae1950 n.d. respiratory tract Bremen, Germany R 8 yes no 
Psae2134 n.d. respiratory tract Timisoara, Rumania R 16 yes no 
Psae2136 n.d. respiratory tract Timisoara, Rumania R 16 yes no 
Psae2162 n.d. n.d. Catania, Italy R ≥ 4 yes no 
Psae2180 n.d. urine n.d. R 4 yes no 
Psae2302 n.d. respiratory tract Rozzano, Italy R 4 yes no 
Psae2305 n.d. respiratory tract Sassari, Italy R 4 yes no 
Psae2307 n.d. respiratory tract Sassari, Italy R 64 yes no 
Psae2319 n.d. n.d. Palermo, Italy R 128 yes no 
Psae2324 n.d. respiratory tract Neubrandenburg, Germany S 0.125 yes no 
Psae2326 n.d. urine Neubrandenburg, Germany R 16 yes no 
Psae2328 n.d. urine Neubrandenburg, Germany S 0.125 yes no 
Psae2335 n.d. urine Trencin, Hungary R 16 yes no 
Psae2338 n.d. respiratory tract Bari, Italy R 64 yes no 
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RKI_100_12 n.d. n.d. n.d. S 0.25 yes no 
RKI_12_11 n.d. n.d. n.d. R > 64 yes no 
RKI_24_11 n.d. n.d. n.d. R 16 yes no 
RKI_339_12 n.d. n.d. n.d. S 0.25 yes no 
RKI_359_11 n.d. n.d. n.d. R 64 yes no 
RKI_360_11 n.d. n.d. n.d. R 64 yes no 
RKI_37_11 n.d. n.d. n.d. I 2 yes no 
RKI_392_11 n.d. n.d. n.d. S 0.125 yes no 
RKI_395_11 n.d. n.d. n.d. R 64 yes no 
RKI_53_11 n.d. n.d. n.d. R > 64 yes no 
RKI_82_10 n.d. n.d. n.d. R 32 yes no 
RKI_96_12 n.d. n.d. n.d. S 0.5 yes no 
RKI_98_12 n.d. n.d. n.d. R 8 yes no 
RKI_99_12 n.d. n.d. n.d. R 8 yes no 
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Ch2671 n.d. tracheal-bronchial secrete Berlin, Germany S 1 yes no 
Ch2672 n.d. n.d. Berlin, Germany R ≥ 4 yes no 
Ch2674 n.d. tracheal-bronchial secrete Berlin, Germany R ≥ 4 yes no 
Ch2675 n.d. tracheal-bronchial secrete Berlin, Germany R ≥ 4 yes no 
Ch2677 n.d. permanent catheter urine Berlin, Germany R ≥ 4 yes no 
Ch2678 n.d. sputum Berlin, Germany R ≥ 4 yes no 
Ch2680 n.d. drainage secrete Berlin, Germany S 1 yes no 
Ch2682 n.d. n.d. Berlin, Germany S ≤ 0.25 yes no 
Ch2706 n.d. rectal swab Berlin, Germany R ≥ 4 yes no 
Ch2734 n.d. tracheal-bronchial secrete Berlin, Germany I 2 yes no 
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CIP, ciprofloxacin; n.d., not determined 
§
CF, patients diagnosed with cystic fibrosis 
*The ciprofloxacin MIC values are given in µg/ml, the classification into resistance (R), intermediate (I) and susceptible (S) 
isolates is according to CLSI guidelines [142]. 
2.1.2 Collection of clinical K. pneumoniae isolates 
A total of 37 clinical K. pneumoniae isolates was included in this study (see Table 2.3). 19 isolates, 
collected at several hospitals in Saxony, were provided by a diagnostic laboratory (Medizinisches 
Labor Ostsachsen, Görlitz, Germany), 12 isolates were sampled at the Charité-Universitätsmedizin, 
Berlin, Germany and three isolates were collected at a medical practice (Dr. Schanz, Salzgitter, 
Germany). Furthermore, three already published K. pneumoniae isolates (MGH 78578 
(http://www.ncbi.nlm.nih.gov/nuccore/NC_009648.1), JH1 and 1162281 [143]) were included. The 
antibiotic susceptibility profile of each isolate, as shown in Table 2.4, was evaluated using the Vitek2 
system (bioMérieux). Breakpoints of antibiotic resistance were determined according to CLSI 
guidelines [142]. 
 
Table 2.3: Clinical K. pneumoniae isolates and patient information 
Origin Isolate Material Patient age Patient sex Sample origin 
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isolate 1_1 rectal swab 65 female Bennewitz, Germany 
isolate 1_2 tracheal secretion n.d. n.d. Riesa, Germany 
isolate 1_3 rectal swab 71 female Bennewitz, Germany 
isolate 1_4 rectal swab 44 male Bennewitz, Germany 
isolate 1_6 wound swab 65 female Bennewitz, Germany 
isolate 1_8 katheter n.d. n.d. Riesa, Germany 
isolate 1_9 midstream urine 89 female Leipzig, Germany 
isolate 1_10 wound swab 81 female Grimma, Germany 
isolate 1_11 rectal swab 61 female Wurzen, Germany 
isolate 1_12 nasal swab 53 female Bennewitz, Germany 
isolate 1_13 rectal swab 81 female Bennewitz, Germany 
isolate 1_15 rectal swab 42 male Bennewitz, Germany 
isolate 1_16 bronchea 68 male Dresden, Germany 
isolate 2_2 wound swab 71 female Dresden, Germany 
isolate 2_4 wound swab 58 male Thalheim, Germany 
isolate 2_8 sputum 71 male Erfurt, Germany 
isolate 2_9 midstream urine 91 female Leipzig, Germany 
isolate 2_10 wound swab 71 male Leipzig, Germany 
isolate 2_14 midstream urine 45 male Weinböhla, Germany 
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isolate 3_4 rectal swab 20 male Berlin, Germany 
isolate 3_5 rectal swab 25 male Berlin, Germany 
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isolate 3_6 blood culture 34 female Berlin, Germany 
isolate 3_7 rectal swab 72 female Berlin, Germany 
isolate 3_8 rectal swab 61 male Berlin, Germany 
isolate 3_10 blood culture 58 male Berlin, Germany 
isolate 3_11 rectal swab 26 male Berlin, Germany 
isolate 3_12 rectal swab 57 male Berlin, Germany 
isolate 3_13 eye swab 85 female Berlin, Germany 
isolate 3_14 pharyngeal swab 69 male Berlin, Germany 
isolate 3_17 rectal swab 71 female Berlin, Germany 
private 
practice, 
Salzgitter, 
Germany 
isolate 1_14 midstream urine 77 male Salzgitter, Germany 
isolate 2_7 midstream urine 90 female Salzgitter, Germany 
isolate 2_11 midstream urine 67 female Salzgitter, Germany 
previously 
published 
MGH 78578  -  -  -  - 
JH1  -  -  -  - 
1162281  -  -  -  - 
n.d., not determined 
 
Table 2.4: Antibiotic resistance profiles of K. pneumoniae isolates 
Origin Isolate AMP* SAM* TZP* CXM* CAZ* IPM* MEM* CIP* LVX* GEN* 
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isolate 1_1 R ≥ 32 R ≥ 32 R ≥ 128 R ≥ 64 R ≥ 64 R ≥ 16 R ≥ 16 R ≥ 4 R ≥ 8 S ≤ 1 
isolate 1_2 R ≥ 32 R ≥ 32 S 16 R ≥ 64 I 8 S ≤ 0.25 S ≤ 0.25 I 2 S 1 R ≥ 16 
isolate 1_3 R ≥ 32 R ≥ 32 R ≥ 128 R ≥ 64 R ≥ 64 R ≥ 16 R ≥ 16 R ≥ 4 R ≥ 8 S 4 
isolate 1_4 R ≥ 32 R ≥ 32 R ≥ 128 R ≥ 64 R ≥ 64 R ≥ 16 R ≥ 16 R ≥ 4 R ≥ 8 S 4 
isolate 1_6 R ≥ 32 R ≥ 32 R ≥ 128 R ≥ 64 R ≥ 64 R >32 R >32 R ≥ 4 
 
n.d. S 4 
isolate 1_8 R ≥ 32 R ≥ 32 S 16 R ≥ 64 
 
n.d. S ≤ 0.25 S ≤ 0.25 R ≥ 4 
 
n.d. S ≤ 1 
isolate 1_9 R ≥ 32 R ≥ 32 R ≥ 64 R ≥ 64 R ≥ 64 R 8 R ≥ 16 R ≥ 4 R ≥ 8 S 4 
isolate 1_10 R ≥ 32 R ≥ 32 R ≥ 128 R ≥ 64 
 
n.d. R ≥ 16 R ≥ 16 R ≥ 4 R ≥ 8 S ≤ 1 
isolate 1_11 R ≥ 32 R ≥ 32 R ≥ 64 R ≥ 64 R ≥ 64 R ≥ 16 R 4 R ≥ 4 R ≥ 8 S 4 
isolate 1_12 R ≥ 32 R ≥ 32 R ≥ 128 R ≥ 64 R ≥ 64 R ≥ 16 R 8 R ≥ 4 R ≥ 8 S 4 
isolate 1_13 R ≥ 32 R ≥ 32 R ≥ 128 R ≥ 64 R ≥ 64 I 2 R ≥ 16 R ≥ 4 R ≥ 8 S 4 
isolate 1_15 R ≥ 32 R ≥ 32 R ≥ 128 R ≥ 64 R ≥ 64 R 8 I 2 R ≥ 4 R ≥ 8 S 4 
isolate 1_16 R ≥ 32 R ≥ 32 R ≥ 128 R ≥ 64 R ≥ 64 S 0.5 I 2 R ≥ 4  n.d. R ≥ 16 
isolate 2_2 R ≥ 32 R ≥ 32 R ≥ 64 R ≥ 64 R ≥ 64 S ≤ 1 S ≤ 0.25 R ≥ 4 I 4 R ≥ 16 
isolate 2_4 R ≥ 32 R ≥ 32 
 
n.d. R ≥ 64 
 
n.d. R 32 R 16 R ≥ 4 R ≥ 8 S 4 
isolate 2_8 R ≥ 32 R ≥ 32 S 8 R ≥ 64 S 4 S ≤ 1 S ≤ 0.25 S ≤ 0.25  n.d. S ≤ 1 
isolate 2_9 R ≥ 32 R ≥ 32 R ≥ 64 R ≥ 64 R ≥ 64 R 8 R 8 R ≥ 4 R ≥ 8 S 4 
isolate 2_10 R ≥ 32 R ≥ 32 R ≥ 128 R ≥ 64 I 8 S ≤ 1 S ≤ 0.25 R ≥ 4 R 4 S ≤ 1 
isolate 2_14 R ≥ 32 R ≥ 32 R ≥ 128 R ≥ 64 R ≥ 64 S ≤ 1 S 1 R ≥ 4 R ≥ 8 R ≥ 16 
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isolate 3_3 R ≥ 32 R ≥ 32 R ≥ 64 R ≥ 64 R 16 R 8 R ≥ 16 R ≥ 4 R ≥ 8 R ≥ 16 
isolate 3_4 R ≥ 32 R ≥ 32 R ≥ 64 R ≥ 64 R 16 R 4 R ≥ 16 R ≥ 4 R ≥ 8 S ≤ 1 
isolate 3_5 R ≥ 32 R ≥ 32 R ≥ 64 R ≥ 64 S 4 R 4 R ≥ 16 R ≥ 4 R ≥ 8 S ≤ 1 
isolate 3_6 R ≥ 32 R ≥ 32 R ≥ 64 R ≥ 64 R 16 R 8 R ≥ 16 R ≥ 4 R ≥ 8 R ≥ 16 
isolate 3_7 R ≥ 32 R ≥ 32 R ≥ 64 R ≥ 64 S 4 R 8 R ≥ 16 R ≥ 4 R ≥ 8 R ≥ 16 
isolate 3_8 R ≥ 32 R ≥ 32 R ≥ 64 R ≥ 64 R 64 R 4 R 8 R ≥ 4 R ≥ 8 R ≥ 16 
isolate 3_10 R ≥ 32 R ≥ 32 R ≥ 64 R ≥ 64 R 16 R 8 R ≥ 16 R ≥ 4 R ≥ 8 R ≥ 16 
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isolate 3_11 R ≥ 32 R ≥ 32 R ≥ 64 R ≥ 64 R 16 R 8 R ≥ 16 R ≥ 4 R ≥ 8 R ≥ 16 
isolate 3_12 R ≥ 32 R ≥ 32 R ≥ 64 R ≥ 64 S 4 R 4 R 8 R ≥ 4 R ≥ 8 R ≥ 16 
isolate 3_13 R ≥ 32 R ≥ 32 R ≥ 64 R ≥ 64 R 16 R 4 R 8 R ≥ 4 R ≥ 8 S ≤ 1 
isolate 3_14 R ≥ 32 R ≥ 32 R ≥ 64 R ≥ 64 R 16 R 4 R 16 R ≥ 4 R ≥ 8 S ≤ 1 
isolate 3_17 R ≥ 32 R ≥ 32 R ≥ 64 R ≥ 64 S 4 R 4 R 8 R ≥ 4 R ≥ 8 R ≥ 16 
private 
practice, 
Salzgitter, 
Germany 
isolate 1_14 R ≥ 32 R ≥ 32 R ≥ 64 R ≥ 64 R ≥ 64 S ≤ 1 S ≤ 0.25 R ≥ 4 I 4 S ≤ 1 
isolate 2_7 R ≥ 32 S ≤ 2 S 4 S 4 S ≤ 1 S ≤ 1 S ≤ 0.25 S ≤ 0.25 S ≤ 0.125 S ≤ 1 
isolate 2_11 R ≥ 32 R 16 S 4 S ≤ 1 S ≤ 1 S ≤ 1 S ≤ 0.25 I 2 I 4 
 
n.d. 
previously 
published 
MGH 78578 R ≥ 32 R ≥ 32 R ≥ 128 R ≥ 64 R ≥ 64 S ≤ 1 S ≤ 0.25 S 1 S 1 R ≥ 16 
JH1 R ≥ 32 S ≤ 2 S ≤ 2 S 2 S ≤ 1 S ≤ 1 S ≤ 0.25 S ≤ 0.25 S ≤ 0.125 S ≤ 1 
1162281 R ≥ 32 R ≥ 32 R ≥ 64 I 16 R ≥ 64 S ≤ 1 S ≤ 0.25 R ≥ 4 R ≥ 8 R 8 
AMP, ampicillin; SAM, ampicillin-sulbactam; TZP, piperacillin-tazobactam; CXM, cefuroxime-axetil; CAZ, ceftazidime; IPM, 
imipenem; MEM, meropenem; CIP, ciprofloxacin; LVX, levofloxacin; GEN, gentamicin; n.d., not determined 
*MIC values are given in µg/ml, the classification into resistance (R), intermediate (I) and susceptible (S) isolates is according 
to CLSI guidelines [142]. 
2.2 Plasmids and Oligomers 
All plasmids and primers used for sequencing, cloning, and mutagenesis are listed in Table 2.5 and  
Table 2.6, respectively. Primers were adopted from previous publications or designed with Primer3 
[144] based on the sequence of the PA14 genome and ordered from Eurofins MWG Operon. Unless 
indicated otherwise, sequencing of PCR products and plasmids was performed at Eurofins MWG 
Operon. 
Isolation and manipulation of recombinant DNA molecules was performed in accordance with 
standard molecular cloning techniques or as indicated by the product manufacturers’ instructions. 
 
Table 2.5: Plasmids used in this thesis 
Plasmid Relevant characteristics Reference 
pME6032 pVS1-p15A E. coli-Pseudomonas shuttle vector, lacI
q
-Ptac expression vector, Tc
r
 [145] 
pEX18Ap Gene replacement vector; oriT+ sacB+, Apr/Cbr [146] 
 
Table 2.6: Primers used in this thesis 
Name Sequence 5' - 3'* Function Reference 
gyrAfp5 GATGCACGTGACGGCCTGAA pyrosequencing [147] 
gyrArp5UBP AGCATGTAGCGCAGCGAGAAGTCGTGACTGGGAAAACCCTGGCG pyrosequencing [147] 
parCfp3 GGCTGGATGCCGATTCCAAG pyrosequencing [147] 
parCrp3UBP CGCCAGGGTTTTCCCAGTCACGACTAACGCATGGCGGCGAAGGACTT pyrosequencing [147] 
UBP 5'-biotin-CGCCAGGGTTTTCCCAGTCACGAC pyrosequencing [147] 
gyrAs246 CCACCCGCACGGCGA pyrosequencing [147] 
parCs256 AAGTTCCACCCGCACGGC pyrosequencing [147] 
gyrBfp4 GAACTGTACATCGTGGAGGGTGA Sanger sequencing [147] 
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gyrBrp4 ACCCCGCGATACTCGTTGAC Sanger sequencing           [147] 
parEfp3 AGGACGCCTTCAGCCTGTG Sanger sequencing [147] 
parErp3 GGAAATGGCGGACGAACAG Sanger sequencing [147] 
rpoD For CGCAACAGCAATCTCGTCTGAAA qRT-PCR [148] 
rpoD Rev GCGGATGATGTCTTCCACCTGTT qRT-PCR [148] 
mexA For GGCGACAACGCGGCGAAGG qRT-PCR [148] 
mexA Rev CCTTCTGCTTGACGCCTTCCTGC qRT-PCR [148] 
mexC For GCAATAGGAAGGATCGGGGCGTTGG qRT-PCR [148] 
mexC Rev CCTCCACCGGCAACACCATTTCG qRT-PCR [148] 
mexE For TCATCCCACTTCTCCTGGCGCTACC qRT-PCR [148] 
mexE Rev CGTCCCACTCGTTCAGCGGTTGTTCGATG qRT-PCR [148] 
mexX For AATCGAGGGACACCCATGCACATCC qRT-PCR [148] 
mexX Rev CCCAGCAGGAATAGGGCGACCAG qRT-PCR [148] 
gyrAfp6XbaI ACATCATCTAGACGCAAGCGCCTGCATTGAAC mutagenesis [147] 
gyrAD87Nr ATGGTGTTGTAGACCGCGGTGTCGCCG mutagenesis [147] 
gyrAT83Ir TGGTGTCGTAGACCGCGATGTCGCC mutagenesis [147] 
gyrAT83ID87Nr TGGTGTTGTAGACCGCGATGTCGCC mutagenesis [147] 
gyrArp6HindIII ACATCAAAGCTTCGATCAACCGCGCCTTGTTC mutagenesis [147] 
gyrAD87Nf CGGCGACACCGCGGTCTACAACACCAT mutagenesis [147] 
gyrAT83If GGCGACATCGCGGTCTACGACACCA mutagenesis [147] 
gyrAT83ID87Nf GGCGACATCGCGGTCTACAACACCA mutagenesis [147] 
gyrBFP5XbaI ACATCATCTAGAACCACGACCATCGGGAGTGA mutagenesis [147] 
gyrBE468Dr CCGACGTCCTGGGAGGAGAGC mutagenesis [147] 
gyrBS466Fr CCGACCTCCTGGAAGGAGAGC mutagenesis [147] 
gyrBS466Yr CCGACCTCCTGGTAGGAGAGC mutagenesis [147] 
gyrBE468Df GCTCTCCTCCCAGGACGTCGG mutagenesis [147] 
gyrBS466Ff GCTCTCCTTCCAGGAGGTCGG mutagenesis [147] 
gyrBS466Yf GCTCTCCTACCAGGAGGTCGG mutagenesis [147] 
gyrBRP5HindIII ACATCAAAGCTTAGGCCGGGGTTTCCATGAG mutagenesis [147] 
parCfp4XbaI AACTACTCTAGAACCTTCCTGCTCGATACCGG mutagenesis [147] 
parCS87Lr GCCTCGTAGCAGGCCAAGTCGCCGTGCGGG mutagenesis [147] 
parCS87Wr GCCTCGTAGCAGGCCCAGTCGCCGTGCGGG mutagenesis [147] 
parCrp4HindIII  AACTGGAAGCTTACCATCGGCAGCTTCTTGG mutagenesis [147] 
parCS87Lf CCCGCACGGCGACTTGGCCTGCTACGAGGC mutagenesis [147] 
parCS87Wf CCCGCACGGCGACTGGGCCTGCTACGAGGC mutagenesis [147] 
nfxBFP1XbaI ACATCATCTAGACGACACCGCAGCCTTCAG mutagenesis [147] 
nfxBRP1 GGATTGGAGGCGCCATGGAGCGATGGGTCCCGGTTGGT mutagenesis [147] 
nfxBFP2 AAACCAACCGGGACCCATCGCTCCATGGCGCCTCCAAT mutagenesis [147] 
nfxBRP2HindIII ACATCAAAGCTTCGGTCGTTGAGACGATCGAG mutagenesis [147] 
mexRFP1XbaI ACATCATCTAGAACTTCGACGGCAGCTTCAC mutagenesis [147] 
mexRRP1 AGGTTTACTCGGCCAAACCAGAACATTCTTTTCGAAGCACAAT mutagenesis [147] 
mexRFP2 GTGCTTCGAAAAGAATGTTCTGGTTTGGCCGAGTAAACCT mutagenesis [147] 
mexRRP2HindIII ACATCAAAGCTTGTCGCTGCCTTCCTTGAACA mutagenesis [147] 
mexSFP1XbaI ACATCATCTAGAAGCACAACCCAAGCGATCAA mutagenesis [147] 
mexSRP1 ATGCACTGCAGAGGTTTGCGCGGGTATTCGAGTTCGACCAG mutagenesis [147] 
mexSFP2 TGGTCGAACTCGAATACCCGCGCAAACCTCTGCAGTGCATC mutagenesis [147] 
mexSRP2HindIII ACATCAAAGCTTAGGTGGGCGAAGATTTCCTG mutagenesis [147] 
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mexZFP1XbaI ACATCATCTAGAGGGTCGATCTGGAACAGCAC mutagenesis [147] 
mexZRP1 GGACGATTGACGCCCTCAGGTGAACGTCCTCACAAGGG mutagenesis [147] 
mexZFP2 TTCCCTTGTGAGGACGTTCACCTGAGGGCGTCAATCGTC mutagenesis [147] 
mexZRP2HindIII ACATCAAAGCTTGCACCTGGTTGCCCATCTC mutagenesis [147] 
gyrARPSacI GATCGAGCTCCCCCGAGCCTTACTCTTCGTT cloning of gyrA [147] 
gyrAFPSacI GATCCGAGCTCAAAGGAACCAGGCTTCTCATGG cloning of gyrA [147] 
gyrAseqF ATGCAGTACATCCCCGGTC sequencing of pME::gyrA [147] 
gyrAseqR CTGAACTGCACCAGCGG sequencing of pME::gyrA [147] 
pMEseqF ACCCTCACTGATCCGCTAGTCC sequencing of pME::gyrA [147] 
pMEseqR TTGCACCATTCGATGGTGTCAA sequencing of pME::gyrA [147] 
phoE:F:604.1:oF GTTTTCCCAGTCACGACGTTGTAACCTACCGCAACACCGACTTCTTCGG MLST Klebsiella [40] 
phoE:R:604.2:oR TTGTGAGCGGATAACAATTTCTGATCAGAACTGGTAGGTGAT MLST Klebsiella [40] 
tonB:1F:oF GTTTTCCCAGTCACGACGTTGTACTTTATACCTCGGTACATCAGGTT MLST Klebsiella [40] 
tonB:2R:oR TTGTGAGCGGATAACAATTTCATTCGCCGGCTGRGCRGAGAG MLST Klebsiella [40] 
ForwardSeq:oF GTTTTCCCAGTCACGACGTTGTA MLST Klebsiella [40] 
ReverseSeq:oR TTGTGAGCGGATAACAATTTC MLST Klebsiella [40] 
wzi_for2 GTGCCGCGAGCGCTTTCTATCTTGGTATTCC wzi typing [149] 
wzi_rev GAGAGCCACTGGTTCCAGAAYTTSACCGC wzi typing [149] 
KPC_FP ATGTCACTGTATCGCCGTCT blaKPC detection [150] 
KPC_RP TTGACGCCCAATCCCTCG blaKPC detection [150] 
*Mutated nucleotides are bold and underlined; restriction sites are italicized and underlined 
2.3 DNA manipulation techniques 
2.3.1 Transformation of chemically competent E. coli 
Chemically competent E. coli Dh5α and S17-1 were prepared following standard laboratory 
protocols. Briefly, 50 ml LB culture of an OD600 of 0.4 - 0.6 were chilled on ice for 10 min and 
centrifuged at 4 °C at 3,200 × g for 15 min. After resuspending the pellet in 10 ml 0.1 M CaCl2 and a 
second incubation on ice for 5 min, the cells were centrifuged and the pellet was resuspended in 1 ml 
0.1 M CaCl2 including 15 % (v/v) glycerol. 100 µl aliquots were stored at -70 °C. 
For transformation, competent cells were gently thawed on ice for 10 min, mixed with the respective 
DNA and further incubated on ice for 30 min. After a heat shock of 42 °C for 30 s, cells were chilled 
on ice, 800 µl LB were added and the cells were incubated with vigorous shaking at 37 °C for 1 h. 
Appropriate dilutions were plated on LB agar plates containing antibiotics for selection of 
transformants and incubated overnight at 37 °C. 
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2.3.2 Electroporation of P. aeruginosa 
To prepare electrocompetent P. aeruginosa cells, a bacterial lawn was scraped with an inoculation 
loop from an overnight grown Columbia agar plate and resuspended in 0.5 ml 300 mM sucrose 
solution. The suspension was centrifuged at 10,000 × g for 2 min and washed twice with sucrose 
solution. The pellet was resuspended in 100 µl sucrose solution und directly used for electroporation 
using 100 ng of plasmid DNA. Electroporation was carried out using electroporation cuvettes (2 mm 
electrode gap) in a Gene Pulser II (Bio-Rad) with following settings: 2.45 kV voltage, 25 µF 
capacitance and 200 Ω resistance. Immediately after discharge, 1 ml pre-warmed LB was added and 
the cells were incubated for 1.5 h at 37 °C. Appropriate dilutions were plated on LB agar plates 
containing antibiotics for selection of transformants and incubated overnight at 37 °C. 
2.3.3 Plasmid transfer by biparental mating 
pEX18Ap mutagenesis constructs (see chapter 2.3.4) were introduced into P. aeruginosa PA14 by 
conjugation with E. coli S17-1 as the donor strain. Therefore, PA14 was grown in 10 ml LB broth for 
24 h at 42 °C, while E. coli S17.1 carrying the respective pEX18Ap plasmid construct was grown in 
10 ml LB broth supplemented with 100 µg/ml ampicillin for 6 - 8 h at 37 °C. Bacterial cells were 
harvested by centrifugation at 6,000 × g for 5 min, washed twice with LB, mixed in a 1 : 4 ratio 
(P.  aeruginosa : E. coli) and applied as a single drop on an LB agar plate. After incubation at 37 °C 
overnight, cells were thoroughly washed off with 2 ml PBS. Different dilutions of the suspension were 
plated on LB agar plates supplemented with 400 µg/ml carbenicillin and 10 µg/ml nalidixic acid to 
select the P. aeruginosa transconjugants. To promote plasmid counterselection, single colonies were 
picked, cultivated overnight in 10 ml LB broth containing 10 % sucrose and passaged in this medium 
three times with 50 µl inoculum and an incubation time of 8 - 16 h for each passage. After the final 
passage appropriate dilutions were plated on LB agar supplemented with 10 % sucrose to obtain 
single colonies. Integration of the desired mutation into the PA14 genome was confirmed using 
Sanger sequencing. 
2.3.4 Construction of knock-out and single-nucleotide polymorphism mutants  
Single nucleotide polymorphisms (SNPs) in gyrA, gyrB, and parC, as well as knockouts of nfxB, mexR, 
mexS, and mexZ in an isogenic P. aeruginosa PA14 background were carried out by homologous 
recombination using the suicide vector pEX18Ap [146]. Therefore, approximately 1,000 bp long 
mutagenic fragments were created by overlap extension PCR as described previously [151]. To 
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generate knockout mutants, the 500 bp long flanking regions upstream and downstream of the gene 
or SNP of interest were amplified using overlapping primers listed in 
Table 2.6 and cloned into the BamHI and XbaI restriction sites of plasmid pEX18Ap. The resulting 
constructs were transferred into PA14 by biparental mating using E. coli S17-1 as the donor strain 
(see chapter 2.3.3). The antibiotic resistance profiles of all mutants were determined in Mueller-
Hinton (MH) broth (Roth) microdilution as described previously [152] (see chapter 2.4.1). 
2.3.5 Cloning of gyrA and complementation of clinical isolates 
To complement gyrA mutations in clinical isolates with the wild-type PA14 allele, gyrA was amplified 
from the PA14 chromosome with primers gyrAFPSacI and gyrARPSacI and was cloned into the SacI 
restriction site of plasmid pME6032 [145], yielding plasmid pME::gyrA. The correct insertion and 
sequence were verified by Sanger sequencing using primers gyrAseqF, gyrAseqR, pMEseqF, and 
pMEseqR. Complementation was performed via electroporation as described in chapter 2.3.2. The 
cells were plated on LB agar plates supplemented with 100 μg/ml tetracycline. The ciprofloxacin 
MICs for isolates containing pME::gyrA with and without the addition of 1 mM isopropyl-β-d-
thiogalactopyranoside (IPTG) were determined using E-test strips (bioMérieux) (see chapter 2.4.2). 
2.4 Antibiotic susceptibility testing 
2.4.1 Broth microdilution 
Bacterial overnight cultures were adjusted to an OD600 of 0.1 in MH broth and diluted 1:100 in fresh 
MH broth. 100 µl of this cell suspension was mixed with 100 µl MH broth supplemented with 
ciprofloxacin in increasing concentrations of a twofold dilution series in 96-well plates. Bacterial 
growth was monitored in triplicates after 18 h incubation at 37 °C without shaking and the lowest 
concentration where no cell growth could be observed was recorded. 
2.4.2 E-test 
Ciprofloxacin susceptibility of clinical P. aeruginosa isolates complemented with the PA14 gyrA allele 
was determined using E-test strips with gradient antimicrobial concentrations (bioMérieux). Isolates 
were grown overnight at 37 °C and 180 rpm in MH broth and diluted with phosphate buffered saline 
(PBS, 137 mM NaCl; 2.7 mM KCl; 10 mM Na2HPO4; 2 mM KH2PO4; pH 7.4) to a final OD600 of 0.15. The 
suspension was applied to LB agar plates supplemented with 100 μg/ml tetracycline, with and 
without IPTG, respectively, by streaking with a cotton swab. Once the remaining liquid was absorbed 
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by the agar, the E-test stripe was applied to the plate. Results were recorded after 24 h of growth at 
37 °C. 
2.5 Phenotypic characterization assays of K. pneumoniae isolates 
2.5.1 Galleria mellonella virulence assay 
Protocols for the Galleria mellonella virulence assay were adjusted from previous publications 
[150,153]. Bacterial isolates were grown in LB until mid-exponential growth phase. Cells were 
harvested at 8.000 rpm for 5 min and washed with sterile phosphate-buffered saline (10 mM PBS, 
pH 7.5). Cultures were adjusted to an OD600 of 0.5 and 10-fold serially diluted in PBS. For each isolate, 
ten randomly chosen, healthy Galleria mellonella larvae (fauna topics GmbH) were inoculated with 
20 μl of a 1:10 dilution containing approximately 8 × 105  colony forming units (CFU) by injection into 
the haemocoel of the rear left proleg with a 100 μl Hamilton syringe and a 30-G needle. The larvae 
were placed in sterile Petri dishes and incubated in the dark at 37 °C. Mortality was monitored for 
72 h. Larval death was assessed by the lack of movement of larvae in response to physical 
stimulation with a sterile inoculating loop. 10 larvae inoculated with 20 µl PBS and ten larvae without 
any treatment were used as negative controls. Each experiment was performed in duplicates on 
different days. Experiments were repeated if more than one larva died in the controls. Colony 
forming units were enumerated by plating appropriate 10-fold dilutions on LB agar plates in 
triplicates. 
2.5.2 Measurement of bacterial growth 
Planktonic growth of K. pneumoniae isolates was monitored in LB, BM2 minimal medium [154] 
(62 mM potassium phosphate buffer, pH 7, 7 mM (NH4)2SO4, 2 mM MgSO4, 10 μM FeSO4) 
supplemented with 50 mM glucose, and BM2 supplemented with 50 mM mannose, respectively 
using an automated growth analysis system (Bioscreen C MBR, Oy Growth Curves Ab Ltd). Cells of 
overnight cultures grown in LB at 37 °C were harvested at 8.000 rpm for 5 min and washed twice 
with the desired medium. Cultures were diluted to an OD600 of 0.02 and 200 µl were transferred into 
a 100-well honeycomb plate (four replicates per isolate). The plates were incubated at 37 °C with 
continuous shaking and 15 min measurement intervals for a period of 24 h. Maximal optical density 
and doubling time were determined using GrowthRates [155]. 
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2.5.3 Crystal violet biofilm assay 
Protocols to measure biofilm formation were adapted from previous publications [156,157]. An 
overnight culture grown in LB at 37 °C and 180 rpm was washed and diluted to an OD600 of 0.02 in 
fresh LB. 8 wells of a 96-well microtiter plate (BD biosciences) were inoculated with 100 µl and the 
plate was incubated at 37 °C in a humid atmosphere. After 24 h wells were washed three times with 
200 µl sterile water and stained with 150 µl crystal violet staining solution (0.1 % m/v in water) for 
30 min. Wells were washed tree times with 200 µl water, crystal violet was extracted with 200 µl 95% 
ethanol for 30 min and absorbance was measured at 590 nm in an EnSpire Multimode Plate Reader 
(PerkinElmer). All experiments were performed with 8 individual repeats per measurement. Isolates 
were regarded as high biofilm producers if their OD590 value was three times the OD590 value of the 
negative control [158]. 
2.6 DNA sequencing 
2.6.1 Identification of mutations in gyrA and parC using pyrosequencing 
To extract DNA for pyrosequencing, 500 μl of an overnight culture of P. aeruginosa clinical isolates 
was harvested and was lysed for 15 min at 95 °C in 100 μl lysis buffer (0.25% m/v sodium dodecyl 
sulfate, 50 mM NaOH). After the addition of 900 μl dH2O, 2 μl were used as a PCR template. 
To identify mutations at amino acid positions 83 and 87 in gyrA and position 87 in parC, a 
pyrosequencing assay was established. Amplification was performed as described by Doostzadeh et 
al. [159] using a 24-mer universal biotinylated primer (UBP) adapted from the work of Royo et al. 
[160] (shown in  
Table 2.6). Sequencing primers gyrAs246 and parCs256 were designed with Primer3 [144] to anneal 3 
bp upstream (gyrA) and 5 bp upstream (parC) of the SNP, respectively. Pyrosequencing was 
performed on a PSQ 96MA pyrosequencer (Pyrosequencing AB) with PyroMark Gold chemistry 
(Qiagen) as described by Royo et al. [160] at the Genome Analytics Group of the HZI. 
2.6.2 Identification of mutations in gyrB and parE using Sanger sequencing 
To identify mutations in gyrB and parE of P. aeruginosa, the QRDRs of both genes were amplified 
with primers gyrBfp4, gyrBrp4, parEfp3, and parErp3 (see  
Table 2.6). PCR products were sequenced using the same sets of primers on a 3730xl DNA analyzer 
(Applied Biosystems) at the Genome Analytics Group of the HZI. 
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2.6.3 Capsular typing of K. pneumoniae 
To determine the K. pneumoniae capsular type, a fragment of the wzi gene was amplified by primers 
wzi_for2 and wzi_rev adopted from [149] and Sanger sequenced with primer wzi_for2 (see  
Table 2.6). The gene wzi encodes an outer membrane protein involved in capsule attachment to the 
cell surface and is conserved in all capsular types of Klebsiella pneumoniae. Sequences were analyzed 
and compared to published results via http://bigsdb.web.pasteur.fr/klebsiella/klebsiella.html. 
2.6.4 Determination of the Klebsiella pneumoniae carbapenemase types 
An 872 bp long fragment from the Klebsiella pneumoniae carbapenemase coding gene blaKPC was 
amplified with primers KPC_FP and KPC_RP from [150] (see  
Table 2.6) with an annealing temperature of 51 °C. Nucleotide sequences were obtained by Sanger 
sequencing (Eurofins MWG Operon) using both primers and compared to known blaKPC alleles in 
MEGA 6.0 [161]. 
2.7 Quantitative real-time reverse transcription-PCR 
The expression levels of the P. aeruginosa genes mexA, mexC, mexE, mexX, and the house-keeping 
gene rpoD were determined by quantitative real-time reverse transcription-PCR (qRT-PCR). RNA was 
isolated at the late-logarithmic growth phase (OD600 of 1.5 to 2.0) from 3 ml MH liquid culture by 
using the RNeasy kit (Qiagen), as described by the manufacturer. RNA was eluted from the RNeasy 
columns in a volume of 50 μl water and was treated with a DNA-free kit (Ambion). cDNA was 
synthesized by using random hexamer primers (Invitrogen) and SuperScript II reverse transcriptase 
(Invitrogen) according to the manufacturer's instructions. qRT-PCRs were performed in duplicate in a 
20-μl volume with 25 ng cDNA and a primer concentration of 500 nmol/l on a LightCycler 480 system 
(Roche Diagnostics) using the SYBR green I master mix. The primers were adopted from the work of 
Tomás et al. [148] and sequences are listed in  
Table 2.6. Gene expression was calculated using the LightCycler 480 software version 1.5 by the ΔΔCT 
method [162] and a standard curve to measure PCR efficiency. All results were normalized to the 
expression of the house-keeping gene rpoD of the same clinical isolate and were calibrated relative 
to expression in P. aeruginosa PA14. According to Cabot et al. [163], isolates with ≥ 3-fold mexA 
overexpression were regarded as positive, whereas values between 2- and 3-fold were regarded as 
borderline expression. For mexC, mexE, and mexX, ≥ 10-fold overexpression was regarded as positive 
and 5- to 10-fold overexpression was regarded as borderline expression.  
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2.8 Deep transcriptome sequencing 
2.8.1 Bacterial culture conditions and RNA extraction 
Bacteria were cultured in LB at 37 °C and vigorous shaking with 180 rpm until late exponential 
growth phase at OD600 of 2.0. Three independent bacterial cultures were pooled and 4 ml thereof 
were mixed with the same amount of RNAprotect (Qiagen). Followed by 10 min incubation at room 
temperature, cells were harvested by centrifugation at 6000 rpm for 5 min. Pellets were stored up to 
two weeks at -70 °C prior to RNA extraction. After thawing on ice, the pellet was thoroughly 
resuspended in 100 µl TE buffer (10 mM Tris-HCl; 1 mM EDTA, pH 8) supplemented with lysozyme 
(800 µg/ml) and incubated for 10 min at room temperature. Total RNA was extracted using 
Qiashredder columns (Qiagen) and the RNeasy plus kit (Qiagen) according to the manufacturer’s 
instructions. Residual DNA was removed by a DNase (Ambion) treatment for 30 min at 37 °C using 
1 µl DNase per 50 µl of total RNA. 
2.8.2 mRNA enrichment, library preparation and Illumina-based RNA sequencing 
Messenger RNAs were enriched using 7 µg of total RNA using the MICROBExpress™ bacterial mRNA 
enrichment kit (Ambion) according to the manufacturer’s instructions. RNA-seq library preparation 
was performed according to [164] with an additional step of tobacco acid pyrophosphatase (TAP, 
epicenter) treatment to convert 5′-triphosphate RNA into 5′-monophosphate RNA before adapter 
ligation according to the manufacturer. The custom-made protocol from Dötsch et al. uses 5’-
barcoded RNA-libraries, which enables a pooled sequencing of several samples. Up to 18 libraries 
were pooled to equal amounts (total 100 ng) and treated with duplex-specific nuclease (DSN, 
Evrogen) for additional rRNA removal according to Illumina’s ”DSN Normalization Sample Preparation 
Guide”. Prior to sequencing, libraries were checked for quality and size distribution on an Agilent 
2100 Bioanalyzer Pico Chip (Agilent). Sequencing was performed on an Illumina HiSeq 2500 at the 
Genome Analytics Group of the HZI generating paired-end reads each of 100 base pairs length. 
Several pools of clinical P. aeruginosa samples were also sequenced on a Illumina Genome Analyzer 
IIx. 
The establishment of the cDNA library protocol as well as sample preparation, sequencing and raw 
data analysis of the 159 clinical P. aeruginosa isolates was performed in equal amounts by Monika 
Schniederjans and Ariane Khaledi (Helmholtz Centre for Infection Research) [164]. 
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2.9 Generation of the K. pneumoniae pan-genome 
11 fully sequenced and annotated K. pneumoniae strains whose sequence information is publicly 
available in GenBank/EMBL were used to generate a non-redundant K. pneumoniae pan-genome. 
Strain 342 was omitted since it is more likely to belong to K. variicola [165]. These 11 K. pneumoniae 
genomes contain 57,312 genes in total, with an average of 5,210 genes per strain (for more detailed 
information see Table 2.7). 
With the aim to generate a non-redundant gene set, all gene sequences were blasted against each 
other using BLASTN, discarding hits having < 90 % length and 90 % sequence identity. Only genes 
having reciprocal homologs in all 11 genomes were considered as “core”; otherwise, they were 
classified as “accessory”. Accessory genes having homologs in 8 to 10 out of the 11 K. pneumoniae 
genomes were manually re-evaluated. The set of core genes detected in the reciprocal blast search 
comprised 3,270 genes with additional 41 genes assigned to the core-genome after re-evaluation. 
Furthermore, small RNAs in K. pneumoniae subsp. MGH 78578 were predicted by using sRNAscanner 
[166] with default parameters. A total of 30 sRNAs were included in the final gene set. To generate a 
single reference sequence file, the pan-genome was concatenated by adding the 50 bp long genomic 
sequence upstream- and downstream of each gene and a separator of 100 “N”s between all genes. 
The generation of the K. pneumoniae pan-genome has been performed together with Uthayakumar 
Muthukumarasamy and Klaus Hornischer (Helmholtz Centre for Infection Research). 
 
Table 2.7: List of completely sequenced K. pneumoniae genomes used to generate the pan-genome 
GenBank 
Accession ID  
K. pneumoniae strain 
Locus tag / 
format used 
Number of 
genes 
MLST sequence 
type 
AP006725 NTUH-K2044 [167] KP1_0001 5123 23 
CP000647 MGH 78578  KPN_00001 4887 38 
CP002910 KCTC 2242 [168] KPN2242_r25078 5035 375 
CP003200 HS11286 [169] KPHS_00010 5404 11 
CP003785 1084 [170] A79E_0001 5067 23 
CP003999 Kp13 [171] KP13_00049 5299 442 
CP006648 CG43 D364_00005 4897 86 
CP006656 JM45 N559_0001 4980 11 
CP006918 30684/NJST258_2 [172] KPNJ2_00001 5545 258 
CP006923 30660/NJST258_1 [172] KPNJ1_00001 5577 258 
CP006659 ATCC BAA-2146 [173] KPN2146_0001 5498 11 
Total genes (including 30 predicted small RNAs): 57342 
 pan-genome: 7859 
 unique genes (singletons): 1598 
 core-genome: 3336 
 accessory genes: 2925 
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2.10 Bioinformatic analyses of RNA-sequencing data  
2.10.1 Mapping and gene expression profiling 
Raw sequencing reads were de-multiplexed by a custom Perl script, adapter and barcode sequences 
as well as low quality sequences were removed using the fastq-mcf script included in the ea-utils 
package (https://code.google.com/p/ea-utils/). Reads with more than one mismatch in the adapter 
sequence were discarded. Processed reads of K. pneumoniae isolates were mapped against the 
K. pneumoniae pan-genome, reads of P. aeruginosa isolates were mapped against the reference 
strain PA14 [139], both with stampy using bwaoptions -q10 [174]. 
Absolute quantification of K. pneumoniae gene expression was performed as described by Dötsch et 
al. [164]. Read counts were extracted from the SAM output files and normalized to generate 
normalized reads per kilobase of gene sequence (nRPK [164]) values according to the following 
equation: 
nRPK = 𝑙𝑜𝑔2 (
1000
𝑙𝑖
∗
𝑅𝑃𝐺
𝐹𝑗
+ 1) 
 
where li is the length in bp of gene i, RPG is the absolute count of reads of gene i and Fj is the size 
factor calculated by DESeq [175] of isolate j. This normalization method delivers more robust data as 
e.g. RPKM when analyzing highly expressed genes [164]. 
A gene was considered as expressed, when the corresponding nRPK value was higher than the 
threshold nRPK0 (Dötsch et al., submitted for publication), whereby nRPK0 is defined as: 
 
nRPK0 = 𝑙𝑜𝑔2 (
1000
𝑙𝑚𝑒𝑑
∗
1
𝐹𝑚𝑖𝑛
+ 1) = 𝑙𝑜𝑔2 (
1000
700
∗
1
0.398
+ 1) ≈ 2.20 
 
where lmed is the median length in bp of all genes in the pan-genome and Fmin is the smallest size 
factor of all RNA-seq libraries (i.e. the lowest sequencing depth) as determined in DESeq. Gene 
expression profiles were further analyzed in R using the packages scatterplot3D and gplots. 
Differential gene expression for P. aeruginosa genes was calculated against the PA14 reference strain 
using the R software package DESeq [175] based on the read counts calculated from the SAM output 
files. For whole transcriptome association studies, nRPK values were calculated based on the formula 
shown above. 
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2.10.2 Variance in K. pneumoniae gene expression 
The variation in gene expression was analyzed in R with DESeq using pairwise comparisons of each 
gene in all possible combinations of two isolates, resulting in 666 comparisons: 
(∑ 𝑘
𝑛
𝐾=1
, with n = 36, the number of comparisons for one isolate)  
In these pairwise comparisons, a gene was regarded as differentially expressed when the absolute 
value of log2 fold change was above one. The value of variation is expressed as the fraction of 
comparisons in which the gene is differentially regulated vs. all comparisons for that specific gene. 
Genes lower as the 10th percentile or higher as the 90th percentile were regarded as very stable and 
highly variable expressed, respectively. 
2.10.3 De novo assembly of accessory genes 
All reads not mapping to the K. pneumoniae pan-genome were mapped with stampy against the 
virulence factors database (VFDB) [176] and also against a manually curated antibiotic resistance 
database, consisting of data from the Antibiotic Resistance Genes Database (ARDB) [177], 
http://www.lahey.org/qnrstudies/, and http://www.lahey.org/Studies/ containing 1365 entries in 
total. The complete resistance database is attached to this thesis as supplementary file S1 in FASTA 
format (resistance_genes.fasta). The coverage of each gene was assessed using a custom Perl script. 
Additionally, these unmapped reads were used as input for a de novo transcriptome assembly with 
OASES [178]. After testing k-mers from 17 to 41, the assembly was performed with k-mer 33 and a 
minimal transcript length of 250 bp. The assembled transcripts were blasted against the microbial 
genome database [179,180] using a minimal hit length of 100 bp and a minimum sequence similarity 
of 70 %. To generate a non-redundant list, the sequences of all positive hits were extracted and 
blasted against each other, discarding hits having less than 80 % length and 80 % sequence identity. 
All reads not mapping to the pan-genome were mapped against this list using stampy. Only genes 
with coverage of at least 70 % were regarded as true positive hits resulting in a dataset of 1482 
genes. 
2.10.4 Nucleotide sequence accession number 
The RNA-seq data of K. pneumoniae has been deposited at the National Center for Biotechnology 
Information sequence read archive (SRA; http://www.ncbi.nlm.nih.gov/sra) under the accession no. 
SRP051240. 
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2.11 Phylogenetic analyses 
2.11.1 Phylogenetic relationship of K. pneumoniae isolates based on commonly 
transcribed genes 
To construct the phylogenetic relationship, a consensus sequence of 404 commonly transcribed 
genes was generated for each K. pneumoniae isolate using the mpileup option in the SAMtools 
package [181]. Only protein coding sequences from the core-genome which are transcribed in every 
isolate with minimal coverage of 5 reads per position were used. The coverage was determined with 
the “depth” command in SAMtools and the sequences of 404 genes fulfilling the criteria were 
extracted using a Perl script. The corresponding orthologous gene sequences from 11 publicly 
available K. pneumoniae genomes were extracted and included in the alignment generation. All 
sequences were aligned with Clustal Omega [182,183] to generate an alignment of 314,561 bp 
length. The consensus Neighbor Joining tree was drawn with MEGA 6.0 [161] using the maximum 
composite likelihood model and 1000 bootstrapping replications. 
2.11.2 Phylogenetic relationship of P. aeruginosa isolates based on core-genome 
genes 
The phylogenetic relationship was studied using a total of 148 genes that were at least 90 % covered 
with sequencing reads in all clinical isolates and had orthologs in the five Pseudomonas aeruginosa 
reference strains PA14, PAO1, LESB58, PACS2, and PA7. The ortholog information was obtained from 
a pre-computed Pseudomonas genome alignment with the Mauve multiple genome alignment tool 
[184]. The respective gene sequences were extracted using the SAMtools package. 
Phylogenetic distances between the isolates were calculated using a k-mer based approach 
developed by Ole Lund and Rolf Kaas (Technical University of Denmark, personal communication). 
The sequences were split into 17-mers and compared pair-wise between tall isolates. The resulting 
distance matrix (generated by Monika Schniederjans, Helmholtz Centre for Infection Research) was 
used to build a neighbor-joining tree in MEGA 6 [161]. Information about ciprofloxacin resistances 
was added and visualized using iTOL (http://itol.embl.de [185]). 
2.11.3 Multilocus sequence typing (MLST) 
To perform MLST [186], sequences from gapA, infB, mdh, pgi and rpoB were extracted by SAMtools’ 
mpileup option [181]. Due to low read coverage, sequencing of phoE and tonB was performed by 
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classical Sanger sequencing according to [40] using universal sequence primers (see Table 2.6) and an 
annealing temperature of 50 °C. Nucleotide sequences were analyzed via 
http://bigsdb.web.pasteur.fr/klebsiella/klebsiella.html. 
2.12 Gene Ontology term enrichment 
The current UniProt Gene Ontology (GO) knowledge database was downloaded on 07/09/14 [187]. 
Using custom Perl scripts, the gene locus IDs (in KEGG format) were mapped to their UniProt 
identifiers and extracted the relevant GO IDs from the flat files. Significantly enriched or depleted 
categories were tested by one-sided hypergeometric tests in R and the retrieved P-values were 
adjusted by the Benjamini-Hochberg correction to control the false-discovery rate. 
2.13 Transcriptome-wide association of differentially expressed genes and 
accumulation of SNPs for infection relevant phenotypes 
Bacterial isolates were classified according to a particular phenotype (biofilm or virulence) and 
compared to identify i) differentially expressed genes in one group vs. the other group using 
Wilcoxon’s rank-sum test and ii) group specific accumulations of mutations using Fisher's exact test. 
In both cases, P-values were adjusted by the Benjamini-Hochberg correction to control the false-
discovery rate. Genes were regarded as differentially expressed, when their median expression 
differed by at least two-fold, the standard deviation was not higher than the median and their 
adjusted P-value was smaller than 0.05. SNPs and short insertions and deletions (indels) were 
detected using SAMtools [181]. SNPs with a Phred quality score above 30 and indels with a score 
above 150 were regarded as positive and further manually verified using the Integrative Genomics 
Viewer [188]. The Phred quality score Q is defined as  
 
𝑄 = −10 𝑙𝑜𝑔10(𝑃) or 𝑃 = 10
(−𝑄)
10 , 
 
with P representing the P-value as estimated by SAMtools. Thus, a Phred score of 30 corresponds to 
a P-value of 0.001 [189,190]. 
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3 Results 
3.1 Quantitative contributions of target alteration and decreased drug 
accumulation to Pseudomonas aeruginosa fluoroquinolone resistance 
In this present study, Sanger sequencing and pyrosequencing was used to determine the nature and 
frequency of hot spot SNP mutations in the quinolone resistance-determining regions (QRDRs) of the 
gyrA and gyrB genes, encoding DNA gyrase, as well as in those of parC and parE, encoding 
topoisomerase IV. A panel of 100 clinical P. aeruginosa isolates obtained from patients of the 
Hannover Medical School, collected over a period of 2 years (2005 to 2007) was analyzed here. The 
isolates were recovered from various clinical sites, and most of them exhibited resistance not only to 
fluoroquinolones (see Table 2.2) but also to various other antimicrobial compounds (data not 
shown). Pyrosequencing technology has been proven to be time and cost competitive and to allow 
efficient detection of SNPs in localized regions where the nucleotide variants are known [191]. Two 
different pyrosequencing assays were designed for sequencing analysis of the most prominent 
mutation hot spots in the QRDR of the A subunit of the DNA gyrase, encoded by gyrA, which spans 
amino acid positions 83 to 87, and in the QRDR of the A subunit of topoisomerase IV, encoded by 
parC, which spans amino acid positions 82 to 84. 
The QRDRs of the B subunits of DNA gyrase (encoded by gyrB) and topoisomerase IV (encoded by 
parE) are larger, spanning amino acid positions 429 to 585 in the GyrB protein and 357 to 503 in the 
ParE protein. Therefore, Sanger sequencing was performed for the identification of relevant 
mutations in the QRDRs of gyrB and parE. 
3.1.1 Frequency and nature of mutations in the QRDRs of gyrA, gyrB, parC, and 
parE in clinical P. aeruginosa isolates 
Sequencing confirmed the presence of mutations in the QRDRs in most of the clinical isolates. The 
relative frequencies of the specific mutations are shown in Figure 3.1A. In accordance with the 
findings of several previous studies [192-198], the most frequently observed mutation, T83I, was 
encoded in the QRDR of gyrA, whereas mutations in gyrB were less frequent [197,199,200]. Here, the 
majority of mutations were found at amino acid positions 466 to 468; however, two isolates 
exhibited an I529V mutation, which has not been described previously. Two mutations within the 
QRDR of parC were detected in the panel of 100 clinical isolates (S87W and S87L), and only three 
mutations were present in parE (one M437I and two A473V mutations). The majority of clinical 
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isolates harbored either a single mutation in gyrA or gyrB or a combination of mutations in gyrA and 
parC (Figure 3.1B). Fewer isolates exhibited mutations in gyrB in combination with parE or in gyrA in 
combination with gyrB, with or without additional mutations in the QRDR of parC. As in previous 
studies [195,200], no single parC mutations were found in the panel of clinical P. aeruginosa isolates. 
Two of the isolates harbored a single mutation in parE, and for 14 isolates, no mutations in the 
QRDRs were detected. 
 
 
Figure 3.1: Mutations identified in the gyrA, gyrB , parC ,  and parE  genes of 100 clinical isolates.  
(A) Co-occurrence of mutations in the QRDRs of gyrA, gyrB, parC, and parE in individual clinical P. aeruginosa isolates. The 
proportions of isolates with a single (light shaded sectors), double (dark shaded sectors), or triple (filled sectors) mutation, 
or with no identified QRDR mutation (open sectors), are shown. 
(B) Frequency and nature of mutations found in the QRDRs of gyrA, gyrB, parC, and parE in 100 clinical Pseudomonas 
aeruginosa isolates. Each mutation (given as the wild-type allele, amino acid position, and mutant allele) is followed by a 
semicolon and the number of isolates harboring the mutation. Δ, deletion at the specified position; wt, wild-type allele or 
silent mutation. Figure published in [147]. 
3.1.2 Correlation of the presence of SNPs in the QRDRs of gyrA, gyrB, parC and 
parE with the ciprofloxacin resistance phenotype in clinical P. aeruginosa 
isolates. 
The presence of SNPs within the QRDRs of gyrA, gyrB, parC and parE was correlated with phenotypic 
resistance to fluoroquinolones in the clinical P. aeruginosa isolates. Figure 3.2 shows the relationship 
of the ciprofloxacin MIC values for all 100 clinical P. aeruginosa isolates to the presence of mutations 
in the QRDRs. The majority of clinical isolates harbored single mutations in parE, gyrA, or gyrB; 
however, those mutations did not necessarily lead to ciprofloxacin MIC values exceeding 2 μg/ml 
(noteworthy, resistance according to the Clinical and Laboratory Standards Institute [CLSI] 
breakpoints is categorized by MIC values exceeding 2 μg/ml). In contrast, combinations of mutations 
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in the QRDRs of gyrA and parC always resulted in a ciprofloxacin-resistant phenotype, with MIC 
values of ≥8 μg/ml. The two isolates that harbored single parE mutations and the 14 isolates without 
mutations in the QRDRs exhibited MIC values that did not exceed 2 μg/ml and thus were categorized 
as susceptible or intermediate according to CLSI breakpoints. 
 
 
Figure 3.2: Correlation of ciprofloxacin MIC values with the presence of mutations in the QRDRs of 
gyrA,  gyrB ,  parC , and parE  (and combinations thereof) for 100 P. aeruginosa  clinical isolates.  
The number of isolates with the same combination of MIC and genotype is given inside each circle. Light, medium, and dark 
shaded circles represent sensitive, intermediate, and resistant isolates, respectively, according to the CLSI clinical 
breakpoints [142]. Figure published in [147]. 
3.1.3 Introduction of dominant SNPs in the QRDRs of gyrA, gyrB and parC into the 
susceptible P. aeruginosa reference strain PA14 
In order to pinpoint the contributions of the most frequent mutations in the QRDRs of gyrA, gyrB, 
and parC to fluoroquinolone resistance, the respective SNPs were introduced into the 
fluoroquinolone-susceptible reference strain PA14 and the resistance profile were measured. 
Plasmid constructs for allelic exchange were generated for two SNPs in gyrA (resulting in amino acid 
exchanges T83I and D87N), three SNPs in gyrB (S466F, S466Y, and E468D), and two SNPs in parC 
(S87L and S87W). These SNPs were introduced into the reference strain singly and in various 
combinations. 
As shown in Table 3.1, the introduction of parC mutations alone had no impact on susceptibility to 
ciprofloxacin, whereas mutations in the QRDR of gyrB or gyrA increased the MIC of ciprofloxacin 8- 
to 16-fold. Similarly, as already reported, the introduction of a single parC mutation did not alter the 
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susceptibility of Escherichia coli to fluoroquinolone [201]. The simultaneous introduction of two SNPs 
into the QRDR of gyrA (T83I and D87N) did not increase ciprofloxacin resistance over that with T83I 
alone. However, the simultaneous introduction of SNPs in gyrA (T83I) and parC (either S87L or S87W) 
increased the ciprofloxacin MIC 256-fold over that for the reference PA14 strain. None of the 
mutations in the QRDRs had any impact on the resistance of the parental strain to beta-lactam 
antibiotics, carbapenems, or aminoglycosides (data not shown). 
 
Table 3.1: MICs of in vitro generated PA14 mutants 
  PA14 mutant CIP MIC  
wild type PA14 0.125 
 
gyrA T83I 2 
 
gyrA D87N 1 
 gyrA T83I-D87N 2 
mutations  gyrB S466F 1 
in QRDR gyrB S466Y 1 
  gyrB E468D 1 
 
parC S87L 0.125 
 
parC S87W 0.125 
 
∆nfxB 2 
 
∆mexR 0.5 
 ∆mexS 2 
efflux ∆mexZ 0.25 
mutations  ∆nfxB + ΔmexZ 2 
 
∆mexR + ΔmexS 2 
 
∆mexR + ΔmexZ 0.5 
  ∆mexS + ΔmexZ 2 
 
gyrA T83I + ∆nfxB 32 
 
gyrA T83I + ∆mexR 8 
 
gyrA T83I + ∆mexS 32 
 
gyrA T83I + ∆mexZ 2 
 
gyrB E468D + ∆nfxB 8 
combination gyrB E468D + ∆mexR 2 
of efflux gyrB E468D + ∆mexS 8 
and QRDR gyrB E468D + ∆mexZ 1 
mutations  gyrA T83I + parC S87L 32 
 
gyrA T83I + parC S87W 32 
 
gyrA T83I + parC S87L + ∆nfxB 256 
 
gyrA T83I + parC S87L + ∆mexR 64 
 
gyrA T83I + parC S87L + ∆mexS 256 
  gyrA T83I + parC S87L + ∆mexZ 32 
 CIP, ciprofloxacin; MIC in µg/ml 
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3.1.4 Most clinical P. aeruginosa isolates harboring mutations in the QRDR 
additionally express efflux pumps 
Mutations in genes encoding the two subunits of DNA gyrase raised the ciprofloxacin MIC 8- to 16-
fold over that for the P. aeruginosa reference strain. Those gyrA mutants, as well as the majority of 
the clinical isolates harboring relevant mutations in the QRDRs of gyrA and/or gyrB, exhibited MIC 
values of ≤ 2 μg/ml. However, clinical isolates with a single mutation in gyrA which reached 
corresponding MIC values of 8 μg/ml were identified. The broad MIC range for clinical P. aeruginosa 
gyrA mutants has been observed in several studies previously [202,203], and although it is tempting 
to speculate that this can be explained by differential expression of efflux pumps [199,204], no clear 
association between increased MICs for the gyrA mutants and increased expression of efflux pumps 
could be demonstrated in previous studies [203,205,206]. Along the same lines, it has been 
demonstrated for some individual clinical P. aeruginosa isolates that elevated meropenem MIC levels 
could not be explained by decreased levels of OprD and/or overexpression of the MexAB-OprM and 
MexEF-OprN efflux pumps [207,208], and it was thought that other resistance mechanisms yet to be 
identified might account for the resistance phenotype. Therefore, to test whether differential 
expression of efflux pumps in those isolates could account for the high MIC values, the expression of 
four efflux pumps—MexAB-OprM, MexCD-OprJ, MexEF-OprN and MexXY-OprM— was monitored in 
29 selected clinical isolates. Nine of these isolates did not harbor mutations in any of the QRDRs; ten 
isolates harbored a single gyrA mutation; and ten isolates had mutations in gyrA in combination with 
parC. The transcription of the genes encoding the membrane fusion proteins of the pumps (mexA, 
mexC, mexE, and mexX) was quantified using qRT-PCR, and the results are shown in Table 3.2. 
  
Results 39 
 
 
Table 3.2: Expression of mexA, mexC, mexE and mexX in 29 clinical isolates and in four in vitro 
generated PA14 knock-out mutants compared to PA14 wild type strain. 
  Fold change in expression of
a)
     
Isolate mexA mexC mexE mexX CIP MIC* QRDR mutation 
MHH10049 0.99 11.6 n.d. 50.57 0.5 wt 
MHH12178 1.72 3.22 3.50 11.87 0.5 wt 
MHH7624 0.93 2.10 1.88 17.25 1 wt 
MHH9229 1.19 18.24 1.82 6.45 1 wt 
MHH9639 0.22 8.52 3.18 93.65 1 wt 
MHH10047 2.48 3.01 5.63 21.86 1 wt 
MHH11935 2.01 5.43 13.05 21.27 1 wt 
MHH9748 0.95 1.24 43.69 4.47 2 wt 
MHH9830 2.87 10.60 33.72 76.38 2 wt 
MHH7508 0.38 3.03 10.75 7.16 1 gyrA D87N 
MHH7807 1.18 1.42 4.94 45.14 1 gyrA D87Y 
MHH7091 0.87 0.80 1.58 63.14 1 gyrA T83I 
MHH11445 1.47 2.00 3.87 110.02 1 gyrA T83I 
MHH7252 1.16 1.93 2.39 6.34 2 gyrA T83I 
MHH14088 0.62 14.94 2.83 74.33 2 gyrA T83I 
MHH7313 1.31 3.04 5.66 15.72 4 gyrA T83I 
MHH11148 0.73 0.67 0.74 27.32 4 gyrA T83I 
MHH12274 0.85 1.25 1.92 55.25 4 gyrA T83I 
MHH7055 4.38 1.88 2.69 38.43 8 gyrA T83I 
MHH6964 0.87 1.13 4.02 42.34 8 gyrA T83I + parC S87L 
MHH6829 1.01 0.9 13.53 6.71 >8 gyrA T83I + parC S87L 
MHH6870 0.92 1.27 5.55 53.41 >8 gyrA T83I + parC S87L 
MHH7176 1.11 1.39 5.36 54.14 >8 gyrA T83I + parC S87L 
MHH7823 0.95 0.73 3.23 37.57 >8 gyrA T83I + parC S87L 
MHH7863 1.17 0.75 4.92 31.39 >8 gyrA T83I + parC S87L 
MHH8349 1.22 1.25 4.46 45.60 >8 gyrA T83I + parC S87L 
MHH8478 1.13 1.83 6.00 56.84 >8 gyrA T83I + parC S87L 
MHH8614 1,00 1.69 6.13 49.78 >8 gyrA T83I + parC S87L 
MHH9652 1.19 1.08 4.43 41.37 >8 gyrA T83I + parC S87L 
∆nfxB 0.59 16.08 0.70 0.58 2 knockout of nfxB in PA14 
∆mexR 1.58 0.64 0.81 0.73 0.5 knockout of mexR in PA14 
∆mexS 0.65 0.33 318.2 0.67 2 knockout of mexS in PA14 
∆mexZ 0.81 0.75 2.30 6.17 0.25 knockout of mexZ in PA14 
CIP, ciprofloxacin; n.d., not determined; wt, wild type or silent mutation 
a) Overexpression is indicated by boldface values and borderline expression values are underlined and italicized (according 
to the work of Cabot et al.[163]). 
*The ciprofloxacin MIC values are given in µg/ml, the classification into resistance (R), intermediate (I) and susceptible (S) 
isolates is according to CLSI guidelines [142]. 
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According to work done by Cabot et al. [163], ≥ 3-fold overexpression of mexA was regarded as 
positive, whereas values between 2- and 3-fold were regarded as borderline expression. For mexC, 
mexE, and mexX, ≥ 10-fold overexpression was regarded as positive, and 5- to 10-fold overexpression 
was regarded as borderline expression. The majority of clinical isolates exhibited increased 
expression of at least one efflux pump; MexXY-OprM expression was increased the most. This result 
has also been observed previously [209]. However, no clear association between the expression of 
efflux pumps and increased fluoroquinolone MIC values for isolates harboring mutations in the 
QRDRs could be observed (see Figure 3.3). 
 
 
Figure 3.3: Influence of multidrug efflux (MEX) pump overexpression and QRDR mutation on 
ciprofloxacin MIC.  
The variations of MIC values for a particular genotype cannot be explained by the additional expression of MEX pumps. The 
figure shows the expression of four MEX pumps in 29 selected clinical P. aeruginosa isolates. Each circle represents one 
clinical isolate while each quarter represents one efflux pump (top left: MexAB-OprM, top right: MexCD-OprJ, bottom left: 
MexEF-OprN and bottom right: MexXY-OprM) with black quarters representing an overexpression of a pump, gray quarters 
representing borderline expression and white quarter representing wild -type expression levels (according to Cabot et al. 
2011 [163]). The isolates were arranged according to their QRDR genotype (wild type, single mutation in gyrA or 
simultaneous mutation in gyrA and parC) and their ciprofloxacin MIC. Figure published in [147]. 
3.1.5 Inactivation of the efflux regulator-encoding genes mexR, nfxB, mexS, and 
mexZ in the susceptible P. aeruginosa reference strain 
In order to pinpoint the contributions of overexpression of the MexAB-OprM, MexCD-OprJ, MexEF-
OprN, and MexXY-OprM efflux pumps to fluoroquinolone resistance, the respective efflux regulator-
encoding genes in the fluoroquinolone-susceptible reference strain PA14 were inactivated and the 
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resistance profile measured suing the Vitek2 system (bioMérieux, Nürtingen, Germany). Deletion of 
the efflux regulator-encoding gene mexR, nfxB, or mexZ or of the oxidoreductase-encoding gene 
mexS led to overexpression of the efflux pump MexAB-OprM by 1.6-fold, MexCD-OprJ by 16-fold, 
MexXY-OprM by 6-fold, or MexEF-OprN by 320-fold, respectively (Table 3.2). Additionally, the efflux 
regulator-encoding genes were inactivated in the PA14 strain background in various combinations 
(ΔnfxB + ΔmexZ, ΔmexR + ΔmexS, ΔmexR + ΔmexZ, and ΔmexS + ΔmexZ) and also combined with 
mutations in the QRDRs (gyrA, gyrB, and gyrA in combination with parC, respectively). As shown in 
Table 3.1, overexpression of the efflux pumps clearly increased the ciprofloxacin MIC values for the 
susceptible P. aeruginosa reference strain 2- to 16-fold. Inactivation of nfxB or mexS had the most 
pronounced phenotype. The combined inactivation of various efflux regulator-encoding genes (ΔnfxB 
+ ΔmexZ, ΔmexR + ΔmexS, ΔmexR + ΔmexZ, and ΔmexS + ΔmexZ) did not lead to further increases in 
MIC levels. This absence of an additive effect might be explained by antagonistic interactions of 
efflux pumps during planktonic growth, which have been found to occur in nfxB mutants [210]. 
However, the inactivation of efflux regulator-encoding genes in the PA14 gyrA, gyrB, and gyrA/parC 
mutant backgrounds clearly enhanced the fluoroquinolone resistance level further in an additive 
manner. In agreement with these results, the deletion of efflux pumps in resistant P. aeruginosa 
strains with multiple target alterations has been demonstrated previously to lead to a reduced 
fluoroquinolone MIC [211]. It might thus be surprising that a clear correlation between increased 
fluoroquinolone MIC values for clinical isolates harboring a particular QRDR genotype and the 
expression of major efflux pumps could not be identified. 
3.1.6 Mutation in the QRDR of gyrA adds to preexisting isolate-specific resistance 
levels 
Although overexpression of efflux pumps further enhanced fluoroquinolone resistance in a QRDR 
mutant background, a clear association between the expression of efflux pumps and increased 
fluoroquinolone MIC values in the set of clinical isolates could not be identified. Therefore we 
wondered whether the contribution of a gyrA mutation to the fluoroquinolone resistance level could 
differ for different isolates. To address this question, the wild-type gyrA was cloned gene into the 
pME6032 vector, resulting in vector pME::gyrA, and introduced into various clinical isolates in trans. 
All of those clinical isolates exhibited gyrA mutations, but the MIC values ranged from 0.25 μg/ml to 
2 μg/ml (see Table 3.3). 
 
 
Results 42 
 
 
Table 3.3: Complementation of clinical isolates with plasmid pME::gyrA 
  CIP MIC in µg/ml 
Dif
a)
 log2 
Mutation 
Isolate -IPTG +IPTG in gyrA 
7252 2 0.5 2 T83I 
7444 4 0.5 3 T83I 
7807 0.25 0.25 0 D87Y 
8044 1 0.25 2 T83A 
8931 1 0.25 2 D87N 
9481 1 0.25 2 T83I 
9674 8 2 2 D87Y 
12207 1 0.5 1 T83I 
13224 1 0.5 1 D87N 
13428 0.5 0.125 2 D87N 
14088 0.5 0.125 2 T83I 
PA14 gyrA T83I 1 0.125 3 T83I 
PA14 wt 0.125 0.125 0 wt 
a) Dif, difference in log2 of ciprofloxacin MIC 
 
In all but one cases, complementation with the wild-type gyrA gene led to a 2- to 8-fold reduction in 
fluoroquinolone resistance irrespective of the original resistance level. These results indicate that 
mutations within the gyrA QRDR add to preexisting isolate-specific resistance levels of unknown 
origin. Two comprehensive screenings of a P. aeruginosa PA14 mutant library have shown that 
approximately 100 to 200 genes are involved in the ciprofloxacin resistome [133,136] It thus will be 
interesting to determine which of the identified gene inactivations, if any, play a role in 
fluoroquinolone resistance in clinical settings.  
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3.2 Antibiotic resistance profiling in clinical Pseudomonas aeruginosa 
isolates using global transcriptomics 
To gain deeper insights into the ciprofloxacin resistome of P. aeruginosa, the complete transcriptome 
of a collection of 159 clinical isolates from diverse origins, sampled from several hospitals across 
Europe, was studied. The majority of these isolates was collected at the Hannover Medical School 
[n=87]. A further set of a 72 clinical isolates from the Charité Berlin [n=10] and three strains 
collections, containing isolates from several hospitals, were included (Robert Koch Institute, 
Wernigerode [n=14]; University of Freiburg [n=40]; National Reference Laboratory, Bochum [n=8]).  
Here, this collection of clinical isolates was used to explore the molecular mechanisms contributing 
to ciprofloxacin resistance in P. aeruginosa. 
3.2.1 Phylogenetic distribution of clinical P. aeruginosa isolates 
The 159 clinical strains exhibited a broad taxonomical distribution as depicted in the phylogenetic 
tree, which was constructed on the basis of the sequence of 148 commonly expressed genes (Figure 
3.4). The tree is separated into three clusters of isolates being closely related to the reference strains 
PAO1, PA14 and PA7, respectively. The largest cluster, highlighted in light gray in Figure 3.4, 
contained 92 clinical isolates and the strains PAO1, PACS2, and LESB58. Another big cluster included 
64 clinical isolates and the PA14 reference strain, highlighted in dark gray in Figure 3.4. Three isolates 
(MHH6887, MHH13682, MHH13684) were taxonomically distant from all others and closer related to 
the known outlier PA7 [212]. 
When analyzing the phylogenetic relationship of all isolates in greater detail, a cluster of 15 isolates 
showed very high sequence similarities in the 148 genes used to construct the phylogenetic tree. 
These 15 isolates originated all from the Hannover Medical School and were furthermore isolated 
within a short period of just a few months. These isolates were all part of the PAO1 cluster, as 
indicated by an arrow in Figure 3.4. Because of this close phylogenetic relationship and the short 
temporal distance these isolates were collected, they are very likely to resemble a clonal spread of a 
single successful strain within one hospital. Since this possible clonal outbreak might influence 
follow-up analyses, these 15 isolates were excluded from all subsequent transcriptome-wide 
association studies. 
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Figure 3.4: Phylogenetic relationship of clinical P. aeruginosa  isolates based on 148 genes.  
A: The unrooted neighbor-joining tree includes all 159 clinical isolates and additionally five reference strains (PA14, PAO1, 
LESB58, PACS2 and PA7). The phylogenetic relationship is based on a distance matrix calculated from k-mers (17-mers) of all 
genes that were covered by reads to at least 90 % in all isolates and had a respective ortholog in all reference strains (in 
total 148 genes) in MEGA 6 [161]. The scale indicates the number of base substitutions per site. Isolates clustering together 
with the PAO1 reference strain are highlighted in light gray and all isolates in the PA14 cluster in dark gray. Isolates are 
colored according to their origin as indicated in the legend. Arrow indicates possible clonal outbreak at Hannover Medical 
School. 
B: The true phylogenetic distance between the PAO1 and the PA14 clusters towards the PA7 cluster is indicated here. 
 
The antibiotic susceptibility profiles of all 159 isolates (see Table 2.2) were determined using the 
automated Vitek2 system (bioMérieux). According to CLSI antibiotic resistance breakpoints [142], 
most of the isolates were categorized as multidrug-resistant with non-susceptibility to three or more 
antimicrobial classes [213] (data not shown). Antibiotic resistance profiling demonstrated that 82 
isolates (51.6 %) were resistant to ciprofloxacin with MIC values exceeding 2 µg/ml. 31 isolates (19.5 
%) showed an intermediate resistance phenotype with an MIC value of 2 µg/ml and 46 isolates (28.9 
Results 45 
 
 
%) were classified as susceptible with MIC values below 2 µg/ml. Figure 3.5 shows the ciprofloxacin 
resistance profile in association with the phylogenetic relationship and reveals a broad distribution of 
ciprofloxacin non-susceptibility with only a weak association of resistance to phylogenetic distance. 
 
 
 
Figure 3.5: Phylogenetic association of ciprofloxacin susceptibility within 159 clinical isolates.  
The phylogenetic tree includes all 159 clinical isolates and additionally five reference strains (PA14, PAO1, LESB58, PACS2 
and PA7). The phylogenetic relationship is based on a distance matrix calculated from k-mers (17-mers) of all genes that 
were covered by reads to at least 90 % in all isolates and had a respective ortholog in all reference strains (in total 148 
genes). The tree was built using the neighbor-joining algorithm and PA7 as a outgroup in MEGA 6 [161] and is shown 
irrespective of the tree branch length. Reference strains are framed in blue. The ciprofloxacin resistance profile (according 
to CLSI [142]) is indicated by colored bars (see legend) and was integrated using iTOL [185]. 
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3.2.2 Nature and dimension of chromosomal ciprofloxacin resistance conferring 
mutations in P. aeruginosa 
In order to provide a detailed analysis of ciprofloxacin resistance conferring mechanisms, the 
transcriptomic data of the 159 clinical isolates were used to extract genomic information about 
sequence variations within the QRDRs of the of gyrA, gyrB, parC and parE. Therefore, SNPs and short 
indels were extracted using SAMtools [181] and further verified using the Integrative Genomics 
Viewer [188]. In 13 isolates, where the coverage of cDNA sequencing reads was not satisfying, the 
respective sequence information was taken, if possible, from the analyses in chapter 3.1. Sequence 
coverage was below the threshold of three sequencing reads per position for parC (n=9), gyrB (n=1) 
and parE (n=7) of 13 isolates in total. In the case of a single isolate the sequence information of parE 
could not be added, since this isolate was not included in the previous analyses. 
A total of 123 isolates (77.4 %) harbored at least one mutation within the QRDRs with the majority of 
these showing either a single mutation in gyrA (n=45) or a combination of a gyrA mutation with a 
mutation in parC (n=47), parE (n=5) and gyrB (n=2), respectively. 20 isolates harbored a single 
mutation in gyrB (n=18) or parE (n=2), four isolates had a triple mutation in gyrA, gyrB and parC and 
36 isolates had no amino acid alterations within the QRDRs (see Figure 3.6). 
 
 
Figure 3.6: Mutations identified by RNA-seq in gyrA,  gyrB , parC,  and parE  of 159 clinical isolates.  
A: Co-occurrence of mutations in the QRDRs of gyrA, gyrB, parC, and parE in individual clinical P. aeruginosa isolates. The 
proportions of isolates with a single (light shaded sectors), double (dark shaded sectors), or triple (filled sectors) mutation, 
or with no identified QRDR mutation (open sectors), are shown. 
B: Frequency and nature of mutations found in the QRDRs of gyrA, gyrB, parC, and parE in 159 clinical Pseudomonas 
aeruginosa isolates. Each mutation (given as the wild-type allele, amino acid position, and mutant allele) is followed by a 
semicolon and the number of isolates harboring the mutation. wt, wild-type allele or silent mutation. 
 
The association of mutations within the QRDRs of gyrA, gyrB, parC, and parE with the ciprofloxacin 
MIC is depicted in Table 3.4. It shows that a singular mutation in gyrA raised the median ciprofloxacin 
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MIC from 0.5 to 4 µg/ml in the panel of clinical isolates. In combination with a mutation in parC (47 
isolates) the median MIC increased to more than 8 µg/ml. Thus, there was a high correlation 
(r=0.766; Spearman nonparametric correlation) between the presence of a particular SNP in gyrA 
(T83I) and parC (either S87L, S87W or E91K) and ciprofloxacin MICs above 8 µg/ml. A minor fraction 
of isolates showed mutations in parE and gyrB, which had a less pronounced effect on the median 
ciprofloxacin MIC with values of 0.75 µg/ml and 2 µg/ml, respectively. With just two exceptions, any 
MIC of more than 4 µg/ml required a mutation in gyrA, rendering the detection of gyrA target 
mutations as suitable resistance markers. 
 
Table 3.4: Association of single and multiple QRDR mutations with ciprofloxacin MIC. 
QRDR mutation Isolates [n] 
MIC ciprofloxacin in µg/ml 
0.125 0.25 0.5 1 2 4 8 >8 Median 
no mutation 36 8 4 9 9 4 
 
1 1 0.5 
parE 2 
  
1 1 
    
0.75 
gyrB 17 
   
6 11 
   
2 
gyrA 45 
   
5 15 10 10 5 4 
gyrB + parE 1 
     
1 
  
4 
gyrA + gyrB 2 
    
1 
 
1 
 
5 
gyrA + parE 5 
     
1 1 3 > 8 
gyrA + parC 47 
      
10 37 > 8 
gyrA + gyrB + parC 4       1 3 > 8 
The table shows the association of mutations within the QRDRs with the ciprofloxacin minimal inhibitory concentration. 
Isolates having MIC values above 8 µg/ml were merged and listed as >8. See supplementary table S2 for a detailed list of 
mutations. 
3.2.3 Expression of multidrug efflux pumps in clinical isolates 
Besides target mutations of gyrase and topoisomerase IV, up-regulation of multidrug efflux pumps 
has been shown to be an initial and very common event that contributes to the development of low-
level resistance in the clinical setting [214,215]. To further investigate the involvement of an 
enhanced efflux in clinical isolates on a broader and unbiased basis, the whole panel of 159 isolates 
was screened for the expression of eleven known RND efflux pumps. 
Figure 3.7 visualizes the expression of all known RND efflux systems in P. aeruginosa, which typically 
consist of genes encoding a membrane fusion protein, an efflux transporter and an outer membrane 
protein. Since the cognate outer membrane protein of MexXY (OprA) is not present in PA14 [216], 
the plot also includes the genes encoding the outer membrane proteins OpmG, Omph and OmpI 
which do not belong to RND efflux pump operons and are known to be possible MexXY interaction 
partners [217,218]. The normalized reads per kilobase of gene sequence (nRPK) values of each gene 
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are plotted with red indicating a high expression (maximal value of 18) and blue indication low 
expression. The plot shows that in terms of absolute expression mexAB-oprM is expressed at highest 
and mexMN and mexPQ-opmE are expressed at lowest levels. Furthermore it indicates that efflux 
pump expression varies largely between the isolates and this variation is independent from the 
phylogenetic background. 
 
 
Figure 3.7: Absolute expression of eleven RND efflux pump in P. aeruginosa  clinical isolates. 
The Circos [219] plot shows the normalized read counts in nRPK of 11 RND efflux pumps and three outer membrane 
proteins. Expression varies from 18 nRPK (red) to 0 nRPK (blue) according to the legend on the left. Genes are arranged in 
segments representing the 11 RND efflux pumps operons and are separated by black lines. The names of all genes are 
indicated outside of the rings. Isolates are arranged according to their phylogenetic relationship shown in Figure 3.5 starting 
with MHH6887 as the outermost ring. With the exception of MHH8607 (shown as the innermost ring), isolates involved in 
the possible clinical outbreak are not shown. 
 
An efflux pump was regarded as overexpressed, in comparison to the PA14 reference strain, when 
both membrane fusion protein and efflux transporter showed at least a two-fold increase in 
expression as determined by DESeq as well as a P-value of less than 0.05 (after Benjamini-Hochberg 
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correction). Using these thresholds, 122 out of the panel of 159 clinical isolates overexpressed 
mexXY, which was therefore by far the most frequently overexpressed efflux pump. Besides mexXY, 
mexAB (48 isolates), mexCD (38 isolates) and mexEF (38 isolates) were also commonly overexpressed 
in comparison to PA14 (see Table 3.5). Out of the remaining seven efflux systems, only muxACB (18 
isolates), mexJK (9 isolates) and mexMN (2 isolates) were overexpressed to some extent, the 
remaining four efflux pumps were never overexpressed. 
 
Table 3.5: Overexpression of RND efflux pumps in 159 clinical isolates as compared to PA14 
Hypothetical 
protein 
Membrane 
fusion 
protein 
Secondary 
Membrane 
fusion 
protein 
Efflux 
transporter 
Secondary 
Efflux 
transporter 
Outer 
membrane 
protein 
Over-
expressing 
isolates [n] 
 
mexA  mexB 
 
oprM 48 
 
mexC  mexD 
 
oprJ 38 
 
mexE  mexF 
 
oprN 38 
 
mexX  mexY 
  
122 
mexG mexH  mexI 
 
opmD 0 
 
mexJ  mexK 
  
9 
 
mexM  mexN 
  
2 
 
mexP  mexQ 
 
opmE 0 
 
mexV  mexW 
  
0 
 
triA triB triC 
  
0 
 
muxA 
 
muxC muxB opmB 18 
The table shows the number of isolates overexpressing one or more of the 11 RND efflux pumps from P. aeruginosa. 
3.2.4 Sequence analysis of efflux pump regulatory genes 
To evaluate how mutations in regulatory genes correlated to efflux pump overexpression, the 
genetic alterations in the negative regulators mexR, nfxB and mexZ as well as in the oxidoreductase 
mexS were examined. SNPs were called using SAMtools with a Phred quality score above 30 and 
indels with a score above 150. Mutations were further manually verified using the Integrative 
Genomics Viewer [188]. Figure 3.8 shows that overexpression of efflux pumps can be explained in 
most isolates by mutations within the respective negative regulatory protein encoding genes. Only 
mexAB and mexXY seem to be in many cases overexpressed without showing mutations within their 
adjacent regulatory gene mexR and mexZ, respectively. This might be explained by the highly 
complex regulatory structure of these two operons and the involvement of several transcriptional 
regulators in the expression of these two efflux pumps [89-91]. 
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Figure 3.8: Correlation of efflux pumps expression and mutations in regulatory genes.  
The percentage of isolates showing overexpression of one of the four efflux pumps (mexAB, mexCD, mexEF and mexXY, 
respectively) is depicted in red, the rate of isolates without overexpression is shown in blue. Additionally, the percentage of 
isolates that harbor at least one mutation (either non-synonymous SNP or indel) in the corresponding negative regulatory 
gene (mexR, nfxB, mexS and mexZ, respectively) is indicated as dark colors, whereas light colors indicate regulatory genes 
with wildtype nucleotide sequence. SNPs occurring between PA14 and PAO1 reference strains were excluded from the 
analysis. 
3.2.5 Correlation of enhanced efflux and fluoroquinolone resistance 
We next correlated efflux pump expression to the ciprofloxacin resistance phenotype of these 
isolates. Although the specific influence of the four main efflux systems (mexAB, mexCD, mexEF and 
mexXY) on ciprofloxacin susceptibility could be clearly shown in isogenic mutants, here, a high 
number of susceptible isolates exhibited strong overexpression of these four efflux pumps. Out of 46 
ciprofloxacin susceptible isolates only six showed no overexpression of these four efflux pumps, 
whereas 21, 11 and eight isolates overexpressed one, two and three efflux pumps, respectively. 
Furthermore, we found large variations of the ciprofloxacin MIC within isolates of the same 
genotype. For example, both isolates Ch2680 and Ch2682 do not have mutations in the QRDRs and 
furthermore overexpress mexAB at similar levels (nRPK of mexA in Ch2680 12.97 and in Ch2682 
13.11), whereas the ciprofloxacin MIC varies from 1 µg/ml (Ch2680) to ≤ 0.25 µg/ml (Ch2682). One 
possible explanation could be the presence of mutations within the structural genes rendering the 
efflux pump nonfunctional. But neither non-synonymous mutations nor indels could be detected in 
these two isolates in the sequence of mexA and mexB, respectively. Another reason could be the 
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presence of other, still unknown, resistance mechanisms that influence the ciprofloxacin resistance 
phenotype. 
3.2.6 Whole transcriptome association studies 
In order to identify possible chromosomally encoded resistance mechanisms, in addition to the 
already identified QRDR mutations, we performed unbiased phenotype-genotype correlations. 
Therefore, whole transcriptome association studies were used to search for the enrichment of SNPs, 
and differentially expressed genes in the non-susceptible isolates vs. the susceptible isolates. The 159 
clinical isolates were classified as non-susceptible, intermediate and susceptible towards 
ciprofloxacin according to current CLSI standards [142]. 82 isolates were categorized as non-
susceptible and 46 isolates as susceptible to ciprofloxacin. 31 isolates showed a MIC of 2 µg/ml and 
were therefore classified as intermediate; these isolates and additionally the isolates which are 
possibly involved in the clonal outbreak were not included in the following studies; summing to 123 
isolates (82 resistant and 41 susceptible) which could be used for whole transcriptome comparisons. 
To test for a group specific accumulation of SNPs, Fisher's exact test was used and differentially 
expressed genes were identified using Wilcoxon’s rank-sum test. In both cases, retrieved P-values 
were adjusted by the Benjamini-Hochberg correction to control the false-discovery rate. 
This transcriptome-wide association study of ciprofloxacin resistant and susceptible isolates for the 
enrichment of adaptive SNPs revealed four non-synonymous mutations to be significantly enriched in 
the ciprofloxacin resistant isolates. Besides these four SNPs causing amino acid alterations, 11 
synonymous SNPs, which do not change the protein sequence, were also significantly enriched (see 
Table 3.6 and Figure 3.9). The two non-synonymous mutations which showed the highest significance 
were located at nucleotide position 2,015,011 in the PA14 reference genome, which corresponds to 
amino acid position 83 within the DNA-gyrase GyrA (T83I), and nucleotide position 5,845,617 which 
corresponds to amino acid position 87 within the topoisomerase IV ParC (either S87L or S87W). Out 
of the 82 resistant isolates, 76 harbored gyrA T83I, whereas only five out of the 42 susceptible 
isolates showed this mutation. The parC mutations S87L and S87W were identified in 38 resistant 
isolates and no susceptible isolate harbored these mutations. 
The other two genes with significantly enriched non-synonymous mutations were kynU (E115D) and 
glmU (H288R). Both, the kynureninase encoded by kynU and glmU, encoding a bifunctional 
uridyltransferase, as well as all genes with synonymous substitutions have not been associated with 
ciprofloxacin resistance in three previous genome-wide mutagenesis screens of antibiotic resistance 
determinants in P. aeruginosa [133,135,136]. 
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When comparing only highly resistant isolates, which showed a MIC of 8 µg/ml or more, with the 
susceptible ones, only the mutations of gyrA and parC were significantly enriched with P-values of 
5.59E-13 and 1.51E-5, respectively. 
 
Table 3.6: Significantly enriched SNPs when comparing resistant vs. susceptible isolates 
Gene locus Gene name Genomic position in PA14 Mutation P-value 
PA14_23260 gyrA 2,015,001 C/T (non-syn) 6.62E-05 
PA14_59910 - 5,334,364 A/G (syn) 0.0021 
PA14_65605 parC 5,845,617 G/C,A (non-syn) 0.0024 
PA14_37610 kynU 3,346,395 A/C (non-syn) 0.0034 
PA14_59910 - 5,334,353 T/C (syn) 0.0057 
PA14_73220 glmU 6,519,825 A/G (syn) 0.0103 
PA14_39330 rbsA 3,501,621 G/A,C (syn) 0.0117 
PA14_50460 flgD 4,484,406 C/G,A (syn) 0.0118 
PA14_35500 bkdB 3,156,528 C/T (syn) 0.0141 
intergenic - 3,621,954 A/G (syn) 00199 
PA14_66400 aefA 5,924,077 C/T (syn) 0.0330 
PA14_07680 prkA 661,363 G/A (syn) 0.0359 
PA14_39330 rbsA 3,501,606 A/G (syn) 0.0362 
PA14_73220 glmU 6,520,084 T/C (non-syn) 0.0373 
PA14_66820 phaC1 5,967,799 C/T (syn) 0.0431 
syn, synonymous; non-syn, non-synonymous 
 
 
 
Figure 3.9: Manhattan plot of SNPs associated with ciprofloxacin resistance.  
The plot shows the genomic position of the PA14 chromosome on the x-axis and the corresponding P-value of each SNP on 
the y-axis (indicated as -10*log10[P-value]) when comparing ciprofloxacin resistant (n=82) versus susceptible isolates 
(n=41). The red dotted line indicates P = 0.05, with genes above having P-values < 0.05. Significantly enriched SNPs are 
colored according to the legend given on the right. 
non-syn, non-synonymous; syn, synonymous; n.s., not significant. 
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Whereas the transcriptome-wide association study of mutations involved in ciprofloxacin resistance 
revealed the presence of SNPs in gyrA and parC as highly significant resistance markers, no 
differentially expressed genes could be identified in the resistance isolates compared to the 
susceptible ones (data not shown). Although numerous genes were enriched after using Wilcoxon’s 
rank-sum test to compare the expression of all genes within these two groups, no hits remained 
significant after applying the Benjamini-Hochberg correction and thus all were regarded as false 
positive hits. 
These findings further highlight the previous results, that ciprofloxacin resistance is predominantly 
determined by mutations in gyrA, especially by the amino acid substitution of threonine to isoleucine 
at position 83, and the occurrence of secondary mutations at amino acid position 87 in ParC, which 
further increases the level of resistance. 
3.2.7 Comparative analysis of RNA-seq accuracy 
To assess the accuracy of RNA-seq concerning gene expression levels and sequence variations, we 
compared the results obtained here with our previous analyses described in chapter 3.1. 87 out of 
the 159 clinical isolates which have been studied by RNA-seq were also analyzed previously by 
Sanger- and pyrosequencing to identify mutations within the QRDRs of gyrA, gyrB, parC and parE. 
The comparison of both results showed a perfect agreement and no inconsistencies between Sanger-
/pyrosequencing and RNA-seq were found, revealing a high accuracy of the transcriptomic approach 
(see supplementary table S2). The only exceptions were the sequences of 17 genes in a total of 13 
isolates; in which the sequence coverage of three reads per position could not be achieved and 
therefore mutations could not be identified. Since samples were pooled for sequencing, a reduction 
of analyzed samples in a single sequencing run is expected to result in an enhanced sequencing 
coverage and improved SNP detection. 
Additionally to the mutations identified by Sanger- or pyrosequencing, the RNA-seq based approach 
led to the identification of further amino acid substitutions in gyrA (D72E and D87H), gyrB (Q467) 
and parC (E91K). The amino acid substitutions D87H in gyrA and E91K in parC have already been 
described in previous publications and could be linked to fluoroquinolone resistance in E. coli [220] 
and P. aeruginosa [221]. 
We next examined the accuracy of differential gene expression analysis by RNA-seq by comparing 
the results with our previous results obtained by qRT-PCRs. The expression of the four membrane 
fusion protein encoding genes mexA, mexC, mexE and mexX has been studied previously in 27 out of 
these 159 clinical isolates (see chapter 3.1.4) and therefore it was possible to compare the results of 
RNA-seq and qRT-PCRs. The correlation of fold change values from both methods is depicted in 
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Figure 3.10. The graph illustrates that determination of gene expression highly correlates between 
both methods, with a Pearson correlation coefficient of 0.77 over all genes and samples. In addition 
to the high quantitative correlation, the qualitative comparison of both methods whether an efflux 
pump was regarded as overexpressed or not, was concordant in 90 out of 107 (> 84 %) possible 
comparisons (the expression of mexE could not be measured in one isolate using qRT-PCR). Both 
values of quantitative and qualitative correlation are therefore in the same ranges, which have been 
reported in the literature and this data furthermore indicates the power and accuracy of RNA-seq 
[222]. 
However, the graph displays some minor discrepancies between RNA-seq and qRT-PCR in some 
samples. These discrepancies might be assigned to technical differences between both methods: For 
instance, qRT-PCR primers were designed based on the PA14 reference sequence and therefore 
might not bind efficiently when analyzing clinical samples containing possible mismatches in the 
binding sequence, whereas RNA-seq allows up to one mismatch per sequencing read. A further 
influencing factor might be a different normalization of these datasets; while qRT-PCRs are analyzed 
in comparison to the expression of the house-keeping gene rpoD using the ΔΔCT method [162], RNA-
seq data is analyzed using DESeq, a method which is based on the negative binomial distribution and 
therefore does not rely on a single reference gene [175].  
 
 
Figure 3.10: Comparison of RNA-seq with qRT-PCR for the expression of the membrane fusion protein 
encoding genes of the  four major RND-efflux pumps 
The graph shows the comparison of retrieved RNA-seq expression values versus qRT-PCR values for the four genes mexA 
(yellow), mexC (green), mexE (blue) and mexX (red) in 27 clinical isolates. Fold change expression values are given in 
comparison to the reference strain PA14. The Pearson correlation coefficient r was determined using GraphPad Prism 5.0.  
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3.3 Transcriptome analysis of clinical Klebsiella pneumoniae isolates 
In the last years, numerous studies focused on the epidemiology, phylogeny and the genomic 
structure of K. pneumoniae [223], yet little is known about the global transcriptome profile of this 
important bacterial pathogen. Only a limited number of transcriptional studies on K. pneumoniae 
have been performed so far. However, they deliver valuable and important insights into the 
transcriptional architecture and regulatory aspects of K. pneumoniae [224,225], its adaptation to 
changing environments [226] and the development colistin resistance [227]. 
3.3.1 Phylogenetic distribution of K. pneumoniae clinical isolates 
With the aim to gain detailed insights into the variation of the K. pneumoniae transcriptional 
landscape, we performed deep transcriptome sequencing on 34 clinical isolates. These isolates were 
sampled from various infection sites like blood, urine, wound- and rectal swabs (see Table 2.3) from 
out-patients as well as in-patients of ten German hospitals. The median patient’s age was 65 years 
with a range from 20 to 90 years. Additionally to these 34 clinical isolates, the three previously 
completely sequenced K. pneumoniae clinical strains (MGH 78578 [228], JH1 and 1162281 [143]) 
were also included in this RNA-seq study. 
The K. pneumoniae isolates were grown under standard laboratory conditions in rich medium at 
37 °C until late logarithmic growth phase. After RNA extraction and ribosomal RNA depletion, strand-
specific, barcoded transcriptome sequencing [164] was performed on an Illumina HiSeq 2500. This 
generated a total of 787 million paired-end reads, each with a length of 100 base pairs. Up to 99 % of 
the reads (13.1 to 36.6 million reads per isolate with a median of 20 million reads, see Table 3.7) 
could be mapped to a non-redundant K. pneumoniae pan-genome. This pan-genome was generated 
on the basis of publicly available DNA sequence data of 11 K. pneumoniae isolates (see chapter 2.9) 
to gain comprehensive and unbiased insights into the transcriptional landscape of this pathogen. 
Since deep transcriptome sequencing delivers not only quantitative data on the gene expression 
profile but also high quality sequence data of transcribed coding sequences [222], we used the 
information on cDNA sequence variations among the strains to analyze their phylogenetic 
relationship. Figure 3.11 depicts the phylogenetic distribution of our set of 37 clinical isolates as well 
as of the 11 previously completely sequenced reference strains. The tree is based on the complete 
sequence of 404 genes corresponding to 314,561 nucleotide positions, all of which were covered by 
at least five sequencing reads in our pool of clinical isolates. Overall 35,796 variable sites were 
detected among the strains. In addition to this cDNA based phylogenetic reconstruction, we 
performed multilocus sequence typing (MLST) [186] and wzi typing [149] for all isolates (the results 
are also shown in Figure 3.11). The Klebsiella MLST scheme consists of the partial sequences of eight 
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house-keeping genes: gapA, infB, mdh, pgi, phoE, rpoB and tonB. The nucleotide sequences of gapA, 
infB, mdh, pgi, and rpoB were extracted from the RNA-seq data. Since the coverage of phoE and tonB 
did not match our strict quality criteria, Sanger sequencing was performed for these two genes as 
already described [186]. The full sequence of the wzi gene, encoding the outer membrane protein 
Wzi, which is involved in cell surface capsule attachment and highly conserved in distinct capsular (K) 
types [149,229,230], was also sequenced by Sanger sequencing. 
 
Table 3.7: Mapping statistics of Klebsiella pneumoniae clinical isolates 
isolate total reads  
mapped 
readsa) 
isolate total reads  
Mapped 
readsa) 
isolate_1_1 19,774,122 98.37 % isolate_2_10 16,771,836 98.37 % 
isolate_1_2 19,997,876 98.40 % isolate_2_11 25,988,654 98.07 % 
isolate_1_3 19,805,660 97.86 % isolate_2_14 24,699,566 98.26 % 
isolate_1_4 19,050,880 98.90 % isolate_3_3 32,203,450 93.18 % 
isolate_1_6 20,013,850 98.94 % isolate_3_4 36,613,354 94.41 % 
isolate_1_8 17,296,248 98.75 % isolate_3_5 13,488,566 94.35 % 
isolate_1_9 21,941,834 98.69 % isolate_3_6 22,986,806 93.94 % 
isolate_1_10 21,271,760 97.63 % isolate_3_7 20,621,076 95.74 % 
isolate_1_11 21,707,348 98.86 % isolate_3_8 15,656,488 94.32 % 
isolate_1_12 24,019,352 98.58 % isolate_3_10 18,126,752 93.46 % 
isolate_1_13 17,915,984 98.70 % isolate_3_11 20,594,442 92.68 % 
isolate_1_14 21,448,234 98.11 % isolate_3_12 15,275,544 95.81 % 
isolate_1_15 19,660,480 98.16 % isolate_3_13 20,154,768 95.07 % 
isolate_1_16 26,170,286 98.21 % isolate_3_14 13,119,036 97.53 % 
isolate_2_2 18,681,538 98.55 % isolate_3_17 28,967,092 93.52 % 
isolate_2_4 23,040,802 98.99 % MGH 78578 17,899,166 98.05 % 
isolate_2_7 15,252,086 98.98 % JH1 30,738,730 96.55 % 
isolate_2_8 19,501,346 98.65 % 1162281 27,353,276 94.82 % 
isolate_2_9 19,630,654 98.15 %       
a) Percentage of reads mapping to the non-redundant K. pneumoniae transcriptome 
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Figure 3.11: Phylogenetic relationship, multilocus sequence types and wzi types of all 37 clinical 
isolates and 11 reference strains. 
The unrooted Neighbor Joining tree was constructed using the aligned sequences of 404 genes which were covered by at 
least 5 nucleotides at each position in all isolates. Bootstrapping values of 1000 replications are indicated at each branch. 
MLST and wzi type results are also listed for each isolate. wzi alleles without perfect matches are indicated by “wzi-like” and 
the nucleotide differences to the closest matching allele are shown in brackets. Isolates included in this study are written in 
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bold letters and reference genomes are indicated by a – k (see Table 2.7). Isolates belonging to the same MLST sequence 
type are highlighted in the same color. The scale indicates the number of base substitutions per site. The insert in the upper 
left corner shows the same tree in a radiation style to demonstrate phylogenetic distances 
 
Our analysis revealed a broad phylogenetic distribution of the K. pneumoniae isolates included in this 
study. We detected 12 different multilocus sequence types (ST), one of which (isolate 2_7, MLST 
pattern: 2-2-2-1-1-1-91) has not been described before and also 12 different wzi types, three of 
which have not been described yet. 
13 of the 37 isolates were of ST101 origin. ST101 isolates are distributed world-wide and are known 
to carry beta-lactamase OXA-48 and the extended spectrum beta-lactamase CTX-M-15 [231]. 
Furthermore, they have been reported to be involved in clinical outbreaks in Europe [232,233]. 11 of 
these 13 ST101 isolates have been isolated from the same hospital within a period of five months. 
They showed no sequence variation in the phylogenetic analysis indicating that these isolates are 
likely to have their origin in a single reservoir. 
Additionally, we identified ten and two isolates, belonging to the broadly distributed multidrug-
resistant high-risk clones ST258 and ST512 [234], respectively. Both sequence types are members of 
the clonal group CG258, sharing seven out of eight MLST alleles [235]. Isolates of the sequence type 
258 are reported to be involved in several European and North American hospital outbreaks 
[236,237] and are the primary reason for the spread of KPC [234]. Here, the K. pneumoniae 
carbapenemase KPC-2 was identified in all ten ST258 isolates, whereas both ST512 isolates carried 
KPC-3. Of note, all other 25 sequenced clinical isolates were found to be KPC negative. Recent studies 
described the heterogeneous nature of ST258 isolates with two large clades ST258 I and ST258 II 
[172,230,238]. All ST258 isolates of this study were members of clade ST258 I (described as ST258a in 
[229]) due to the wzi allele wzi-29 (K41). The two ST512 isolates shared the same wzi-154 allele [239] 
with strains NJST258_1 and NJST258_2 of clade ST258 II and KP13 (ST442), indicating that the ST512 
isolates evolved from an ST258 clade II ancestor as suggested previously [230]. 
Another successful and multidrug-resistant clone is ST15 [240-242]. Our collection contained four 
isolates of sequence type ST15 which split into two distinct phylogenetic groups based on 9 variable 
sites within the sequence of the 404 conserved genes. This separation was also supported by wzi 
sequencing, since two isolates (isolate 1_16 and isolate 2_2) shared allele wzi-24 (K24) (clade ST15 I) 
and two isolates (isolate 1_8 and isolate 2_10) shared wzi-93 (K60) (clade ST15 II). wzi-24 (clade I) has 
been identified previously in ST15 as well as ST59 isolates [149] and wzi-93 (clade II) has been 
identified in a New Delhi metallo-beta-lactamase positive isolate from Nepal [243]. The fact that 
within the group of ST15 isolates two different clades exist further illustrates the prominence of the 
K. pneumoniae capsular polysaccharide gene clusters as an evolutionary hotspot. The remaining 
seven isolates were of diverse phylogenetic origin. 
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3.3.2 The K. pneumoniae pan-genome 
K. pneumoniae, like almost all other Gram-negative bacteria, shows a high variation in genome 
content. The size of the completely sequenced and annotated 11 genomes, which were used as a 
reference in this study, varies from 5.2 to 6.1 Mbp encoding for 4887 to 5577 genes per genome (see 
Table 2.7). Thus, in order to map a maximum of RNA sequencing reads from our collection of clinical 
isolates, we generated a K. pneumoniae pan-genome. This pan-genome is based on the 11 
K. pneumoniae genomes which contain overall 57,312 chromosomal genes, with an average of 5,210 
genes per strain. The non-redundant K. pneumoniae pan-genome contained 7859 genes (see 
supplementary table S3). 3336 of those genes were shared by all 11 reference strains (“core-
genome”) and 4523 genes were absent in at least one of the strains. Among the latter, 1598 genes 
were identified in only one of the reference genomes (“singletons”). Figure 3.12 depicts the 
development of the size of the pan-genome, core-genome and singletons by sequentially adding the 
genomic information of one genome to that of the others. 
Based on the averages, it shows an exponential expansion for all 3 groups with the following 
formulae: pan-genome: f(x) = 4958.2 x0,1807, R2=1.0; core-genome: f(x) = 4891.5 x-0,16, R2=0.998 and 
singletons: f(x) = 1135.7 x0,1481, R2=0.996). With x representing the number of completely sequenced 
genomes. Based on this extrapolated data, it is expected that the size of these groups would change 
by less than 2 % if genomic information of another genome would be added, less than 1 % by adding 
information of 20 genomes, and less than 0.5 % by adding 40 genomes in total. 
 
 
Figure 3.12: Analysis of the Klebsiella pneumoniae  genomic content.  
The amount of genes belonging to the pan-genome (blue dots) core genome (green dots) and unique genes (red dots) is 
plotted as a function of genomes sequentially added in all possible combinations. The number of genes in the single 
genomes is shown as gray dots. Black bars show mean with 95 % confidence intervals. 
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To further explore the genomic content of the pan-genome, we extracted for each gene the gene 
ontology (GO) information and simultaneously deduced the gene function using the COG database 
[244], where possible. As expected, the GO term analysis revealed an enrichment of house-keeping 
genes in the core-genome, which are essential to maintain cellular function and integrity (see Figure 
3.13). 
 
Figure 3.13: Functional annotation and analysis of different sets of genes.  
This bar chart shows the relative enrichment of each functional category of genes within the core-genome, singletons, core-
transcriptome, as well as never, stably and flexibly expressed genes in comparison to the pan-genome (dashed line). 
Results 61 
 
 
Functional annotation was extracted from the COG database. The level of significance is indicated by asterisks with * < 0.05; 
** < 0.01; *** < 0.001; hypergeometric test and Benjamini-Hochberg correction. 
Functional categories are: 
J Translation, ribosomal structure and 
biogenesis 
K Transcription 
L Replication, recombination and repair 
D Cell cycle control, cell division, chromosome 
partitioning 
V Defense mechanisms 
T Signal transduction mechanisms 
M Cell wall/membrane/envelope biogenesis 
N Cell motility 
U Intracellular trafficking, secretion, and vesicular 
transport 
O Posttranslational modification, protein 
turnover, chaperones 
C Energy production and conversion 
G Carbohydrate transport and metabolism 
E Amino acid transport and metabolism 
F Nucleotide transport and metabolism 
H Coenzyme transport and metabolism 
I Lipid transport and metabolism 
P Inorganic ion transport and metabolism 
Q Secondary metabolites biosynthesis, transport 
and catabolism 
R General function prediction only 
S Function unknown 
X not annotated 
3.3.3 The K. pneumoniae transcriptional landscape 
The distribution of normalized reads per kilo base (nRPK) [164], after mapping all RNA sequencing 
reads against the non-redundant K. pneumoniae pan-genome, was found to be continuous and 
unimodal (see Figure 3.14), with a median nRPK of 4.22 and a maximum of 24.01. Depending on the 
isolate, between 4744 and 5378 genes exhibited an expression value above the sensitivity limit of 
2.20 nRPK (see chapter 2.10.1 for definition), thus demonstrating a very high number of transcribed 
genes per isolate under the chosen conditions. Of all 7859 genes in the pan-genome, we identified a 
large set of 3346 genes to be commonly expressed in all isolates above the threshold level. This core-
transcriptome (highlighted in green in Figure 3.14B) accounted for 62 % to 71 % of all transcribed 
genes within one isolate and largely overlapped with the core-genome (2515 genes or 75 % of the 
core-genome was commonly transcribed). Due to this large overlap between core-genome and core-
transcriptome, it was not surprising that the core-transcriptome likewise consisted mostly of genes 
with house-keeping functions, as revealed by a GO term enrichment analysis (Figure 3.13). 
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Figure 3.14: The Klebsiella pneumoniae  transcriptional landscape.  
A: Histogram showing the expression in nRPK of all 7859 genes in the pan-genome over all 37 isolates. 
B: Expression levels of all genes in the K. pneumoniae pan-genome. The median, maximal and minimal expression value (in 
nRPK) of each gene is plotted. Genes are ranked according to their median gene expression on the x-axis (blue line). The 
yellow line denotes the expression sensitivity limit (nRPK0=2.20). All genes with a maximal expression value below the 
sensitivity limit are regarded as never expressed under the given growth conditions and highlighted in red (n=719). All 
genes with a minimal gene expression value above the sensitivity limit are regarded as expressed in every isolate (core-
transcriptome, n = 3346) and are highlighted in green. 
 
On the other end of the scale we found 719 genes within the pan-genome that exhibited maximal 
expression values below the sensitivity limit (highlighted in red in Figure 3.14B). Those genes were 
not expressed in any clinical isolate under standard laboratory conditions. Interestingly, only eight of 
them belonged to the core-genome, whereas 473 (almost 66 %) of these never expressed genes 
were singletons and occurred only in single reference genomes. 
With the aim to map RNA sequencing reads also to potentially non-chromosomally encoded genes, 
we performed a de novo assembly of all reads from the 37 isolates that did not map to the reference 
pan-genome. We found a total of 1482 genes with an average of 251 genes per isolate and a range 
from 57 to 419 that did not map to our reference pan-genome. 1258 (85 %) of these genes had 
homologs with at least 80 % sequence identity to genes that have been previously identified in 
Klebsiella spp.. 150 of the remaining 187 genes had homologs in other members of the 
Enterobacteriaceae family. While the majority of 60 % (900 out of 1486 genes) was encoding for 
hypothetical (including putative and predicted) proteins, many genes were found to be related to 
antibiotic and metal resistance, integrase/transposase, phage-related and involved in plasmid 
integrity. The complete list of genes potentially encoded on plasmids, integrons or other mobile 
elements is shown in supplementary table S4. 
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3.3.4 The K. pneumoniae gene expression variance 
To gain further insights into the expression variance, we calculated the differential expression of 
each gene in any possible pairwise comparison of two of the 37 isolates (overall 666 comparisons). 
Pairwise gene comparison data were considered only if a gene in both isolates reached expression 
values above the sensitivity limit of 2.20 nRPK. The expression variance of one gene was defined as 
the fraction (between 0 and 1) of pairwise comparisons showing at least a two-fold differential 
expression as determined by DESeq [175]. Thus, for example, an expression variance of 0.1 means 
that 10% of the pairwise comparisons showed at least a two-fold difference in expression values. We 
obtained information about the expression variance of overall 5696 genes. Ribosomal RNA coding 
genes were excluded from this analysis due to the influence of rRNA removal during Illumina library 
preparation. 
571 genes were found to be very stably expressed with an expression variance of 0.1 or less (see 
supplementary table S3). These included 28 genes which were never differentially expressed 
according to the DESeq analysis. On the other hand, 575 genes exhibited large gene expression 
variance, between 0.58 and 0.83. A GO term analysis (Figure 3.13) revealed enrichment of genes 
involved in translation, replication, cell cycle control, cell wall synthesis and coenzyme transport in 
the most stably expressed genes; whereas only genes involved in the class of energy production and 
conservation were highly enriched in the set of variably expressed genes. The stably expressed genes 
were slightly, but significantly higher expressed (average nRPK value of 6.82) compared to the 
variably expressed genes (average nRPK value of 6.05; two-tailed Student’s t-test, P-value < 0.001). 
The core-transcriptome exhibited significantly lower expression variance (0.31) as compared to the 
set of genes that did not belong to the core-transcriptome (0.41); two-tailed Student’s t-test, P-value 
< 0.001. Figure 3.15 shows a scatter plot of the expression variance of the core-transcriptome as 
compared to the individual minimal (gray dots) and maximal (black dots) gene expression values. We 
observed a rather homogenous expression pattern across the core-transcriptome with a smoothly 
increasing difference between the average minimal (bottom line) and maximal (top line) gene 
expression. The maximal gene expression correlated positively with the increasing expression 
variance. This was even more pronounced in the set of genes not belonging to the core-
transcriptome (not shown). 
 
Results 64 
 
 
 
Figure 3.15: Expression variance of the core-transcriptome. 
Black and gray dots show the maximal and minimal expression of all genes of the core-transcriptome (n=3346), 
respectively. Black lines show the moving average of minimal and maximal gene expression of 100 genes, respectively. The 
genes are ranked from left to right according to increasing values of their overall expression variance 
3.3.5 Correlation between phylogenetic background and the core transcriptional 
profile 
We next assessed whether and how the genetic background of the various clinical isolates impacts 
on global gene expression profiles. We performed a hierarchical clustering of all 37 K. pneumoniae 
isolates according to the overall similarity of the expression profile of all 7859 genes in the pan-
genome (Figure 3.16A). Hierarchical clustering revealed three major sub-groups: the first included 
the two ST512 isolates together with all ten ST258 isolates, the second group included all except one 
ST101 isolates and the third group included the four ST15 isolates together with various other 
sequence types. A principal component analysis (PCA) (Figure 3.16C) also demonstrates a clear 
separation of the transcriptional profiles of all major phylogenetic linages within our set of isolates. 
This clustering might have been expected since the genomic composition i.e. the presence of distinct 
sets of accessory genes of the various MLST sequence types strongly influences the clustering. 
To exclude the impact of the transcription of accessory genes, we next analyzed the clustering of the 
37 clinical isolates based on variations within genes of the core-transcriptome. Remarkably, 
clustering of the expression profiles based solely on the core-transcriptome (Figure 3.16B) still 
revealed concordance with the phylogenetic clustering. Although the separation into distinct 
phylogenetic groups - becoming especially apparent in the PCA (Figure 3.16D) - was not as strong as 
observed for the hierarchical clustering based on the pan-genome, the phylogenetic groups could be 
clearly separated. 
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Figure 3.16: Phylogenetic relationship is reflected in the core -transcriptome. 
The heat maps show the expression of the pan-genome (A) and core-transcriptome (B), respectively. Genes (vertical) are 
hierarchically clustered using Pearson correlation distances, and the isolates (horizontal) are clustered according to their 
Spearman rank correlation. The same datasets are shown in C and D as 3D principal component analyses. Sequence types 
are highlighted by colors: ST512 (magenta), ST258 (purple), ST101 (green), ST15 (orange) and ST38 (MGH 78578) (blue). 
 
3.3.6 Virulence of K. pneumoniae in Galleria wax moth larvae is independent of 
the phylogenetic background 
Since the overall expression profiles of the core-transcriptome seemed to be associated with a 
distinct K. pneumoniae sequence type, we wondered whether this global expression profile 
determines bacterial behavior which might contribute to the success of global clonal lineages. The 
larvae of the greater wax moth Galleria mellonella are widely used as a model to study the virulence 
of pathogens [153,245,246], including K. pneumoniae [150,239,247,248]. Here, we used the 
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G. mellonella infection model to test the virulence of the various isolates. Healthy G. mellonella 
larvae were injected with an average dose of 7.5 x 105 CFU K. pneumoniae and the larval survival was 
monitored for 72 hours at 37 °C (see Figure 3.17 and Table 3.8). Virulence differed greatly not only 
among the various MLST groups but also within them. Furthermore, isolates with the same capsular 
type, which was previously shown to play an important role in K. pneumoniae virulence [249], did not 
exhibit similar virulence profiles. Our data indicate that virulence-associated traits are independent 
from the phylogenetic background, and therefore are rather isolate specific. 
 
 
Figure 3.17: Galleria survival assay.  
The graph shows the rate of dead larvae 72 hours post infection. Diamonds represent the mean of duplicate experiments 
with 10 larvae each. They are colored according to increasing rates of dead larvae (green ≤ 0.1; yellow <0.5; orange < 0.9 
and red ≥ 0.9). Horizontal and vertical bars indicate mean and standard deviation of each phylogenetic group, respectively. 
 
We found one isolate (isolate 3_8 of ST101) that exhibited a very low virulence. When we analyzed 
the growth behavior of all isolates in rich medium and in minimal medium supplemented with two 
different carbon sources (glucose and mannose, respectively; Table 3.8), this isolate exhibited a 
severe growth defect, which might explain its low virulence potential [239]. For all other isolates 
there was no correlation between growth and pathogenicity. 
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Table 3.8: Growth parameters in different media. 
Isolate 
Sequence 
type 
surviving 
larvae 
after 
72h 
LB BM2+glucose BM2+mannitol 
doubling 
time
a
 
+/- 
OD600 
max 
doubling 
time 
+/- 
OD600 
max 
doubling 
time 
+/- 
OD600 
max 
1_1 512 70 % 24.30 0.29 2.33 35.50 0.31 1.70 43.90 0.28 1.45 
1_2 405 0 % 22.10 0.36 2.78 35.50 0.65 2.33 41.80 0.36 1.93 
1_3 258 5 % 25.90 0.22 2.42 39.20 0.28 2.32 43.30 0.34 1.44 
1_4 258 10 % 27.10 0.32 2.52 39.80 0.33 2.43 44.50 0.50 1.73 
1_6 512 35 % 24.90 0.46 2.36 32.20 0.40 2.21 38.30 0.34 1.76 
1_8 15 10 % 20.80 0.24 2.41 35.30 0.44 2.25 40.90 0.34 1.48 
1_9 258 65 % 22.60 0.21 2.57 35.20 0.29 2.32 45.20 0.64 1.27 
1_10 258 40 % 22.90 0.12 2.59 35.40 0.21 2.44 42.70 0.32 1.95 
1_11 258 55 % 22.60 0.12 2.54 37.50 0.24 2.39 44.30 0.42 1.73 
1_12 258 60 % 22.10 0.12 2.53 35.00 0.25 2.28 43.00 0.61 1.73 
1_13 258 55 % 21.30 0.13 2.63 36.00 0.42 2.32 42.50 0.40 2.00 
1_14 147 55 % 22.50 0.30 2.74 41.00 0.36 2.39 44.80 0.61 2.09 
1_15 258 25 % 22.00 0.20 2.59 38.80 0.40 2.29 45.40 0.47 1.37 
1_16 15 5 % 21.80 0.05 2.66 33.40 0.48 2.42 40.10 0.45 2.13 
2_2 15 50 % 23.50 0.39 2.95 30.80 0.48 2.49 45.60 0.80 1.98 
2_4 258 25 % 21.90 0.09 2.63 36.90 0.35 2.47 45.70 0.61 2.06 
2_7 novel 75 % 22.40 0.21 2.77 38.10 0.14 2.24 42.30 0.20 1.81 
2_8 34 55 % 22.30 0.25 2.69 38.50 0.36 2.35 44.00 0.69 1.35 
2_9 258 0 % 21.30 0.19 2.69 36.30 0.30 2.24 41.70 0.57 1.40 
2_10 15 60 % 19.60 0.56 3.19 44.10 0.49 2.22 41.60 0.49 1.89 
2_11 35 60 % 21.00 0.41 2.74 36.30 0.80 2.31 42.40 0.78 1.87 
2_14 101 45 % 22.80 0.46 2.67 37.40 0.56 2.26 42.90 0.41 1.75 
3_3 101 50 % 22.50 0.42 2.70 39.20 0.48 2.18 42.90 0.68 1.84 
3_4 101 30 % 22.70 0.47 2.78 36.80 0.45 2.20 42.80 0.63 1.89 
3_5 101 10 % 22.60 0.44 2.75 34.40 0.38 2.16 39.90 0.53 1.80 
3_6 101 30 % 23.00 0.52 2.76 35.60 0.42 2.23 41.80 0.69 1.89 
3_7 101 35 % 23.00 0.38 2.75 35.60 0.39 2.18 44.70 0.58 1.90 
3_8 101 95 % 24.10 0.17 2.42 38.30 0.31 1.11 44.60 0.50 1.03 
3_10 101 50 % 22.20 0.46 2.73 34.80 0.40 2.15 39.00 0.57 1.78 
3_11 101 60 % 22.30 0.46 2.73 35.10 0.36 2.15 40.30 0.49 1.80 
3_12 101 25% 21.80 0.33 2.72 36.10 0.37 2.17 42.50 0.68 1.90 
3_13 101 35 % 23.20 0.33 2.67 34.70 0.43 2.18 42.60 0.62 1.86 
3_14 101 55 % 22.60 0.30 2.70 36.40 0.43 2.13 41.60 0.60 1.79 
3_17 101 5 % 25.50 0.38 2.71 36.80 0.46 2.08 39.90 0.52 1.67 
MGH 78578 38 0 % 23.30 0.52 2.76 44.70 0.44 2.19 57.40 0.33 1.92 
JH1 134 0 % 22.20 0.39 2.67 35.80 0.38 1.94 50.70 0.37 1.48 
1162281 133 0 % 22.10 0.27 2.30 34.40 0.28 2.06 40.10 0.65 1.77 
a) Doubling time in min 
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To identify possible virulence-associated genetic determinants, the transcriptomes of 11 highly 
virulent isolates (≥ 90 % dead larvae after 72 hours, red diamonds in Figure 3.17) were compared 
with 12 lowly virulent isolates (between 10 % and 50 % dead larvae, yellow diamonds in Figure 3.17) 
and searched for differentially transcribed genes within these two subsets. However, we could not 
identify any statistically significant differences in gene expression profiles (data not shown). 
Since virulence among the isolates could also be variable due to the presence of accessory genes on 
plasmids or integrons acquired by horizontal gene transfer [250], all reads that did not map to the 
K. pneumoniae pan-genome were extracted. A comparison of these accessory transcriptomes to the 
virulence factor data base (VFDB) [176] revealed the presence of several virulence-associated genes 
in the two sets of isolates (see supplementary table S5) but none of these were significantly enriched 
in the group of highly virulent isolates versus the lowly virulent ones. 
3.3.7 ST258 isolates produce significantly less biofilm as compared to other MLST 
sequence types 
In addition to virulence, the capability to form biofilms is a clinically relevant bacterial phenotype. 
We next analyzed the capability of each clinical isolate to produce biofilms by the use of a crystal 
violet assay (Figure 3.18A). Interestingly, as opposed to the virulence phenotype, the capability to 
produce biofilms seemed to be associated with the affiliation to a specific sequence type (Figure 
3.18B). As shown previously [156], biofilm formation was significantly lower in ST258 isolates as 
compared to other isolates, with a median OD590 of 0.06 versus 0.28 for all other isolates, 
respectively (two-tailed Student’s t-test, P-value < 0.01). The isolate with the highest absorbance in 
the crystal violet assay was the one isolate of ST101 (isolate 3_8) that already exhibited a non-
virulent phenotype in the Galleria assay and showed a severe growth defect in minimal media. 
Among all other isolates, growth was not associated with high or low biofilm formation. 
 
 
Figure 3.18: Quantitative analysis of biofilm formation by K. pneumoniae clinical isolates. 
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A: The raw absorbance at 590 nm of 8 replicate measurements with standard error of the mean (SEM). Isolate are arranged 
according to their MLST sequence type. The dashed line shows the separation into high and low biofilm producing isolates 
(which corresponds to three times the medium control (absorbance at 590nm = 0.187)). 
B: Differences in biofilm formation as determined by crystal violet staining between groups of isolates belonging to the 
same MLST type were analyzed using two-tailed Student’s t-test. 
 
We classified the clinical isolates according to their ability to form biofilm into high producers (OD590 
> 0.187, 11 isolates (all but one ST101 isolate were not included due to their probable clonal nature)) 
and low producers (OD590 < 0.187, 15 isolates) and analyzed whether we can detect group specific 
gene expression profiles using Wilcoxon’s rank-sum test. Retrieved P-values were furthermore 
adjusted by the Benjamini-Hochberg correction to control the false-discovery rate. 
 
 
Figure 3.19: Transcriptome-wide association of genes involved in biofilm formation.  
Volcano plot showing differentially expressed genes in biofilm forming isolates compared to non-biofilm forming isolates. 
Colored dots indicate genes that display large differences in their median gene expression (x-axis) as well as high statistical 
significance (-log10 of P-value, y-axis) with red and green indicating a fold change of ≥ 4 (nRPK of 2), respectively and black 
having a fold-change of ≥ 2 (nRPK of 1). Genes which are statistically not significantly expressed or having a fold-change less 
than 2 are shown in gray. The dotted line indicates P = 0.05, with genes above having P-values < 0.05. 
 
In this transcriptome-wide association study, we could identify a total of 165 genes whose expression 
was significantly different in the high biofilm forming group as compared to the low biofilm forming 
group (Figure 3.19). Out of these 159 genes, 46 genes were more than 4-fold upregulated in biofilm 
forming isolates (indicated as green dots in Figure 3.19) and 38 genes were upregulated on 
intermediate levels between 2- and 4-fold (black dots). The list of 46 genes which were at least 4-fold 
higher expressed (Figure 3.19 and Table 3.9) included mrkA, encoding the major pilin subunit of type 
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3 fimbriae [251], which has been shown previously to be crucial for binding to abiotic surfaces [252]. 
The remaining genes of the mrk operon, mrkB to mrkF, were also found to be higher expressed, 
although with a corrected P-value higher than 0.05. MrkB, MrkC and MrkF are chaperones, outer 
membrane usher and minor pilin subunit, respectively [253]. MrkD is the adhesive subunit of type 3 
fimbriae and has been shown to facilitate binding to extracellular matrix proteins [254]. Another 
fimbrial cluster of three genes (D364_17530, D364_17540 and D364_17550) from a fimbria coding 
operon of K. pneumoniae CG43 was also significantly higher expressed in the biofilm forming isolates. 
Besides fimbrial genes, the genes acsA, bcsB and bcsC were identified to be higher expressed. They 
all are involved in cellulose synthesis, an extracellular polysaccharide found in bacterial biofilms 
[255]. It has been shown that the cellulose synthase BcsB is activated via cyclic di-GMP [256], a 
bacterial second messenger well known for its control of biofilm formation [257]. Another operon 
which was higher expressed was the fumarat reductase operon. Although, only frdD is listed in Table 
3.9, frdA, frdB and frdC were also expressed on higher levels, but just below our strict threshold of a 
median difference by at least 2 nRPK (indicating a 4-fold stronger expression). It has been shown that 
inhibition of the fumarate reductase in Porphyromonas gingivalis significantly inhibited biofilm 
formation [258]. Furthermore, the outer membrane protein ompW was expressed at higher levels in 
the biofilm forming isolates. It has been shown previously that the ompW homolog in P. aeruginosa 
oprG is highly expressed in biofilms [259] and an oprG deletion mutant produced lower biofilm 
volumes as compared to the wild-type [260]. Figure 3.20 depicts the gene expression profile of the 
clinical isolates for the 46 genes found to be higher expressed in the biofilm-proficient isolates. 
Clearly, a reduced expression of the majority of these genes became apparent within the low biofilm 
producing ST258 isolates. 
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Table 3.9: List of genes being highly expressed in biofilm forming isolates 
gene_name / locus dnRPK gene_name / locus dnRPK 
bcsB 2.66 A79E_2827 3.62 
bcsC 2.67 A79E_2841 3.03 
A79E_0470 5.91 ompW (yciD) 3.26 
A79E_0471 6.76 A79E_3106 3.57 
A79E_0472 2.58 dmsA 2.07 
ttdA 3.40 A79E_4441 6.15 
ttdB 2.27 ulaC (ptxA) 2.30 
A79E_0491 2.09 ulaB (sgaB) 2.36 
mrkA 6.00 frdD 2.21 
dalT 2.31 D364_02760 6.30 
A79E_2240 3.19 D364_02765 6.86 
A79E_2397 4.75 D364_17515 5.08 
A79E_2413 6.18 D364_17530 2.71 
A79E_2451 5.51 D364_17540 3.26 
A79E_2489 2.12 D364_17550 6.62 
A79E_2492 2.07 acsA 2.89 
A79E_2600 3.31 KP13_01340 4.29 
A79E_2740 2.63 KP13_04177 6.84 
A79E_2741 3.16 KP13_32375 2.45 
astB 3.38 KPN2242_20090 5.99 
astD 3.10 KPN_01389 2.37 
A79E_2744 3.20 KPN_01390 3.36 
astC 2.88 KPN_01391 3.52 
d-nRPK: Difference in nRPK between the groups of high and low biofilm forming isolates 
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Figure 3.20: Differences in gene expression between high and low biofilm forming isolates  
The circular plot shows the normalized read counts (in nRPK) of all genes which were identified to be highly expressed in 
biofilm forming K. pneumoniae isolates. Expression varies from 13 nRPK (dark gray) to 0 nRPK (white). All 46 genes are 
labeled on the outside. Isolates are represented as rings and are arranged according to their biofilm phenotype. The 12 high 
biofilm forming isolates are shown in the outer rings, followed by the 14 low biofilm forming isolates in the inner rings. The 
MLST type is indicated as colored segments: ST512 (magenta), ST258 (purple), ST101 (green), ST15 (orange) and ST38 (MGH 
78578) (blue). 
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3.4 Overview of antibiotic resistance determinants in K. pneumoniae clinical 
isolates 
The antibiotic susceptibility profile of each isolate (see Table 2.3 and Table 2.4) was determined using 
the automated Vitek2 system (bioMérieux) and according to CLSI antibiotic resistance breakpoints 
[142], most of the isolates were categorized as multidrug-resistant (resistant to three or more 
antimicrobial classes) [213] with the highest rate of resistance to penicillin and fluoroquinolone 
antibiotics (see Figure 3.21). The collection included also two isolates which were susceptible to all 
antibiotics with the only exception of ampicillin. 
 
 
Figure 3.21: Antibiotic resistance in the clinical K. pneumoniae  isolates 
The figure shows the percentage of resistant (R; red columns), intermediate (I, yellow columns) and sensitive (S, green 
columns) isolates to ten antibiotics of different classes. Antibiotic resistance breakpoints are evaluated according to CLSI 
guidelines [142]. 
AMP, ampicillin; SAM, ampicillin-sulbactam; TZP, piperacillin-tazobactam; CXM, cefuroxime-axetil; CAZ, ceftazidime; IPM, 
imipenem; MEM, meropenem; CIP, ciprofloxacin; LVX, levofloxacin; GEN, gentamicin. 
 
In order to provide an overview of the mechanisms leading to antibiotic resistance, different 
strategies were used to analyze the RNA-seq data: i) horizontally acquired resistance enzymes were 
identified via a de-novo assembly of all reads which did not map to the pan-genome; ii) chromosomal 
mutations in the QRDRs of gyrA, gyrB, parC and parE were extracted using SAMtools and 
iii) differences in expression profiles of genes known to be involved in antibiotic resistance were 
analyzed. 
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3.4.1 Beta-lactam resistance 
The main driver of beta-lactam resistance in Gram-negative bacteria is the presence of beta-
lactamases, enzymes that are able to cleave the lactam ring and hydrolyze these antibiotics [261]. 
Although further mechanisms like an enhanced expression of efflux pumps [86], reduced membrane 
permeability [113] or target modification through mutations in penicillin-binding proteins [262] are 
known to contribute to a reduced susceptibility, beta-lactamases are the primary and most common 
cause of resistance to these drugs [261,263,264]. 
 
3.4.1.1 Carbapenemases 
Table 3.10 shows all horizontally acquired beta-lactamases that were identified in the accessory 
transcriptome of all isolates. The analyses revealed the presence of carbapenemase KPC-2 in all 
ST258 isolates and KPC-3 in both ST512 isolates. These findings were additionally confirmed by 
Sanger sequencing of blaKPC PCR products. The association of ST258 and ST512 isolates with KPC 
enzymes is well known and the global dissemination of ST258 clones including its close relatives is 
the main driver of the global KPC spread [237,265,266]. All KPC expressing isolates were non-
susceptible to the carbapenem meropenem. In all other KPC negative isolates which were resistant 
to meropenem (of note, only ST101 isolates) the carbapenemase OXA-48 could be identified, an 
oxacillinase with strong carbapenem-hydrolyzing activity [267]. The other two identified OXA beta-
lactamases OXA-1 and OXA-9 are narrow-spectrum beta-lactamases without carbapenem or 
cephalosporin hydrolyzing activity [268,269]. The carbenicillinase CARB-2 (first reported in 
P. aeruginosa and designated PSE-1 [270]), a beta-lactamase capable to hydrolyze carbapenems, was 
identified in one isolate (1162281). But since this isolate was fully susceptible to meropenem, the 
influence of CARB-2 on the MIC cannot be estimated here. 
In conclusion, meropenem non-susceptibility can be explained almost entirely by the presence of 
either KPC or OXA-48 carbapenemases. Only one single isolate (1_16) showed reduced susceptibility 
on an intermediate level without expressing a carbapenemase. The elevated resistance level might 
be explained by porin alterations [271]. Due to incomplete sequence coverage for most porins, 
involvement of porin alteration in meropenem non-susceptibility in this isolate cannot be 
determined. 
 
3.4.1.2 Extended spectrum beta-lactamases 
Almost all isolates contained further beta-lactamases or extended-spectrum beta-lactamases (ESBLs) 
of different classes of TEM, SHV and CTX-M types. The sequences of these types of ESBLs are highly 
variable and the spectrum of hydrolyzed beta-lactam antibiotics varies largely between the different 
variants of these enzymes [272,273]. For example, the TEM variants TEM-1 and TEM-2 are no ESBLs, 
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whereas the variant TEM-3 (differs from TEM-2 by two amino acid substitutions [274]) is able to 
hydrolyze the third-generation cephalosporins cefotaxime and ceftazidime. Likewise, the SHV 
variants SHV-1 or SHV-11 are no ESBLs but the variant SHV-2 has cefotaxime (and to a lesser degree 
ceftazidime) hydrolyzing activity [275] which is facilitated by a single amino acid substitution of 
glycine to serine at position 238 [272]. 
The CTX-M beta-lactamases are the most widespread enzymes and most of them provide a high level 
of resistance to cefotaxime but only few are able to hydrolyze ceftazidime [276]. One of these 
examples is the variant CTX-M-15 that differs from its parental enzyme CTX-M-9 (which does not 
hydrolyze ceftazidime) by a single mutation of aspartic acid to glycine at position 240 [277]. 
Besides ESBLs, third-generation cephalosporins are also hydrolyzed by KPC enzymes [278], whereas 
all OXA carbapenemases (including OXA-48) do not or only very poorly hydrolyze cefotaxime and 
ceftazidime [264]. 
Six out of the 37 isolates had the CTX-M-15 variant (including all ST15 isolates) and the association of 
CTX-M-15 with sequence types 15 and 147 has been previously described [240,279]. The transcript of 
another 11 isolates showed close relation to CTX-M-9 (exclusively in ST101 isolates) and one isolate 
had the CTX-M-1 variant. SHV beta-lactamases, one of the most common ESBLs [280] with more than 
180 known variants (http://www.lahey.org/studies/), were expressed in all ST258 isolates and in 
MGH 78578; all of them could be identified as SHV-11. CTX-M- and SHV-enzymes are usually plasmid 
encoded but have been integrated into the chromosome of two reference strains (Kpn2146 and 
1084, respectively) and are therefore included in the pan-genome used in this study as a reference to 
map RNA-seq reads (see Figure 3.22). TEM beta-lactamases were identified in 29 isolates, but in 13 of 
them the transcript could not be typed due to low sequence coverage. The remaining 16 isolates 
showed the variant TEM-1. 
Due to this partially low sequencing coverage and the resulting uncertainties in the determination of 
the exact type of TEM, SHV and CTX-M beta-lactamases, it was not possible to elucidate the influence 
of ESBLs on the ceftazidime resistance phenotype. Therefore, ESBL typing needs to be improved e.g. 
by directed Sanger resequencing of single genes or by whole genome sequencing.  
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Table 3.10: Expressed beta-lactamases in all K. pneumoniae clinical isolates 
Origin Isolate MLST MEM CAZ KPC OXA CARB TEM SHV CTX-M 
M
ed
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 G
er
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y 
isolate 1_1 512 R ≥ 16 R ≥ 64 KPC-3 
  
TEM-1 
  
isolate 1_2 405 S ≤ 0.25 I 8 
 
OXA-1 
 
TEM-1 
 
CTX-M-15 
isolate 1_3 258 R ≥ 16 R ≥ 64 KPC-2 
   
SHV-11 
 
isolate 1_4 258 R ≥ 16 R ≥ 64 KPC-2 
   
SHV-11 
 
isolate 1_6 512 R >32 R ≥ 64 KPC-3 
  
TEM-1 
  
isolate 1_8 15 S ≤ 0.25 
 
n.d. 
 
OXA-1 
 
TEM-1 
 
CTX-M-15 
isolate 1_9 258 R ≥ 16 R ≥ 64 KPC-2 
  
TEM-1 SHV-11 
 
isolate 1_10 258 R ≥ 16 
 
n.d. KPC-2 OXA-9 
 
TEM-1 SHV-11 
 
isolate 1_11 258 R 4 R ≥ 64 KPC-2 
  
TEM-1 SHV-11 
 
isolate 1_12 258 R 8 R ≥ 64 KPC-2 
  
TEM-1 SHV-11 
 
isolate 1_13 258 R ≥ 16 R ≥ 64 KPC-2 
   
SHV-11 
 
isolate 1_15 258 I 2 R ≥ 64 KPC-2 
  
TEM-1 SHV-11 
 
isolate 1_16 15 I 2 R ≥ 64 
 
OXA1 
 
TEM-1 
 
CTX-M-15 
isolate 2_2 15 S ≤ 0.25 R ≥ 64 
 
OXA1 
 
TEM-1 
 
CTX-M-15 
isolate 2_4 258 R 16 
 
n.d. KPC-2 
   
SHV-11 
 
isolate 2_8 34 S ≤ 0.25 S 4 
     
CTX-M-1 
isolate 2_9 258 R 8 R ≥ 64 KPC-2 
   
SHV-11 
 
isolate 2_10 15 S ≤ 0.25 I 8 
 
OXA-1 
 
TEM-1 
 
CTX-M-15 
isolate 2_14 101 S 1 R ≥ 64 
 
OXA1 
 
TEM-1 
  
C
h
ar
it
e-
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isolate 3_3 101 R ≥ 16 R 16 
 
OXA-9 + OXA-48 
 
TEM-like 
 
CTX-M-9-like 
isolate 3_4 101 R ≥ 16 R 16 
 
OXA-9 + OXA-48 
 
TEM-like 
 
CTX-M-9-like 
isolate 3_5 101 R ≥ 16 S 4 
 
OXA-9 + OXA-48 
 
TEM-like 
 
CTX-M-9-like 
isolate 3_6 101 R ≥ 16 R 16 
 
OXA-9 + OXA-48 
 
TEM-like 
 
CTX-M-9-like 
isolate 3_7 101 R ≥ 16 S 4 
 
OXA-9 + OXA-48 
 
TEM-like 
 
CTX-M-9-like 
isolate 3_8 101 R 8 R 64 
 
OXA-1 + OXA48 
 
TEM-like 
 
CTX-M-like 
isolate 3_10 101 R ≥ 16 R 16 
 
OXA-9 + OXA-48 
 
TEM-like 
 
CTX-M-9-like 
isolate 3_11 101 R ≥ 16 R 16 
 
OXA-9 + OXA-48 
 
TEM-like 
 
CTX-M-9-like 
isolate 3_12 101 R 8 S 4 
 
OXA-9 + OXA-48 
 
TEM-like 
 
CTX-M-9-like 
isolate 3_13 101 R 8 R 16 
 
OXA-48 
 
TEM-like 
 
CTX-M-9-like 
isolate 3_14 101 R 16 R 16 
 
OXA-48 
 
TEM-like 
 
CTX-M-9-like 
isolate 3_17 101 R 8 S 4 
 
OXA-9 + OXA-48 
 
TEM-like 
 
CTX-M-9-like 
Private 
practice, 
Salzgitter, 
Germany 
isolate 1_14 147 S ≤ 0.25 R ≥ 64 
   
TEM-1 
 
CTX-M-15 
isolate 2_7 novel S ≤ 0.25 S ≤ 1 
      
isolate 2_11 35 S ≤ 0.25 S ≤ 1 
   
TEM-1 
  
previously 
published 
MGH 78578 38 S ≤ 0.25 R ≥ 64 
 
OXA-9* 
 
TEM-1 SHV-11 
 
JH1 134 S ≤ 0.25 S ≤ 1 
      
1162281 133 S ≤ 0.25 R ≥ 64 
  
CARB-2 TEM-like 
  
* Sequence contains a premature stop codon at nucleotide position 336, -like: identified sequences contained SNPs or was 
incomplete, therefore the closest hit is given; MEM, meropenem; CAZ, ceftazidime; MICs in µg/ml, breakpoints according to 
CLSI [142]. 
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3.4.2 Aminoglycoside resistance 
Resistance to aminoglycosides arises from several mechanisms like alteration of the ribosomal 
binding sites (only for streptomycin), a decreased intracellular concentration of the drug and the 
expression of aminoglycoside-modifying enzymes (AMEs) which inactivate the antibiotic [128]. 
Whereas a reduction in drug uptake through membrane impermeabilization occurs mostly in 
P. aeruginosa and the clinical significance of an active efflux remains uncertain, the main mechanism 
of aminoglycoside resistance in K. pneumoniae is the acquisition of these AMEs. [128]. 
In this set of clinical isolates, enzymes from the three main classes of AMEs, namely N-
acetyltransferases (AAC), O-phosphotransferases (APH), and O-nucleotidyltransferases (ANT), were 
present in all but five isolates (see Table 3.11). Whereas only few isolates expressed ANT and APH 
enzymes, most of the isolates contained AAC(6')-Ib C or its variant AAC(6')-Ib cr. Due to insufficient 
read coverage, the exact type could not be determined. Enzymes of the AAC(6’)-I subgroup confer 
resistance to tobramycin, kanamycin, netilmicin and either amikacin or gentamicin. Whereas AAC(6')-
Ib C (encoded by aacA4) does not show activity against gentamicin [281,282], the variants AAC(6')-Ib 
cr (encoded by aac(6')-Ib'-cr) and AAC(6')-Ib' (encoded by aac(6')-Ib') do have gentamicin modifying 
activity [110,283]. Therefore, the exact type of N-acetyltransferase is of importance and needs to be 
clarified in further studies. 
Besides the known involvement of AMEs in aminoglycoside resistance, there are reports of an 
involvement of bacterial efflux contributing to aminoglycoside resistance. The K. pneumoniae 
homologs of the E. coli RND multidrug efflux transport acrD [284] as well as the MFS transporter 
mdfA (also named kdeA [285]) and bcr [286] are known to extrude aminoglycosides [287]. These 
three genes were homogenously expressed at medium levels in all isolates (nRPK values between 3.5 
and 6.8, see also Figure 3.22) and although the influence on aminoglycoside resistance could be 
clearly shown in-vitro, their involvement in a clinical setting still remains unclear.  
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Table 3.11: Horizontally acquired aminoglycoside modifying enzymes 
Origin Isolate MLST GEN AAC ANT APH 
M
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isolate 1_1 512 S ≤ 1 
   
isolate 1_2 405 R ≥ 16 AAC(6')-Ib cr-like 
 
APH(3“)-Ib + APH(6)-Id 
isolate 1_3 258 S 4 AAC(6')-Ib C-like 
  
isolate 1_4 258 S 4 AAC(6')-Ib C-like 
  
isolate 1_6 512 S 4 AAC(6')-Ib C-like 
  
isolate 1_8 15 S ≤ 1 AAC(6')-Ib-cr-like + AAC(3)-Ia C 
  
isolate 1_9 258 S 4 AAC(6')-Ib C-like 
  
isolate 1_10 258 S ≤ 1 AAC(6')-Ib C-like 
  
isolate 1_11 258 S 4 AAC(6')-Ib C-like 
  
isolate 1_12 258 S 4 AAC(6')-Ib C-like 
  
isolate 1_13 258 S 4 AAC(6')-Ib C-like 
  
isolate 1_15 258 S 4 AAC(6')-Ib C-like 
  
isolate 1_16 15 R ≥ 16 AAC(6')-Ib cr-like ANT(3”)-Ia 
 
isolate 2_2 15 R ≥ 16 AAC(6')-Ib cr-like 
  
isolate 2_4 258 S 4 AAC(6')-Ib C-like 
  
isolate 2_8 34 S ≤ 1 
   
isolate 2_9 258 S 4 AAC(6')-Ib C-like 
  
isolate 2_10 15 S ≤ 1 AAC(6')-Ib-cr-like + AAC(3)-Ia C 
  
isolate 2_14 101 R ≥ 16 AAC(6')-Ib cr-like 
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isolate 3_3 101 R ≥ 16 AAC(6')-Ib C-like ANT(3”)-Ia* APH(6)-Id 
isolate 3_4 101 S ≤ 1 AAC(6')-Ib C-like 
 
APH(6)-Id 
isolate 3_5 101 S ≤ 1 
  
APH(6)-Id 
isolate 3_6 101 R ≥ 16 AAC(6')-Ib C-like ANT(3”)-Ia* APH(6)-Id 
isolate 3_7 101 R ≥ 16 AAC(6')-Ib C-like 
 
APH(6)-Id 
isolate 3_8 101 R ≥ 16 AAC(6')-Ib cr-like 
  
isolate 3_10 101 R ≥ 16 AAC(6')-Ib C-like ANT(3”)-Ia* APH(6)-Id 
isolate 3_11 101 R ≥ 16 AAC(6')-Ib C-like ANT(3”)-Ia* APH(6)-Id 
isolate 3_12 101 R ≥ 16 AAC(6')-Ib C-like 
 
APH(6)-Id 
isolate 3_13 101 S ≤ 1 
  
APH(6)-Id 
isolate 3_14 101 S ≤ 1 
  
APH(6)-Id 
isolate 3_17 101 R ≥ 16 AAC(6')-Ib C-like 
  
Private 
practice, 
Salzgitter, 
Germany 
isolate 1_14 147 S ≤ 1 AAC(6')-Ib C-like   
 
isolate 2_7 novel S ≤ 1 
   
isolate 2_11 35 
 
n.d. 
   
previously 
published 
MGH 78578 38 R ≥ 16 AAC(6')-Ib C-like ANT(2”)-Ia 
 
JH1 134 S ≤ 1 
   
1162281 133 R 8 
 
ANT(2”)-Ia 
 
* only fragments were identified; aminoglycoside modifying enzymes are named according to [132]; -like: identified 
sequences contained SNPs or was incomplete, therefore the closest hit is given; GEN, gentamicin MIC in µg/ml, breakpoints 
according to CLSI [142].  
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3.4.3 Fluoroquinolone resistance 
Fluoroquinolone resistance is primarily conferred via mutations in the gyrase subunits GyrA and GyrB 
as well as mutations in the topoisomerase IV subunits ParC and ParE. In particular, high levels of 
ciprofloxacin resistance are mostly determined by mutations in gyrA at amino acid position 83 in 
combination with mutations in parC at position 87. Besides these chromosomal target mutations an 
enhanced efflux [86] and the presence of transferable quinolone resistance genes [111] like Qnr 
[288] or AAC(6′)-Ib-cr [110] are known to be involved in the development of fluoroquinolone 
resistance. 
To provide insights into the nature and dimension of ciprofloxacin resistance in our panel of clinical 
K. pneumoniae isolates, chromosomal mutations within the four fluoroquinolone target genes and 
the presence of plasmid-mediated quinolone resistance (PMQR) determinants were evaluated. Using 
transcriptomic data, several mutations in the QRDR of gyrA, gyrB and parC were determined, while 
no mutations in parE could be detected (see Table 3.12). Furthermore several types of Qnr proteins 
and the aminoglycoside acetyltransferase AAC(6′)-Ib-cr were identified in the majority of isolates. 
Our analysis revealed the presence of gyrA mutations at amino acid position 83 (S83I, S83F and S83Y, 
respectively) in all ciprofloxacin non-susceptible isolates and moreover, all but two non-susceptible 
isolates harbored additionally a non-synonymous mutation in parC at position 87 (always S80I). 
Further mutations in gyrA at amino acid position 87 and in gyrB at position 466 were also identified, 
although always in combination with mutations in gyrA and parC. Therefore the influence of these 
mutations on the ciprofloxacin MIC cannot be clarified based on this dataset. 
Both non-susceptible isolates without a mutation of gyrA in combination with parC expressed PMQR 
determinants, which are most likely responsible for the reduced susceptibility [289]. One of these 
two isolates (1162281) expressed qnrA1 [290] along with a S83F mutation in gyrA, whereas the other 
isolate (1_2) expressed the aminoglycoside acetyltransferase encoding gene aac(6′)-Ib-cr in 
combination with qnrB1 [291]. Since all other isolates expressing plasmid encoded enzymes do also 
have gyrA and parC double mutations, the specific influence on the MIC of these enzymes remains 
unclear.  
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Table 3.12: QRDR mutations and horizontally acquired fluoroquinolone resistance enzymes 
Origin Isolate MLST CIP gyrA S83 gyrA D87 gyrB E466 parC S80 AAC(6')-Ib-cr Qnr 
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isolate 1_1 512 R ≥ 4 S83I - E466D S80I 
  
isolate 1_2 405 I 2 
 
- - - AAC(6')-Ib-cr-like QnrB1 
isolate 1_3 258 R ≥ 4 S83I - E466D S80I 
  
isolate 1_4 258 R ≥ 4 S83I - E466D S80I 
  
isolate 1_6 512 R ≥ 4 S83I - E466D S80I 
  
isolate 1_8 15 R ≥ 4 S83F D87A - S80I AAC(6')-Ib-cr-like 
isolate 1_9 258 R ≥ 4 S83I - E466D S80I 
  
isolate 1_10 258 R ≥ 4 S83I - E466D S80I 
  
isolate 1_11 258 R ≥ 4 S83I - E466D S80I 
  
isolate 1_12 258 R ≥ 4 S83I - E466D S80I 
  
isolate 1_13 258 R ≥ 4 S83I - E466D S80I 
  
isolate 1_15 258 R ≥ 4 S83I - E466D S80I 
  
isolate 1_16 15 R ≥ 4 S83F D87A - S80I AAC(6')-Ib-cr-like 
isolate 2_2 15 R ≥ 4 S83F D87A - S80I AAC(6')-Ib-cr-like 
isolate 2_4 258 R ≥ 4 S83I - E466D S80I 
  
isolate 2_8 34 S ≤ 0.25 - - - - 
  
isolate 2_9 258 R ≥ 4 S83I - - S80I 
  
isolate 2_10 15 R ≥ 4 S83F D87A - S80I AAC(6')-Ib-cr-like 
isolate 2_14 101 R ≥ 4 S83Y D87N - S80I AAC(6')-Ib-cr-like 
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isolate 3_3 101 R ≥ 4 S83Y D87N - S80I 
 
QnrS1 
isolate 3_4 101 R ≥ 4 S83Y D87N - S80I 
 
QnrS1 
isolate 3_5 101 R ≥ 4 S83Y D87N - S80I 
 
QnrS1 
isolate 3_6 101 R ≥ 4 S83Y D87N - S80I 
 
QnrS1 
isolate 3_7 101 R ≥ 4 S83Y D87N - S80I 
  
isolate 3_8 101 R ≥ 4 S83Y D87N - S80I AAC(6')-Ib-cr-like 
 
isolate 3_10 101 R ≥ 4 S83Y D87N - S80I 
 
QnrS1 
isolate 3_11 101 R ≥ 4 S83Y D87N - S80I 
 
QnrS1 
isolate 3_12 101 R ≥ 4 S83Y D87N - S80I 
 
QnrS1 
isolate 3_13 101 R ≥ 4 S83Y D87N - S80I 
  
isolate 3_14 101 R ≥ 4 S83Y D87N - S80I 
  
isolate 3_17 101 R ≥ 4 S83Y D87N - S80I   QnrS1 
Private 
practice, 
Salzgitter, 
Germany 
isolate 1_14 147 R ≥ 4 S83I - - S80I 
  
isolate 2_7 novel S ≤ 0.25 - - - - 
  
isolate 2_11 35 I 2 S83I - - S80I     
previously 
published 
MGH 78578 38 S 1 S83Y - - - 
  
JH1 134 S ≤ 0.25 - - - - 
  
1162281 133 R ≥ 4 S83F - - -   QnrA1 
–: the wild type allele was present; -like: identified sequences contained SNPs or was incomplete, therefore the closest hit is 
given; CIP, ciprofloxacin MIC in µg/ml, breakpoints according to CLSI [142]. 
3.4.4 Influence of other, non-specific resistance mechanisms 
Besides the presence of horizontally acquired resistance enzymes and specific target mutations, the 
enhanced expression of efflux pumps, porins and beta-lactamases are well known examples of 
mechanisms that confer antibiotic resistance [292]. Figure 3.22 gives a broad overview about the 
expression of 65 genes involved in antibiotic resistance over all 37 clinical isolates. The figure 
illustrates the expression of six described and putative beta-lactamases, six porins and 53 genes 
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involved in the extrusion of antibacterial compounds. All efflux genes are arranged into the following 
clusters: i) Resistance-Nodulation-Cell Division (RND) Superfamily, ii) Major Facilitator Superfamily 
(MFS), iii) Small Multidrug Resistance (SMR) proteins, iv) ATP-binding Cassette (ABC) transporter, and 
v) Multi-antimicrobial extrusion (MATE) transporter. The operon structure of efflux pumps is 
indicated on the outside of the graph. 
Figure 3.22 reveals a low and uniform expression of most efflux systems, only acrAB and oqxAB were 
expressed on high levels in this set of clinical isolates. The pump with the highest average expression 
was the RND efflux pump AcrAB with nRPK values of acrA and acrB of 9.98 and 10.69, respectively. 
AcrAB is known to be involved in beta-lactam and fluoroquinolone resistance in K. pneumoniae as 
well as E. coli [293-295]. Whereas acrAB was highly expressed in all isolates, only oqxA and oqxB 
were highly variably expressed. The RND efflux system OqxAB is composed of the membrane fusion 
protein OqxA and the multidrug efflux transporter OqxB [296] and is involved in resistance to 
fluoroquinolone, cephalosporin, and glycylcycline antibiotics in K. pneumoniae [295,297]. The 
expression of oqxAB is tightly regulated by the negative GntR-type transcriptional regulator OqxR and 
overexpression of this pump usually requires either mutations in OqxR, rendering the negative 
regulator ineffective or an upregulation of the transcriptional AraC-type activator RarA [298,299]. 
Sequence analyses revealed that all isolates overexpressing this efflux pump harbored mutations 
within oqxR, whereas all other 22 isolates do not have altered amino acid sequences of this 
transcriptional repressor. All ST258 and ST512 isolates contained a SNP in oqxR (T389C) which caused 
the amino acid substitution V130A. Two other isolates, 1162281 and 1_16, contained also amino acid 
alterations in OqxR (V137A and A117E, respectively) and isolate 1_8 had an insertion of 24 
nucleotides after nucleotide position 206 which most likely led to a nonfunctional OqxR protein. 
Interestingly, the gene encoding the positive regulator RarA is always overexpressed when mutations 
in oqxR occur (data not shown) and therefore the strong expression of rarA might enhance the effect 
of the oqxR mutation on the expression of oqxAB [298]. 
Besides beta-lactamases and efflux genes, Figure 3.22 shows additionally the expression of six outer 
membrane proteins (porins) which are known to be involved in antibiotic resistance. Porins are 
water-filled channels in the bacterial cell membrane and facilitate the uptake of hydrophilic 
compounds [83]. Whereas K. pneumoniae possesses several, diverse porins, only the two major non-
specific porins OmpK35 (homolog of the E. coli porin ompF) and OmpK36 (homolog of the E. coli 
porin ompC) play an eminent role in the clinical setting [300]. Loss of OmpK35 is known to be 
involved in resistance to fluoroquinolones [301], cephalosporins, carbapenems, and chloramphenicol 
[302] and loss of OmpK36 plays a critical role in the development of carbapenem resistance [303]. 
Only four out of the six porins were expressed at high levels in the panel of 37 clinical isolates 
analyzed here in this thesis; ompN and ompS showed only a negligible expression. Remarkably, all 
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ST258 isolates expressed porins generally lower as compared to all other isolates (including the two 
ST512 isolates). The expression of ompK35, ompK36 and ompC was 4-fold lower and the expression 
of ompW even 16-fold lower. Besides this effect, no correlation between phylogeny and porin 
expression could be detected. Despite high expression values, a detailed and comparative sequence 
analysis was not possible for most of the porins due to an uneven distributed read coverage leaving 
large parts of these genes without reliable sequence information. Nevertheless, several mutations 
could be clearly identified in ompK35 as compared to the sequence of the reference strain 1084: All 
ST258 and both ST512 isolates showed a deletion of a G in codon 40 and all ST101 harbored an 
insertion of a single G in codon 61. These two mutations are causing a frameshift in the open reading 
frame and therefore most-likely render the protein nonfunctional. Additionally to these two indels, 
at least two isolates showed missense mutations causing an amino acid exchange in the sequence of 
ompK35: D159N in isolate 1_3 and I183V in isolate 2-9 which are located in the external loop L4 and 
in the beta-strands between loops L4 and L5, respectively [302]. The influence of deleterious 
mutations in ompK35 and ompK36 was shown in clinical samples and could be demonstrated in vitro 
in an isogenic background [302,304]. Therefore it is very likely that porin disruptions also contribute 
to antibiotic resistance in this set of clinical isolates, but further studies are needed to determine the 
exact influence of these mutations on the MIC. 
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Figure 3.22: Expression of antibiotic resistance associated genes.  
The circular plot shows the normalized read counts (in nRPK) of 65 genes which are described to be associated with 
antibiotic resistance. Expression varies from 16 nRPK (dark gray) to 0 nRPK (white). Genes are arranged in segments 
according to the functional class of their product with indicated operon structures on the outside. Isolates are represented 
as rings and are arranged according to their phylogenic relationship (see Figure 3.11). Isolates with the same MLST profile 
are framed by colored rings: ST512 (magenta), ST258 (purple), ST101 (green) and ST15 (red). 
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4 Discussion 
4.1 Antimicrobial resistance is a major global threat 
Hospital and community acquired infections with Gram-negative pathogens have an dramatic and 
increasing impact on human health, due to the emerging threat of multidrug resistant and highly 
virulent clinical isolates. Two of the most worrisome examples of Gram-negative pathogens are the 
Gammaproteobacteria Pseudomonas aeruginosa and Klebsiella pneumoniae, since infections with 
these pathogens are reaching alarming rates in the clinical setting. The U.S. CDC classified 
carbapenem-resistant Enterobacteriaceae (including K. pneumoniae) as an urgent public health 
threat (representing the highest out of five categories) requiring “urgent and aggressive action” [48]. 
Furthermore, extended spectrum beta-lactamase (ESBL) producing Enterobacteriaceae as well as 
multidrug-resistant P. aeruginosa were classified as microorganisms with a threat level of serious 
(the second highest level) demanding “prompt and sustained action” to guarantee that these 
problems do not grow in the future [48]. In 1999 the U.S. CDC, FDA and the National Institutes of 
Health (NIH) created the “Interagency Task Force on Antimicrobial” to combat antimicrobial 
resistance in a concerted manner. They released their “Action Plan to Combat Antimicrobial 
Resistance” in 2001 with the latest update from 2012 as a “blueprint for specific, coordinated actions 
to address the growing threat of antimicrobial resistance” (available at 
http://www.cdc.gov/drugresistance/pdf/action-plan-2012.pdf). In this plan, the consortium 
highlighted the following focus areas of four overarching categories of i) surveillance, ii) prevention 
and control, iii) research, and iv) product development, with the aim to develop novel treatment 
strategies to contain the spread of multidrug resistant Gram-negative pathogens. 
4.2 Nature and dimension of QRDR mutations 
In this thesis, a combination of Sanger sequencing, pyrosequencing, quantitative real-time PCRs and 
RNA-seq was used to determine the nature and frequency of hot spot mutations in the QRDRs of the 
genes gyrA and gyrB encoding the DNA-gyrase as well as parC and parE encoding the topoisomerase 
IV and the involvement of bacterial efflux in fluoroquinolone resistance in a panel of 172 clinical 
P. aeruginosa isolates. Most of those isolates were resistant to multiple antimicrobial agents (data 
not shown) and the majority (including all ciprofloxacin resistant strains) expressed at least one SNP 
within one of the QRDRs. In accordance with several previous studies [192-198], the by far most 
frequently observed mutation was within the QRDR of gyrA, with the amino acid substitution T83I 
being the prevailing mutation, whereas mutations in gyrB were less frequent [197,199,200]. In gyrB, 
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the majority of mutations were found at amino acid positions 466 to 468; however we also found 
one isolate with an insertion of CCG (Proline) at position 458 and two I529V mutations which have 
not been described previously. Five different parE mutations and three parC mutations were found, 
interestingly all parC mutations exclusively in strains that harbored the predominant gyrA T83I 
mutation. Single parC mutations were not found in the panel of MDR P. aeruginosa – as also 
observed in previous studies [195,200]. Additionally, it could be shown in the isogenic background of 
the P. aeruginosa reference strain PA14 that the parC mutations S87W and S87L only contribute to 
an increased fluoroquinolone resistance in the presence of a gyrA mutation. This has been indicated 
previously by several studies on fluoroquinolone resistance in clinical isolates of different species like 
E. coli [201,305-307], P. aeruginosa [203] or Streptococcus pneumoniae [308,309], but has never 
been shown in an isogenic background of P. aeruginosa so far. The data shown here strongly 
indicates that parC mutations only occur as secondary mutations increasing the resistance towards 
fluoroquinolones synergistically with previously acquired gyrA mutations. 
With this combined approach of different sequencing strategies, 53 and 23 strains with a single 
mutation in either gyrA or gyrB, respectively, were identified. However, those strains exhibited MIC 
values that spanned a broad range between 1 µg/ml and > 8 µg/ml. In contrast, and as already 
described in several previous studies [195,197,205], double mutations in gyrA and parC always 
revealed high level ciprofloxacin resistance with MICs of 8 µg/ml or more in clinical MDR strains. 
Accordingly, the introduction of the most frequent SNPs within the QRDRs of gyrA and gyrB into the 
susceptible reference stain PA14 only conferred MIC values of 1 - 2 µg/ml, whereas the introduction 
of a secondary mutation in the parC QRDR always resulted in high level ciprofloxacin resistance. This 
broad MIC range in clinical P. aeruginosa gyrA mutants has been observed in studies before 
[202,203] and although it is tempting to speculate that this can be explained by a differential efflux 
pumps expression [199,204], no clear association of increased MICs in gyrA mutants and an 
increased expression of efflux pumps could be demonstrated previously [203,205,206]. Similarly, in 
this study, the large variation of MIC values in isolates with only single mutations within the QRDRs 
could not be linked to an additional differential expression of one or more of the four major efflux 
pumps involved in ciprofloxacin resistance as determined by either qRT-PCR in 29 selected clinical 
isolates (see Table 3.2 and Figure 3.3) or by RNA-seq (see Figure 3.7) Additionally, we found that 
complementation with the wild-type gyrA gene led to a 2- to 8-fold reduction in fluoroquinolone 
resistance irrespective of the original resistance level. These results indicate that mutations within 
the gyrA QRDR add to a preexisting isolate-specific resistance level of unknown origin. 
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4.3 Unbiased phenotype-genotype correlation reveals that ciprofloxacin 
resistance is predominantly determined by specific QRDR mutations 
Three comprehensive screenings of P. aeruginosa mutant libraries have shown that approximately 
100 to 200 genes are involved in the intrinsic ciprofloxacin resistome [133,135,136]. These 
publications could show that antibiotic resistance might be the result of complex and multifactorial 
networks of interactions among bacterial proteins of diverse functional categories. To determine 
which of the gene inactivations identified in these large mutant screening, if any, play a role in 
fluoroquinolone resistance in the clinical setting and to identify possible additional mechanisms of 
fluoroquinolone resistance that go beyond the known resistance determinants of target mutations 
and increased efflux, the complete transcriptome of a large and phylogenetic diverse collection of 
clinical isolates was studied in its full complexity. 
High throughput sequencing of messenger RNAs (RNA-seq) offers the ability to study gene expression 
at single nucleotide resolution. Therefore, it allows not only the measurement of transcript 
abundancies but also the detection of point mutations, deletions and insertions of transcribed genes. 
Hence, RNA-seq provides an advantage over whole genome sequencing to obtain information of 
both transcript abundancies and sequence variations in a single approach. Thus, it gives the 
possibility to draw global phenotype-genotype correlations to study the interplay of genome and 
transcriptome [310-312]. Recently, RNA-seq has been applied successfully in the elucidation of 
ceftolozane resistance by the group of Antonio Oliver in collaboration with our group. Ceftolozane is 
a novel beta-lactam antibiotic of the cephalosporin class which is used in combination with the beta-
lactamase inhibitor tazobactam for the treatment of complicated urinary tract infections, 
complicated intra-abdominal infections, and ventilator-associated bacterial pneumonia [313]. 
Resistance of P. aeruginosa to ceftolozane requires changes in gene expression as well as amino acid 
alterations. By using RNA-seq, it was possible to identify multiple mutations leading to an 
overexpression of ampC as well as to describe the structural modification of this chromosomal beta-
lactamase in a single approach [314]. 
Here, RNA-seq was used to study the mechanisms leading to fluoroquinolone resistance in a 
phylogenetically broad and diverse panel of 159 clinical P. aeruginosa isolates in an unbiased 
manner. By performing whole transcriptome comparisons, it was possible to identify 15 single 
nucleotide polymorphisms which were highly enriched in non-susceptible isolates. Among these 15 
identified SNPs, four SNPs lead to an amino-acid substitution in the corresponding gene product. The 
by far best hits, which showed the highest significance, were the fluoroquinolone resistance 
determining mutations of T83I in gyrA and S87L/W in parC. The finding that SNPs in gyrA and parC, 
and especially combinations thereof, are an absolute requirement in of high level ciprofloxacin 
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resistance is further supported by the comparison of only highly-resistant isolates with a MIC of 
≥ 8 µg/ml with the susceptible ones. In this comparison, only the SNPs in gyrA (T83I) and parC 
(S87L/W) were highly significantly enriched in the group of resistant isolates. 
Besides the two mutations within the QRDRs of gyrA and parC, two additional non-synonymous 
SNPs, located in the genes kynU (PA14_37610) and glmU (PA14_73220), were significantly enriched 
in the comparison of non-susceptible versus susceptible isolates. kynU encodes the enzyme 
kynureninase which is involved in the aerobic degradation of tryptophan via the anthranilate 
pathway [315]. Anthranilate in turn serves as a precursor of the quorum-sensing signal molecules 4-
hydroxy-2-alkylquinolines which regulate numerous virulence genes and are associated with iron 
chelation [316,317]. Therefore it has been suggested previously, that the cellular supply of 
anthranilate could provide a viable drug target whose disruption could lessen the virulence of 
P. aeruginosa [318]. GlmU is a bifunctional acetyltransferase/uridyltransferase enzyme facilitating 
the biosynthesis of UDP-N-acetylglucosamine which is involved in the biosynthesis of 
lipopolysaccharide, peptidoglycan and teichoic acid components of bacterial cell walls [319]. Since 
GlmU is an essential enzyme in both Gram-negative and Gram-positive bacteria and furthermore 
lacks a homolog in eukaryotes, it is regarded as a potential antibacterial target [320]. 
Both genes were previously not associated with resistance to antimicrobial drugs in the 
aforementioned four global transposon mutagenesis screenings. Although they seem to be 
correlated with fluoroquinolone resistance here, correlation does not necessarily imply causation. 
Therefore further studies, e.g. the incorporation of these SNPs in an isogenic background, are 
required to elucidate the involvement of these SNPs in the development of antimicrobial resistance 
and furthermore the proficiency of these enzymes to act as a potential novel drug target. 
4.4 Occurrence of certain QRDR mutations in distinct niches 
It has been observed before that highly resistant P. aeruginosa strains harboring a double gyrA and 
parC mutation are almost exclusively isolated from non-CF patients, whereas in CF single mutations 
within the QRDRs dominate [202,209,321]. Interestingly, in accordance with these previous reports, 
26 of the 30 gyrA/parC mutants with available patient information were isolated from non-CF 
patients. It has been suggested that higher drug levels of ciprofloxacin in non-CF patients might 
account for this phenomenon, since drug levels in CF-sputum were found to be significantly lower 
than in blood [322]. Although the lower drug concentration levels might select for intermediate 
resistant strains in distinct niches, it might also indicate that there is a co-selection of single 
mutations in QRDRs with other phenotypic traits that provide the strains with a selective advantage. 
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Thereby, the unique environment of the CF lung might play a significant role and potentially 
influences the process of mutation and selection [321]. 
The broad use of the fluoroquinolones is known to be a risk factor for the development of resistant 
strains, however, the lower the MIC of a first-step mutation the higher is the likelihood that those 
mutations will be cleared from an infectious site under antimicrobial therapy. 74 of the 172 
P. aeruginosa isolates studied here harbored a single mutation within only one of the QRDR and 48 
of those showed MIC values of 2 μg/ml or less. Although these P. aeruginosa isolates are categorized 
as susceptible or intermediate, it remains to be shown that it is safe to treat them with 
fluoroquinolones [111]. This is a key factor to consider in the treatment of Pseudomonas infections in 
CF patients, since drug concentrations in the CF lung do not reach sufficient levels [323] and sub-
inhibitory concentrations might promote population diversification [324]. 
The stepwise enrichment of fluoroquinolone resistance mutations has been described previously in 
several in vitro studies [325-327]. Mutants at each step are enriched when drug concentrations fall 
within a specific range called the mutant selection window [98,328]. Furthermore, even antibiotic 
concentrations below the MIC might select for resistance-conferring mutations. In a recent study, it 
could be demonstrated that ciprofloxacin concentrations at 1/10 the MIC were sufficient to select 
fluoroquinolone-resistant mutants de novo in E. coli [329]. Although low level resistance conferred by 
first-step mutations in the QRDRs does not prevent bacterial killing in the presence of sufficient levels 
of a quinolone, they may substantially enhance the number of (secondary) resistant mutants that can 
be selected from this population. In line with this, it has been demonstrated that deletion of efflux 
pumps significantly reduces the frequency of emerging fluoroquinolone-resistant isolates [211,327]. 
A key to preventing fluoroquinolone resistance in P. aeruginosa may therefore be to strictly avoid the 
use of low doses of fluoroquinolones and thus to preclude the emergence of first-step mutations that 
confer resistance to fluoroquinolones. 
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4.5 The global K. pneumoniae transcriptional landscape 
The alarming increase of infections caused by multidrug-resistant pathogens poses a serious threat 
to human health, the global economy and to society in general [65,68,72]. To successfully combat 
infections it is crucial to understand the molecular processes of bacterial adaptation to infection-
relevant habitats; especially, since the effectiveness of proven antibiotics to control bacterial 
infections is diminishing and novel treatment-strategies and -targets are urgently needed. Over the 
past decade, there were multiple reports on the epidemic dissemination of multidrug-resistant 
Enterobacteriaceae, among which the carbapenemase-producing organisms have been some of the 
most concerning [33]. The spread of certain epidemic clones that are involved in numerous hospital 
outbreaks worldwide is an emerging and a major concern [234] and infections with carbapenem-
resistant Enterobacteriaceae are common in German intensive care units [330]. The global success of 
these clonal lineages of multidrug-resistant pathogens is expected to be determined by a complex 
interplay between pathogenicity, epidemicity, and antibiotic resistance. While the impact on 
virulence and fitness of several individual antibiotic resistance mechanisms on the global success of 
the bacterial pathogens seems to be established, other specific adaptive traits that may explain the 
success of epidemic high-risk clones remain largely unexplored [223]. Understanding the reasons for 
the success of these clones could be crucial for designing specific and targeted treatment and 
infection control strategies. 
In the cross-sectional study described in chapters 3.3 and 3.4, the advantages of deep transcriptome 
sequencing (RNA-seq) were exploited to gain an unbiased view on the global transcriptional 
landscape of clinical K. pneumoniae isolates. Besides valuable transcriptomic information, RNA-seq 
allows for the extraction of the genomic sequences on the single nucleotide level of sufficiently 
transcribed genes, which, together with multilocus sequence typing [186] and capsular typing based 
on the wzi gene sequence [149,230], provided detailed insights into the phylogenetic relationship of 
the 37 clinical K. pneumoniae isolates studied in this work. The phylogenetic data revealed that most 
of the clinical isolates belong to the two sequence types ST101 and ST258 - including the closely 
related isolates of ST512. Both groups comprise world-wide distributed, often multidrug-resistant 
epidemic clones with a high risk potential. Of note, while 12 out of 13 ST101 isolates in this study 
seemed to originate from a common reservoir and therefore could likely be involved in a hospital 
outbreak, the ST258 isolates were less closely related and were obtained from various hospitals. 
In this study, unprecedented high-resolution transcriptome data of clinical K. pneumoniae isolates 
was recorded in its full complexity. We combined the transcriptome data with an analysis of infection 
relevant phenotypes such as of biofilm formation and virulence in a Galleria infection model and 
explored potential biological parameters that may explain the success of these high-risk clones. By 
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using a pan-genome as a reference assembled from 11 previously published and publicly available 
genome sequences, we observed that a large set of 3346 genes was expressed in all isolates. These 
genes showed great overlap (75 %) with the core-genome consisting of 3336 genes and, like the core-
genome, consists mostly of genes with central house-keeping functions. Most strikingly, we found 
clustering of isolates based on differential expression profiles of those commonly expressed genes. 
These results are in stark contrast to those obtained from Pseudomonas aeruginosa [331] and 
Escherichia coli [332]. The size of the core-genome with 3336 genes is very similar to the one of E. 
coli with approximately 3000 genes [333], considering the average K. pneumoniae genome is around 
10 % larger with a size of 5.5 Mb as compared to E. coli with 5.1 Mb; nevertheless, the phylogenetic 
background in E. coli was only reflected in the overall gene expression profiles, which included 
accessory gene sets, lacking subgroup-specific differences in core-genome expression profiles [332]. 
In P. aeruginosa even the acquisition of accessory genes seemed to be isolate specific and was 
independent of the phylogenetic background [331]. 
Since K. pneumoniae ST258 isolates showed striking sequence type specific differences in their global 
expression profiles, we sought to correlate the expression profiles with the infection relevant 
phenotypes of virulence and biofilm formation. In a Galleria infection model, virulence has been 
shown to correlate to resistance to human serum [239] and was linked to the occurrence of the K1 
and K2 capsular type [248]. However, none of our isolates were of K1 or K2 type. Nevertheless, we 
observed differences in the virulence of the isolates between the various sequence types, but also 
within isolates of the same sequence type. These results clearly indicate that virulence - as measured 
under the chosen experimental conditions in the Galleria infection model - is not associated with a 
particular sequence type. The same variation in virulence was previously described for ST258 isolates 
containing the wzi-154 allele (which is also shared by ST512 isolates) in a Galleria infection model, 
macrophage killing assay and human serum resistance assay [239]. Thus, it seems that 
K. pneumoniae virulence is not exclusively determined by the capsular type or a sequence type, but 
rather that certain yet to be identified virulence traits contribute to the bacterial pathogenicity. The 
analysis of ex vivo transcriptomes recorded during the course of infection [332,334-336] might 
provide valuable information on how this pathogen adapts to the host. 
Biofilm formation experiments showed that all ST258 isolates formed only poor biofilms, while in 
most of the other clinical strains biofilm formation was more common [156]. Classifying the strains 
into biofilm-proficient and -deficient isolates revealed differential expression of 90 genes, some of 
which have previously been linked to biofilm formation. 41 of those belonged to the core-
transcriptome. These results indicate that the high-risk clone ST258 has adopted poor biofilm 
formation as a common trait, and this trait is determined by distinct changes in the transcriptome. 
This finding might be unexpected since the capability to form biofilms has been associated with more 
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successful survival in the clinical environment [337]. Nevertheless, the finding that the ST258 isolates 
share a non-biofilm-specific gene expression profile within their core-transcriptome strongly 
implicates that this trait confers to an advantageous phenotype that might be linked to the 
establishment and maintenance of an infection within the human host but it might also be linked to a 
more successful spreading or survival of this clonal linage in the hospital setting. Further studies are 
inevitable to explore a possible correlation of the incidence of the ST258 K. pneumoniae sequence 
type with distinct patient or hospital environmental settings that might privilege biofilm-deficient 
isolates and whether there are specific hospital settings that favor the dissemination of ST258 
isolates over those of other epidemic clones. 
4.6 Genetic determinants of antibiotic resistance in clinical K. pneumoniae 
isolates 
In order to gain detailed insights into the molecular mechanism leading to antimicrobial resistance in 
the clinical K. pneumoniae isolates, this comprehensive RNA-seq data set was analyzed for the 
occurrence of horizontally acquired enzymes, chromosomal mutations and differences in gene 
expression. Although antimicrobial resistance in Gram-negative bacteria can be caused by a plethora 
of diverse and variable resistance conferring mechanisms, it was very surprising to see, that 
resistance to the most important classes of fluoroquinolones, carbapenems and aminoglycosides can 
be explained by the presence of just a few resistance determinants (see Figure 4.1) 
 
 
Figure 4.1: Overlap of antibiotic non-susceptibility with occurrence of certain antibiotic resistance 
determinants.  
The Venn diagrams show the overlap of antibiotic non-susceptibility and the occurrence of certain resistance determining 
mechanisms for ciprofloxacin (A), meropenem (B) and gentamicin (C). All isolates which were non-susceptible (classified as 
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either resistant or intermediate according to CLSI guidelines [142]) were taken into account for the graphs. All resistance 
determinants are listed in more detail in Tables 3.11-13. Venn diagrams were created using VENNY [338]. 
CIP, ciprofloxacin, MEM, meropenem, GEN, gentamicin, PMQR, plasmid-mediated quinolone resistance 
 
Similarly to P. aeruginosa, fluoroquinolone resistance in this panel of K. pneumoniae isolates is 
largely dependent on target mutations within gyrA and parC, whereas further mechanisms like 
enhanced efflux and the occurrence of plasmid mediated quinolone seem to play a minor role. 
Almost all non-susceptible isolates exhibited a mutation within the QRDRs of gyrA and parC, 
rendering these SNPs appropriate resistance markers. Only a single non-susceptible isolates could be 
detected which did not show any amino acid alterations in these genes. Nevertheless, non-
susceptibility in this isolate can be explained by the presence of the plasmid-mediated quinolone 
resistance determinants AAC(6')-Ib-cr and QnrB1.  
Carbapenem resistance is known to be facilitated by an interplay of diminished drug uptake through 
porin deficiencies and the production of carbapenem hydrolyzing enzymes. Here, in all but one 
isolates non-susceptibility to meropenem can be attributed to the expression of either KPC or OXA-
48 carbapenemases and furthermore, none of these determinants were identified in susceptible 
isolates. Only a single isolate, which showed intermediate resistance to meropenem, does not exhibit 
detectable resistance mechanisms. 
The most prevalent mechanism causing aminoglycoside resistance in Enterobacteriaceae is the 
presence of certain, mainly horizontally acquired, AMEs and consequently, all non-susceptible 
isolates contained at least one of these enzymes. On the contrary, the majority of susceptible isolates 
also contained at least one AME, mostly of AAC(6’)-type. Since AMEs are highly specific in their 
substrate spectrum and activity varies greatly between their different types [132], it is crucial to 
identify AMEs precisely to study the mechanism causing aminoglycoside resistance. For example, the 
N-acetyltransferase AAC(6')-Ib-C does not confer resistance to gentamicin [281,282], whereas the 
variants AAC(6')-Ib’ [283] and AAC(6')-Ib-cr [110] are known for their gentamicin inhibiting nature. 
Here, due to low or incomplete sequencing coverage of AMEs in many isolates, it was not possible to 
extract the complete sequence and therefore their exact type could not be determined. Further 
additional studies, e.g. Sanger sequencing of resistance cassettes, are needed to be able to draw 
conclusions on the aminoglycoside resistance conferring mechanisms. 
Although our results suggest that deep transcriptome sequencing is highly valuable in identifying 
molecular mechanisms associated with antimicrobial resistance, in several K. pneumoniae isolates 
the resistance phenotypes could not be explained to its full extend by the presence or absence of 
known resistance markers. This highlights one of the pitfalls of RNA-seq where the detection of 
mutations or presence of genes is highly dependent on the expression thereof. The combination of 
RNA-seq with complimentary analysis such as whole genome sequencing will therefore allow 
Discussion 93 
 
 
researchers to study the molecular mechanisms leading to antimicrobial resistance in their full 
complexity. So far, several studies have used whole genome sequencing to identify antimicrobial 
resistance -related factors and correlated this information with susceptibility data, but all of them 
lacked information about transcript abundancies [339-343]. To our knowledge, only one study used 
the combination of whole genome and transcriptome sequencing to study antimicrobial resistance. 
In this publication, Wright and colleagues could successfully elucidate colistin resistance in clinical 
K. pneumoniae isolates [227]. 
4.7 Prediction of antibiotic resistance based on genotypic data 
The recent major advances in (next generation) sequencing technologies have positioned this 
valuable method to become an essential tool to control antibiotic resistance. Highly increasing 
accuracy, rapidly falling costs and ever decreasing turnaround times will facilitate the 
implementation of whole-genome sequencing into diagnostic and public health microbiology in the 
near future [344]. In clinical microbiology next generation sequencing has the power to tackle three 
essential tasks at the same time: species identification, determination of its properties e.g. antibiotic 
resistance and virulence and infection control through surveillance [345]. Recent studies 
demonstrated the power of whole genome sequencing as an analytical tool to investigate clinical 
outbreaks. Köser et al. studied an outbreak of methicillin-resistant S. aureus to identify transmission 
events and delivered valuable information within a clinically relevant time frame of 1.5 days from 
DNA extraction to sequence analysis [346]. Snitkin and colleagues combined whole-genome 
sequencing with epidemiological data to reveal the transmission route of an outbreak of 
carbapenem-resistant K. pneumoniae and therefore provided valuable information for clinicians [47]. 
Reuter et al. accurately discriminated between outbreak and non-outbreak isolates of several Gram-
negative pathogens and demonstrated that whole genome sequencing was superior to conventional 
typing methods [347]. Recent advances in sample preparation have even enabled whole genome 
sequencing directly from single bacterial colonies [348], thereby dramatically decreasing the time 
between isolation of a pathogen and identification of its species and properties. 
Currently, microbiological diagnosis involves the pathogen identification followed by antimicrobial 
susceptibility testing via various, highly standardized methods like broth microdilution, antimicrobial 
gradients, disc diffusion or automated systems (e.g. Vitek2). However, antimicrobial susceptibility 
depends substantially on the growth of bacteria and requires usually 16 hours, but can be 
significantly longer in the case of slow growing organisms like Mycobacteria [349]. An early and rapid 
reporting of antibiotic susceptibility is crucial to facilitate a quick, efficient and successful treatment 
with appropriate antibiotics and has both clinical and financial benefits [350]. Hence, novel molecular 
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approaches facilitating fast and reliable pathogen identification and susceptibility testing are needed. 
A promising strategy to detect molecular markers of antibiotic resistance is the application of reliable 
and cost-effective targeted resequencing methods. 
Microarray analysis has been widely used to detect antibiotic resistance genes in clinical isolates of 
various origins and current arrays have the capability to analyze the presence of numerous 
sequences of a broad range of organisms. The recently published NanoCHIP® enables the detection 
of 400 resistance markers of carbapenemase producing K. pneumoniae, methicillin-resistant 
S. aureus and vancomycin-resistant Enterococcus directly from swab cultures in a single approach 
[351]. However, the application of microarrays in clinical antibiotic susceptibility testing bears some 
major disadvantages, since the design of microarrays is labor-intensive and errors introduced during 
probe synthesis are problematic. Furthermore the production of custom microarrays is expensive 
and its inflexibility makes the use of an microarray inefficient for clinical diagnostics [352]. 
Another promising technology for microorganism typing and detection of genomic antibiotic 
resistance markers is the application of mass spectrometry to analyze nucleic acid sequences [353]. 
One example is the MassARRAY® iPLEX® genotyping platform (former Sequenom, now Agena 
Bioscience) which detects distinct mass differences of the four nucleotides by coupling single base 
primer extension PCRs with matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry (MALDI-TOF). MassARRAY allows the detection of SNPs, indels and copy number 
variants and, when using cDNA, can also be applied to quantify differential gene expression 
[354,355]. MassARRAY genotyping is a time- and cost-effective high-throughput method which 
simultaneously exhibits excellent sensitivity and specificity. It has already been applied to detect 
resistance determinants in human cancer cells [356], mosquitoes [357], viruses [358,359] and 
bacteria [360]. Furthermore, it has successfully been used in the typing of clonal lineages of 
Mycobacterium tuberculosis [361], Neisseria gonorrhoeae [362] and Yersinia pestis [363]. 
In conclusion, the application of novel genotyping methods, for example whole genome sequencing, 
microarrays or genotyping via mass spectrometry, is becoming the method of choice for monitoring 
pathogens and identification of outbreaks in research facilities [345]. However, the implementation 
in the clinic requires exhaustive knowledge about the nature and impact of molecular resistance 
determinants. Therefore, further studies on the cellular processes leading to antimicrobial resistance, 
like the ones presented in this thesis, are needed to accurately predict antibiotic resistance based on 
genotypic data. 
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5 Appendix 
The following supplementary files are stored on a compact disc and have been attached at the end of 
this thesis: 
 
supplementary file S1:  resistance_genes.fasta 
supplementary table S2: QRDR mutations and expression of the four major efflux pumps in 
clinical P. aeruginosa isolates 
supplementary table S3: Complete list of the K. pneumoniae pan-genome with information 
about transcription conservation and variation 
supplementary table S4: Complete list of the accessory transcriptomes of clinical K. 
pneumoniae isolates 
supplementary table S5: Identified virulence associate genes in the accessory transcriptome of 
clinical K. pneumoniae isolates 
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